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Blindness and visual impairment due to eye disease results in significant loss in 
patient quality of life. Although therapeutics to treat these diseases may exist, specific 
targeting of diseased ocular tissue, while sparing other tissues, is difficult with traditional 
ophthalmic routes of administration. The suprachoroidal space (SCS, a potential space 
bordered by the choroid and sclera) is being explored as a site for drug delivery since 
high bioavailability and targeting can be achieved at the retina, choroid, and ciliary body. 
A hollow microneedle sized to pierce the sclera, while preventing penetration through the 
chorioretina, enables injections into the SCS in a reliable and efficient manner. The safety 
and efficacy of microneedle injections into the SCS is being investigated for posterior 
segment indications in ongoing clinical trials.  
 
One goal of this thesis was to investigate the distribution and clearance kinetics of 
formulations injected into the SCS using a microneedle. Specifically, we identified 
anatomical barriers in the SCS that impeded circumferential spread of particles. We next 
looked for other factors that could influence particle and molecule spread. We found that 
increasing injection volume resulted in increased particle and molecule coverage, with 
molecules occupying a larger area than particles. Increasing formulation viscosity 
reduced this discrepancy in area coverage. We next studied the SCS thickness, and found 
that injection volume had a minor effect and formulation injected had a major effect on it. 
We investigated the kinetics and routes of clearance of fluid and molecules injected into 
the SCS. We found that molecules exited the SCS via reflux, pressure-mediated trans-
scleral transport, and diffusion-mediated clearance by the choroid. We also showed 
 xix 
greatly prolonged residence time in the SCS was possible with very large 
macromolecules.  
A second goal was to develop a controlled release system for use in the SCS. We 
demonstrated 1-month efficacy of a controlled-release microparticle system injected into 
the SCS to treat glaucoma in a rabbit model. Dose sparing was achieved compared with 
conventional therapy. 
This work advances our understanding of the SCS as an emerging route of 






Visual perception is a complex sensation that allows humans to identify objects, 
navigate the world, awaken in the morning, and appreciate a smile. Visual perception 
begins with visible light (~400-700 nm in wavelength) that is transmitted, reflected, 
refracted, or absorbed by an object1. The eyes are a pair of organs located in the head that 
detect this visible light, and process and transmit signals to the brain that subsequently 
become vision.  
Unfortunately, ocular diseases can cause vision loss, robbing an individual of 
arguably the most important of the senses. Drugs can be used to treat or cure these 
diseases, however, targeting drugs within the eye can be challenging. This work further 
examines the use of microneedle injections to specifically target regions of the SCS to 
treat ocular diseases. 
1.1 Anatomy and Physiology of the Eye 
The human eye is a spherical organ composed of three concentric layers 
surrounding fluid (Figure 1.1). The outermost fibrous layer consists of the cornea 
anteriorly and sclera posteriorly; the intermediate layer consists of the uvea, which can be 
sub-classified as iris, ciliary body, and choroid; and the innermost layer is the 
neurosensory retina1. The retina is a thin sheet of light-sensitive neurons that detects and 
processes light. Within these three layers is the watery aqueous humor in the anterior 
segment and the jelly-like vitreous humor in the posterior segment. The eye weighs ~7.3 
g, and occupies a volume of 6.2 to 7.2 mL1. The ocular globe has dimensions of 24.2 mm 




Figure 1.1 – Diagram of the human eye. Suprachoroidal space is potential space between sclera and 
choroid.(1) sclera, (2) choroid, (5) cornea, (6) iris, (7) pupil, (8) aqueous humor, (10) ciliary body, (11) 
lens, (12) vitreous humor, (13) retina, (14) optic nerve, (15) zonules. Credit: Talos, colorized by Jakov 
(https://commons.wikimedia.org/wiki/Human_eye#/media/File:Eye_scheme_mulitlingual.svg)  
As light enters the eye, the cornea and lens refract light so as to focus it on the 
retina. The iris dynamically controls the amount of light reaching the retina by changing 
the size of the pupil. The lens can dynamically change shape to adjust its own refractive 
power, allowing fine adjustments in the focal plane of the eye. The aqueous and vitreous 
humor maintain the shape and rigidity of the eye so the focal plane of the light does not 
shift away from the retina. The retina detects light, processes the signal, and transmits 
electrical impulses (i.e., action potentials) along the optic nerve to the visual cortex of the 





Posterior segment Anterior segment 
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1.1.1 Anterior segment of the ocular globe 
The anterior segment of the eye is generally responsible for focusing light on the 
retina, controlling light intensity, and controlling intraocular pressure (IOP)1. The anterior 
segment consists of the cornea, ciliary body, iris, lens, and aqueous humor. 
1.1.1.1 Cornea 
The cornea (5 in Figure 1.1) is the transparent fibrous layer in the anterior 
segment of the eye. It is comprised of five layers, from anterior to posterior: corneal 
epithelium, Bowman’s layer, corneal stroma, Descemet’s Layer, and corneal 
endothelium1. In humans, central corneal thickness is 536 ± 31 µm (mean ±SD)3.  
The corneal epithelium is comprised of stratified squamous cells, with Bowman’s 
layer as its basement membrane. The epithelium forms a barrier to the outside world that 
keeps microbes out4. These cells are continually renewed by corneal stem cells, which 
reside in the limbus5. Newly formed epithelial cells migrate towards the center of the 
cornea and anteriorly, replenishing the cornea every 1-3 weeks6.  
The cornea stroma forms the bulk of the cornea (~90% of its thickness)1. The 
stroma is composed of aligned collagen fibers with uniform thickness, which are 
organized into parallel sheets7. To maintain transparency, the stroma is kept in a 
dehydrated state so the distance between fibers is constant (<200 nm)8. The highly 
organized stromal fibers act as Rayleigh scatterers that allow visible light (400-700 nm) 
to pass through the stroma with minimal interference7. On the other hand, UV light (<400 
nm) experiences destructive interference when passing through the stroma, and 
consequently, does not reach the retina. 
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The stroma’s radius of curvature and refractive index accounts for most of the 
eye’s refractive power9. Because the refractive index of air is quite dissimilar from that of 
cornea, the anterior surface of the cornea accounts for most of the refractive power. The 
refractive power of the cornea is ~43 D (diopters) and does not change through 
adulthood1, 8. 
The corneal endothelium is the innermost layer of the cornea. It is actually a 
single layered epithelium – with Descement’s layer as its basement membrane – that does 
not regenerate with age. The cornea endothelium actively pumps water out of the cornea 
to maintain the relatively dehydrated state of the stroma10.  
1.1.1.2 Iris 
The iris (6 in Figure 1.1) serves as a biological aperture (called the pupil, 7 in 
Figure 1.1) for the neurosensory retina, adjusting the diameter of the pupil depending on 
ambient light conditions1. The iris receives both sympathetic and parasympathetic 
innervations.  
1.1.1.3 Ciliary body 
The ciliary body (10 in Figure 1.1) consists of the ciliary muscles and the ciliary 
processes. The function of the former is to alter the refractive power of the lens by 
controlling the tension of the zonules, which are fibers that attach the ciliary muscles to 
the lens1. The ciliary muscle forms a ring anchored to the sclera near the scleral spur. 
When the ciliary muscles contract, the zonules are placed under tension, and the lens is 
pulled, reducing its radius of curvature and its refractive power, and vice versa11, 12. 
 The ciliary processes is continuous with the uveal tract. It produce aqueous 
humor, which is a transparent nutrient-rich fluid derived from blood13, 14. The aqueous 
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humor is required to feed the avascular cornea and lens (these tissues are necessarily 
devoid of blood vessels so as to maintain their transparency). The interior of the ciliary 
body contains a rich blood vessel network. The ciliary processes is lined by two layers, 
called the pigmented and unpigmented ciliary epithelium, which sequentially filter blood 
into aqueous humor13. They collectively form the blood-aqueous barrier which keeps 
blood from leaking into the aqueous humor15. 
1.1.1.4 Aqueous humor 
Aqueous humor (8 in Figure 1.1) contains nutrients necessary to feed the corneal 
epithelium and endothelium, as wells as the lens epithelium, since the cornea and lens are 
avascular1. It is produced by the ciliary epithelium lining the ciliary body. Aqueous 
humor production (and elimination) is also important in maintaining the intraocular 
pressure (IOP)13. This IOP keeps the eye inflated, which is necessary to maintain the 
focal plane of the eye on the retina, especially when externally forces are applied on the 
eye13. Elimination of aqueous humor is possible through two paths: the ‘traditional 
outflow’ and uveoscleral outflow13, 16. Traditional outflow occurs through the trabecular 
meshwork. Fluid flowing through the trabecular meshwork enters Schlemm’s canal, 
which is a circular channel near the limbus. Fluid collected by Schlemm’s canal is 
eventually shunted into the episcleral veins13. The uveoscleral outflow is usually less than 
traditional outflow, though there are drugs that can dramatically increase uveoscleral 
outflow. In uveoscleral outflow, fluid flows through the iris root and into the 
suprachoroidal space16. Aqueous humor production in humans is 2.4 ± 0.6 µL/min, and 





The lens (11 in Figure 1.1) is an avascular transparent tissue that is suspended in 
the anterior segment by zonules. The lens accounts for about one-third the refractive 
power of the human eye (with the cornea accounting for the remainder)17. It can 
dynamically adjust the focal plane of the eye when it changes shape. The lens epithelium 
surround the lens and grown inwards18. The lens nucleus is made of enucleate fibers 
(cells that have lost their nucleus). In young adults, the lens is smaller and can change its 
shape easily, allowing accommodation. However, with age, the lens becomes larger and 
more rigid19. Lens opacity can result from damage to the lens epithelium, or aggregation 
of the proteins found in the lens fibers19.  
1.1.2 Posterior segment of the ocular globe 
The posterior segment of the eye is responsible for detecting light and 
transmitting a signal to the brain. The posterior segment consists of the sclera, choroid, 
retina, optic nerve, and vitreous humor. 
1.1.2.1 Retina 
The retina (13 in Figure 1.1) is a part of the central nervous system. Total 
thickness of the human retina is 230 ± 15 µm20. The neurosensory retina is a highly 
organized collection of neural layers responsible for detecting and processing light, and 
transducing a complex spatiotemporal pattern along the optic nerve to the brain 
representing light and darkness1. The photoreceptors, which are the outermost layer of the 
retina, are responsible for detecting photons and initiating signal transduction. There are 
two types of photoreceptors: rod and cone. Rods are capable of detection in low light 
settings (down to single photons) but have low spatial resolution5. There are 
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approximately 91 million rod photoreceptors in the eye, mostly distributed in the 
periphery21. Cones are capable of detection in high light settings with high spatial 
resolution. Furthermore, there are three subtypes of cones that have maximal sensitivity 
at 420, 534, and 564 nm, respectively9. There are 4.5 million cone photoreceptors, the 
vast majority of which are found in the center region of the retina called the macula21. At 
the center of the macula is a pit that contain only cone photoreceptors, called the fovea. 
The fovea is responsible for central vision, allowing for tasks such as reading.  
The retinal pigment epithelium (RPE) is a single monolayer of epithelial cells that 
supports the outer retina (i.e., the photoreceptors) structurally and metabolically22, 23. It is 
located between the outer retina and the choroid22-25, with Bruch’s membrane serving as 
the basement membrane for both RPE and choroid. The RPE shuttles nutrients from the 
choroid to the outer retina, while shuttling waste out of the outer retina26.  
Interneurons, such as the bipolar cells, horizontal cells, and amacrine cells, 
process and convey the information to the retinal ganglion cells1. Müller cells support the 
retina structurally and metabolically. Inner retinal blood vessels supply the inner retina 
with nutrients25. The axons of the retinal ganglion cells coalesce at the optic disc to form 
the optic nerve. The optic nerve exits the ocular globe, heading towards the brain. 
1.1.2.2 Choroid 
The choroid (2 in Figure 1.1) is a rich vascular bed that supplies nutrients to the 
outer layers of the neurosensory retina26, 27. Larger caliber vessels are found in the outer 
choroid, while capillaries, termed choriocapillaris, are found in the inner choroid. The 
choriocapillaris is one of the densest capillary beds with one of the highest perfusion rates 
of the body28, 29. The total thickness of the choroid in humans is 354 ± 111 µm at the 
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center of the visual axis30. Individual choriocapillaries can be classified as non-sinusoidal 
fenestrated capillaries31. The large supply of nutrients and oxygen is necessary for the 
metabolic demand and health of the retina. Since the oxygen consumption of the outer 
retina does not deplete the choroid’s carrying capacity29, 32, some have posited that the 
choroid can function as a heat sink that regulates retinal temperature. 
1.1.2.3 Suprachoroidal space 
The suprachoroidal space is a potential space that exists between the sclera and 
the choroid. Pigment can migrate into this space. In healthy adults, the suprachoroidal 
space is approximately 30 µm thick due to the negative pressure relative to intraocular 
pressure that keeps the space closed1, 33, 34. Furthermore, there are connective tissue fibers 
that connect the sclera to the choroid and ciliary body1, 35. A strain of about “5 g/cm” 
(calculated to be ~490 Pa) is required to break these fibers1, 36, 37. The minimal but 
nonzero thickness allows the sclera to slide relative to the choroid during 
accommodation38. Due to negligible lymphatics39, drainage of the suprachoroidal space is 
through intravascular (into the choroid)11, 31, trans-scleral8, 35, 36, 40, and perivascular16, 41-44 
routes. 
1.1.2.4 Sclera 
The sclera (1 in Figure 1.1) encapsulates the posterior segment of the eye and is 
continuous with the cornea, meeting at the limbus. The sclera has three layers: the 
episcleral layer, the sclera proper, and the lamina fusca1. The episcleral layer is a 
composed of loose elastic tissue and attaches the sclera to Tenon’s capsule. The sclera 
proper forms the bulk of the sclera. Unlike the corneal stroma, the scleral stroma is 
opaque since the sclera’s collagen fibers are not aligned nor are they uniform in size1. In 
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humans, scleral thickness is 530 ± 140 µm at the limbus, and ~900 µm near the optic 
nerve45. The lamina fusca is the innermost layer of the sclera, and is loosely arranged. 
The lamina fusca contains many pigment cells.  
1.1.2.5 Vitreous humor 
The vitreous humor (12 in Figure 1.1) is a jelly-like substance that occupies much 
of the ocular globe1. It is composed mostly of water (99%) with hyaluronic acid46. With 
age, the vitreous can partially liquefy, changing its diffusional properties47, 48.  
1.1.3 Extra-ocular structures 
Other structures surround the eye but are not a part of the ocular globe. These 
include the conjunctiva, Tenon’s capsule, extraocular muscles, and eyelid. 
1.1.3.1 Eyelid 
The eyelids are folds of skin that can close to protect the eye1. Muscles can open 
or close the eyelid. When the eyelids are opened, the cornea and conjunctival surfaces are 
exposed to the outside world. The blink reflex helps to replenish the tear film and to wash 
away particulates that may have deposited on the eye1, 4. The two muscles that elevate 
and depress the eyelid are considered extraocular muscles. 
1.1.3.2 Conjunctiva 
The conjunctiva is a clear membrane that covers the sclera, but not the cornea, 
and the inner surface of the eyelids1. Thus, the only region of the ocular globe actually 
exposed to the outside world is the cornea. Secretory cells located in the conjunctival 
membrane produce mucus and tears, which help lubricate the eye. Many blood vessels 
and lymphatics run in the subconjunctival space31, 39.  
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1.1.3.3 Tenon’s capsule 
Tenon’s capsule is a thin membrane that envelops the ocular globe from the optic 
nerve to the limbus1. Tenon’s capsule adheres to conjunctiva anteriorly, and to the outer 
surface of the sclera posteriorly. It helps to keep the retro-orbital tissues (e.g., retro-
orbital fat) separated from the eye.  
1.1.3.4 Extraocular muscles 
There are six extraocular muscles that move the eye in the orbit to position the 
eye in different directions1. The muscles typically work in concert to reposition the eye, 
as well as hold it stationary. Pairs of muscles work together in a push-pull system. For 
example, to elevate the eye, the superior rectus muscle contracts, while the inferior rectus 
relaxes. Since the extraocular muscles are innervated by cranial nerves, they can elucidate 
the health status of the cranium.  
1.2 Ocular Pathology 
Many pathologies can affect the eye, which in turn affect vision. Selected ocular 
diseases are described below to better motivate the need for targeted ophthalmic drug 
delivery. 
1.2.1 Primary open angle glaucoma 
Glaucoma is a group of ocular diseases with characteristic optic neuropathy49. 
Patients with glaucoma will slowly and painlessly lose peripheral vision and eventually, 
central vision. The most common form of glaucoma is primary open-angle glaucoma 
(POAG). It is a leading cause of blindness in the United States, affecting nearly 3 million 
individuals with an annual cost of $2.9 billion50, 51. POAG is usually associated increased 
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intraocular pressure (IOP) but elevated IOP is neither causative nor requisite for 
glaucoma52. Lowering IOP has been shown to prevent the progression of glaucoma53, 54, 
and IOP is strongly linked with aqueous humor production and outflow4, 13.  
Medical and surgical therapy seek to decrease intraocular pressure. Medical 
therapy is first-line treatment, and calls for of a topical eye drop regimen (common 
regimens are presented in Table 1.1)4, 53, 54. 
Table 1.1 – Summary of medications used to treat glaucoma 
Patient adherence to eye drop regimens is low, with an estimated adherence of 
~60%, in part because patients do not notice the slow painless loss of vision from the 
periphery 4, 55-58. The low compliance is due to a number of reasons including regimen 
difficulties (e.g., refill, cost), patient factors (e.g., knowledge, memory, and motivation), 
provider factors (e.g., dissatisfaction, communication), or situational/environmental 
issues (e.g., change in routine, competing activity)53, 55-58. Situational/ environmental 
factors accounted for about half of all adherence barriers58. Simplifying the dosing 
regimen (i.e., using a once-per-day eye drop vs. twice-per-day eye drops) did increase 
adherence, but did not result in perfect (100%) adherence56.  
 
 






Decrease aqueous humor 
production 









Decrease aqueous humor 
production 




Decrease aqueous humor 
production, increase 
aqueous humor removal 
Brimonidine 0.1% 3/d 150 
Miotic agent Increased aqueous outflow Pilocarpine 0.5% 3-4/d 750 
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1.2.2 Posterior segment diseases 
Selected ocular diseases that affect the posterior segment are presented below. 
The posterior segment can be separated geographically into the macula (necessary for 
central, high-resolution vision) and the periphery (necessary for vision in dark 
environments). Since these diseases only affect specific regions, targeted treatment to 
those regions may be more efficacious and/or mitigate side effects (Table 1.2).  
Table 1.2 – Selected posterior segment diseases and their distribution 
Disease 






Corticosteroids in anterior segment of 
eye can cause side effects. 
Age-related macular 
degeneration 
x   
Retinitis pigmentosa  x 
Treatments under investigation include 
gene therapy; transfection in other 
regions of eye may be undesirable. 
Ocular tumors ? ? 
Lesions can develop anywhere in eye. 
Chemotherapy in other regions of eye 
can cause side effects. 
1.2.2.1 Noninfectious posterior uveitis 
Noninfectious posterior uveitis is typically an autoimmune inflammation of the 
entire choroid59. Patients can experience photopsia or pain from light. Current treatment 
calls for corticosteroids administered systemically, topically, or intravitreally59-61. 
However, long term steroid use causes cataract formation due to inadequate 
compartmentalization of drug away from nontarget tissues (e.g., lens) 61, 62.  
1.2.2.2 Age-related macular degeneration (AMD) 
Age-related macular degeneration (AMD) is an ocular disease that affects the 
macula, or the central part of the retina. AMD affects 10 million Americans63. The cause 
of AMD is not known, but certain genetic mutations, smoking and other forms of 
oxidative stress, and age increase the risk of developing AMD64, 65. AMD can be sub-
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classified as wet-form or dry-form. In dry AMD, there are subretinal deposits of cellular 
debris known as drusen in the macular region. Dry AMD progresses slowly towards 
geographic atrophy of the macula. One the other hand, wet AMD is characterized by the 
rapid uncontrolled growth of the choroidal vasculature (termed choroidal 
neovascularization or CNV). These newly formed choroidal vessels are leaky and can 
disrupt the macula, all of which can cause blindness66.  
There is no FDA-approved treatment for dry AMD. Wet AMD is currently 
managed with monthly intravitreal injections of anti-VEGF monoclonal antibodies (such 
as ranibizumab or aflibercept) that suppress CNV and macular edema67-70. There is 
mounting evidence that anti-VEGF therapy can cause visual impairment through the total 
suppression of VEGF signaling24, 71-73.  
1.2.2.3 Retinitis pigmentosa 
Retinitis pigmentosa is a group of genetic diseases where the rhodopsin gene is 
mutated74. Rhodopsin is the photo-pigment found exclusively in rod photoreceptors, and 
thus the disease primarily affects rod photoreceptors. Patients experience night blindness 
and tunneling of vision, and eventual blindness. Because of the distribution of rod vs. 
cone photoreceptors, the peripheral retina is affected in early/mid-stage disease, while the 
macula is spared.  
Though there is no current FDA-approved treatment, there are clinical trials 
underway that are testing the safety and efficacy of gene therapy to ‘fix’ the mutated 
rhodopsin gene (e.g., NCT01482195)75, 76 and a visual prosthesis that electrically 




1.2.2.4 Ocular tumors 
Primary ocular tumors are typically focal lesions that affect one specific region of 
the ocular globe. The most common primary tumor in children is retinoblastoma79 and in 
adults is uveal melanoma80. The goal of treatment is to kill cancer cells (including any 
metastatic seeds) while sparing noncancerous cells. If the cancerous cells cannot be 
controlled, the eye is enucleated. 
1.3 Ophthalmic Imaging Modalities 
The healthy and diseased eye can be readily imaged using post mortem and in 
vivo imaging techniques. Since the eye is a largely transparent light detector, imaging the 
interior surfaces of the eye is possible. In fact, the eye is one of the only regions in the 
human body where nerves can be visualized. The following subsections briefly review 
the pros and cons of various imaging techniques. 
1.3.1 Post mortem imaging techniques 
These methods can enable definitive diagnosis, however, they also require tissue 
harvesting. Thus, they are not useful in clinical medicine, but can be valuable tools in 
research. Due to tissue processing, kinetic information is lost.  
1.3.1.1 Dissection 
After enucleation, the eye can be dissected to provide gross visualization of the 
inner surfaces of the eye. The suprachoroidal space of albino eyes can be easily seen 
since there is no pigment in the RPE or choroid, and thus, the retina and choroid are 
transparent81. Such a technique is sacrificial as the eye must be cut open. Since 
enucleation of the eye must occur, temporal resolution is limited (on the order of 
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minutes). However, the eye can be frozen in ethanol chilled over liquid nitrogen to arrest 
fluid movement.  
1.3.1.2 Histology 
Histology can be performed to visualize a cross-section of the eye at the cellular 
level. The eye must be enucleated and fixed to preserve the cellular structure. Thin slices 
(~10 µm in thickness) are cut in cross-section. Different stains can be applied to 
accentuate different cellular or extracellular features. For example, a hematoxylin & 
eosin (H&E) stain is commonly used to identify cells82. Care must be taken to choose an 
appropriate histological processing technique since most techniques are quite harsh and 
can destroy structures or objects of interest. For example, H&E stains require xylene 
washes, however, xylene will dissolve polymeric particles and denature fluorescent 
proteins.  
1.3.2 In vivo imaging techniques 
These techniques can be carried out in live subjects, and can thus be used to study 
kinetics. Some imaging modalities are not useful in the eye but are covered here since 
they are commonly used techniques. Since ophthalmology is so visual, many imaging 
techniques have been developed specifically for the eye83. 
1.3.2.1 Magnetic resonance imaging (MRI) 
Magnetic resonance imaging (MRI) enables three-dimension (3D) views of 
anatomical (and some functional) structures84, 85. The subject is placed in a strong 
magnetic field and radio frequency pulses are used to excite hydrogen atoms; the 
resulting changes in radio waves can be detected and processed into a 3D stack. No 
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ionizing radiation is used. Anatomical structures in the eye can be seen under MRI. MRI 
contrast agents exist, though there is not enough resolution to simultaneously track two 
different contrast agents. Due to the low signal-to-noise ratio (SNR) of radio frequency, 
long imaging sessions are necessary to ensure sufficient signal. Furthermore, spatial 
resolution is limited. For example, the Bruker Pharmascan 7T (available in the Institute 
of Bioengineering and Bioscience (IBB) core facility at Georgia Tech) acquired a 3D 
image of the eye with a resolution of ~200 µm in 45 min. This temporal and spatial 
resolution are insufficient to study kinetics in the rabbit eye. Figure 1.2 is an example 
image of an ex vivo rabbit eye after microneedle injection of contrast agent. Due to long 
image acquisition, the localization of contrast agent is unclear. 
 
Figure 1.2 – Single slice of ex vivo rabbit eye acquired with Bruker Pharmascan 7T MRI imager after 
microneedle injection of contrast agent. Contrast agent shows up as bright signal against ocular tissue. 
Voxel size was a cube with sides ~200 µm. Acquisition time was ~45 min. 
1.3.2.2 Computed tomography 
Computed tomography (CT) is a technique whereby multiple X-ray images are 
acquired and processed into a 3D stack. Ionizing radiation is used. Anatomical structures 
are not visible since all ocular tissue has roughly equal X-ray attenuation properties. 
Contrast agent can be used. The spatiotemporal resolution of µCT is limited. For 
example, the Scanco µCT 40 scanner was able to image the whole eye with a resolution 
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of ~50 µm in approximately 1 hr. Since anatomical structures are not readily visible on 
CT, localization of injected contrast agent in the eye is difficult (Figure 1.3).  
 
Figure 1.3 – Single slice of ex vivo rabbit eye acquired with Scanco µCT 40 scanner after microneedle 
injection of contrast agent (Left). 3D render of eye (Right). Note that it was impossible to differentiate 
ocular tissue from these images. Voxel size was a cube with sides ~50 µm. Acquisition time was ~1 h. 
1.3.2.3 Fundus photography 
Planar images of the inner surface of the eye can be acquired noninvasively83. 
Optics are needed account for the refractive power of the eye so that a camera can resolve 
fundus. There are many types of commercial ophthalmic imaging tools, including slit 
lamp microscopes, direct and indirect ophthalmoscopes, and contact and non-contact 
retinal cameras83 Contact retinal cameras (e.g., Clarity Medical Systems Retcam II 
pediatric ophthalmic imaging system) have wide field lenses that enable visualization 
into the far periphery (>130° from the optic nerve). Albino subjects can be used so the 
suprachoroidal space is readily visible. Some cameras also have single wavelength light 
sources and optical filters that match the excitation and emission spectra of fluorescent 
molecules, such as fluorescein. Furthermore, these cameras can be modified to visualize 





1.3.2.4 Ultrasound B-scan 
Ultrasonography can be used to acquire cross-sectional views of ocular tissue 
noninvasively83, 86. The ultrasound probe emits high-frequency soundwaves that echo off 
tissue, and processes the data to show the spatial distribution of density. A single line of 
information (called an A scan) can be rastered to form a 2D image (called a B scan). 
Ultrasound B-scan can be used to image through optically opaque tissue (e.g., sclera). 
Since the suprachoroidal space is a potential space, injection of fluid distends the tissue. 
This space is visible as a void between the tissues under ultrasound.  
1.3.2.5 Optical oherence tomography 
Optical coherence tomography (OCT)83, 87 also generates cross-sectional views of 
ocular tissue noninvasively using similar techniques as ultrasound (except with shorter 
wavelengths). Typically, OCT is used to image the retina along the visual axis and is thus 
not suitable for imaging the far periphery. 
1.4 General Overview of Ophthalmic Drug Delivery 
1.4.1 Ocular barriers of the eye 
Since the retina is a part of the central nervous system, the eye is a site of immune 
privilege4, 88. The difficulty in maintaining a sterile and immune privileged environment 
are compounded by the fact that a part of the eye (i.e., cornea) is exposed to the outside 
world. In the healthy eye, multiple barriers maintain this immune privilege by selectively 
controlling the entry of particulates (e.g., microbes) and molecules into the eye from 
systemic circulation, as well as the outside world. The barriers that prevent entry from the 
outside world include the tear flow, the cornea, and aqueous humor flow. The barriers 
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that prevent particulates and molecules floating in systemic blood from reaching the 
retina include the blood-aqueous barrier and the blood-retinal barrier. Ocular 
inflammation can override these barriers so immune cells may enter the eye. 
 
Figure 1.4 – Diagram of the ocular barriers in eye. Adapted from: Talos, colorized by Jakov 
(https://commons.wikimedia.org/wiki/Human_eye#/media/File:Eye_scheme_mulitlingual.svg)  
1.4.1.1 Pre-corneal and corneal barriers 
Tear flow and tear drainage form the first barrier to entry into the eye from the 
outside world (Figure 1.4 B). Glands located in the conjunctiva and eyelids secrete a 
constant flow of tears that lubricate the eyes and wash away particulates, such as dust or 
microbes, that may settle on the external surface of the eye. In humans, basal tear film 
volume is 7.0 ± 2.0 µL and the rate of tear film turnover is 10.3 ± 3.7 %/min89, 90. In 
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addition, antimicrobial proteins, such as lactoferrin and lysozymes, are secreted into the 
tears as an additional means to prevent infection4.  
The cornea is the next barrier to entry from the outside world (Figure 1.4 B). Due 
to the unique barrier function of the cornea, bioavailability of drugs across the cornea is 
low, estimated at 1-7%4. The corneal epithelium’s barrier function and the dense collagen 
of the stroma inhibit diffusion of particulates and macromolecules through the cornea. 
Only small molecules within a tight hydrophobic/hydrophilic range may diffuse through 
the cornea91. 
Corneal epithelial cells form and maintain tight junctions between adjacent cells, 
which prevent the passage of ions and macromolecules between the cells92. Because 
intracellular transport is limited by tight junctions, the transport of molecules through the 
epithelium happens via para-cellular or trans-cellular means91. In both para-cellular and 
trans-cellular transport, the diffusing molecule must easily pass into and out of the 
lipophilic plasma membrane. The corneal stroma is the second structure encountered in 
the cornea. The collagen fibers and dispersed proteoglycans, which comprise the stroma, 
are strongly charged and can inhibit the passage of lipophilic molecules. Furthermore, the 
dense network of collagen fibers physically prevents the movement of particulates and 
macromolecules. The corneal endothelium provides little barrier function relative to the 
epithelium and stroma.  
Though the barrier function of the sclera is similar to the cornea, the conjunctiva 
and the subconjunctival space (both of which overlay the sclera) are strong barriers to 
entry into the eye. The subconjunctival space contains many blood vessels and 
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lymphatics that drain the space; thus, molecules and particulates within the 
subconjunctival space are preferentially cleared before diffusing through the sclera4, 93.  
Of the fraction of molecules that are able to pass through the cornea into the 
anterior chamber (1-7%), there is a small but constant convective current caused by 
aqueous humor outflow that severely limits diffusion deep into the eye to the posterior 
segment (Figure 1.4 B). Aqueous humor production in humans is 2.4 ± 0.6 µL/min and is 
directed posterior (from the ciliary body) to anterior (out the trabecular meshwork)13. By 
calculating the Péclet number of the anterior segment, which is dimensionless number 
that relates the advective transport rate to the diffusion transport rate, we find that 
advective transport dominates in the anterior chamber94. Thus, molecules that cross the 
cornea will not diffuse towards the back of the eye; rather, they will be pushed by the 
bulk fluid flow of newly produced aqueous humor into the trabecular meshwork.  
1.4.1.2 Blood-retinal barrier 
The interior tissues of the eye are separated from the systemic circulation by the 
blood-aqueous barrier in the ciliary body and the blood-retinal barrier in the retina 
(Figure 1.4 C and D)25. The pigmented and non-pigmented epithelium of the ciliary body 
form the blood-aqueous barrier (Figure 1.4 C). These cell layers maintain tight junctions 
that prevent the passage of large macromolecules and cells into the eye15. The ciliary 
epithelium actively transport selected molecules, such as ions, amino acids, and glucose, 
to form the filtrate that is aqueous humor14. 
Since the retina is a highly metabolically-active tissue, the retina derives nutrients 
from two separate blood supplies. The inner retina is fed by the retinal vasculature, and 
the outer retina is fed by the choroid. Each blood supply has its own blood retinal-barrier 
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(i.e., there is an inner and an outer blood-retina barrier) that limits movement from 
systemic circulation to the retina (Figure 1.4 D)25. The inner blood-retinal barrier is 
inherent to the retinal arteries and their branches. Similar to the vessels that feed the 
central nervous system, the retinal vasculature is comprised of non-fenestrated capillaries 
with tight junctions31. This limits passive transport of molecules <1 nm (~5kDa) into the 
inner retina. To enter the inner retina, larger molecules must be actively transported by 
pericytes that surround the capillary31. The outer blood-retinal barrier is comprised of the 
retinal pigment epithelium (RPE) that separates the outer retina from the choriocapillaris. 
The choriocapillaris does not have any inherent barrier function because they are 
fenestrated non-sinusoidal vessels25, 95, 96. As with most epithelial layers, the RPE 
maintains tight junctions that prevent intercellular transport. The RPE actively transports 
select molecules from the choroid to the outer retina.  
1.4.2 Traditional ophthalmic drug delivery techniques 
The ability for a pharmacologic agent (i.e., drug) to prevent, treat, or cure a 
disease has had a profound effect on healthcare. Despite the knowledge that a drug will 
have a therapeutic effect, it is also essential to deliver drugs to the appropriate site88. 
Optimal drug delivery technologies must balance two sometimes opposing goals: (1) 
ensuring sufficient drug concentrations are at the drug’s site of action to induce a 
therapeutic effect, and (2) ensuring low drug concentrations are at non-target tissues to 
minimize side effects. Because of the unique barriers of the eye as well as its small size, 




Figure 1.5 – Diagram of the human eye demonstrating the common ophthalmic drug delivery routes: 
intravitreal injections and topical eye drops. Adapted from : Talos, colorized by Jakov 
(https://commons.wikimedia.org/wiki/Human_eye#/media/File:Eye_scheme_mulitlingual.svg)  
Pharmacokinetics is the study of the movement (including the absorption, 
distribution, and elimination) of drugs or therapeutic agents in the body. The unique 
barriers of the eye limit absorption and distribution (e.g., the cornea prevents the bulk 
movement of drugs into the eye) and increase clearance (e.g., the conjunctival lymphatics 
clear drug away from the eye into the systemic circulation)88. Understanding the 
pharmacokinetics of each drug delivery method can help us evaluate the advantages and 
shortcomings of that method. The most common methods for ocular drug delivery are (1) 
systemic dosing, (2) topical eye drops, and (3) intravitreal injections.  
1.4.2.1 Systemic delivery 
With systemic dosing, the drug is delivered either orally or parenterally so the 
entire body is bathed in drug. The drug could distribute into the eye, though the eye’s 
small size (<0.1% of the total mass of an adult) limits the amount of drug that would 
naturally diffuse into the eye97. The actual amount entering the eye is even less due to the 
blood-retinal barriers. Thus, systemic dosing is inefficient in treating isolated ocular 






ocular involvement. For example, intravenous injections of an antifungal are appropriate 
for fungal endophthalmitis in the presence of systemic candidiasis.  
1.4.2.2 Topical eye drops 
Topical eye drops are a common drug delivery method used for diseases of the 
anterior segment, such as glaucoma and keratitis4, 97. In practice, a patient instills ~50 µL 
of a drug solution onto their eye. Some manual dexterity and experience are needed to 
place the drop on the eye and not on the cheek. Tear drainage and corneal barriers limit 
the total amount of applied drug (~1-7%) that can enter the eye and reach its ultimate site 
of action4. Since the capacity of the lacrimal lake is only about 7-10 uL4, 89, the vast 
majority of the eye drop is lost immediately with tear drainage. Drugs that can diffuse 
through the cornea are moderately-uncharged small molecules91. The low bioavailability 
and fast clearance from the eye necessitate frequent dosing, typically once to four times a 
day. Because the rate of aqueous humor production is greater than the diffusional rate of 
the drug (large Péclet number), drugs administered as eye drops do not diffuse deep into 
the eye94.  
1.4.2.3 Intravitreal injections 
Intravitreal injections have become common with the introduction of anti-VEGF 
monoclonal antibodies (such as bevacizumab and ranibizumab) for wet AMD69, 98, 99. 
Nowadays, intravitreal injections are used for most posterior segment diseases, including 
AMD, diabetic retinopathy, and uveitis100. In the outpatient clinic setting, a trained 
ophthalmologist uses a 27-30-gauge hypodermic needle to penetrate through all the 
layers of the eye and inject a drug solution into the vitreous. Such a technique bypasses 
the ocular barriers of the front of the eye, allowing the delivery of macromolecules (e.g., 
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bevacizumab has a molecular weight of ~146 kDa) into the eye100. Unfortunately, 
intravitreal injections carry a small but significant risk of choroidal hemorrhage, retinal 
detachment, and infection101. After the injection, the vitreous serves as a drug depot, 
prolonging time between doses. It is estimated that ranibizumab injected intravitreally has 
a half-life of 2.9 days and was detectable in the vitreous after 29 days102.  
Intravitreal injections are typically intended to treat diseased tissues in the 
posterior segment diseases (such as the macula in AMD and the choroid in posterior 
uveitis), not the vitreous itself. The drug must diffuse through the vitreous and reach the 
site of action in the posterior segment. However, there is no preferential driving force for 
the injected drugs towards the site of action in the back of the eye, nor is there the ability 
to direct drug towards specific regions within the back of the eye. The injected drug can 
freely diffuse throughout the vitreous humor and affect tissue throughout the eye. This 
nonselective dosing can result in side effects caused by dosing non-target tissues. For 
example, corticosteroids injected intravitreally for the treatment of uveitis will cause 
drug-induced cataracts because the corticosteroids can diffuse through the vitreous to the 
lens61, 62.  
1.4.2.4 Other ophthalmic drug delivery techniques 
Other less commonly used ocular drug delivery techniques can be used to deliver 
drugs around the eye100. These techniques are also not targeted towards specific regions 
or tissues in the eye. 
Because the subconjunctival space is a potential space, it is possible to place drug 
depots inside for extended release applications. This might result in less drug washing 
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away immediately with the tear film. However, clearance by blood and lymphatic vessels 
from the subconjunctival space is high95, 103.  
Alternatively, drugs can be placed in Tenon’s capsule, the fibrous capsule 
encapsulating the back of the eye100. Besides their posterior position, sub-Tenon’s 
injections are similar to conjunctival injections in they do not penetrate into the ocular 
globe, and thus, are subject to clearance by lymphatics. To have a therapeutic effect in the 
eye, the drug deposited in the sub-Tenon’s space must diffuse through the sclera, which is 
a diffusional barrier for larger molecules95, 104.  
1.5 Microneedle Injections to Access Suprachoroidal Space 
1.5.1 Microneedles 
Microneedles are needles with sub-millimeter dimensions. Use of microneedles 
allows reliable access to superficial tissues that may be difficult to target with 
conventional means. There are three general classes of microneedles: (1) hollow 
microneedles enable the injection of drug solutions or suspensions into superficial tissues 
(Figure 1.6, left); (2) coated microneedles can be used to penetrate into superficial tissues 
and deliver drugs that are coated on the microneedle (Figure 1.6, middle); and (3) 
dissolving microneedle are shaped drug-polymer mixtures that can penetrate into 
superficial tissue and release drug upon dissolution of the polymer (Figure 1.6, right)8, 81, 
105-113.  
The main advantage for using microneedles is that they can reliably deliver drug 
into spaces directly below the body’s protective surfaces. In many cases, this can result in 
less pain, ease of administration, and/or increased efficacy and potency8, 105-107, 112, 113. 
The main disadvantage to using microneedles is the limited amount of drug that can be 
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delivered (<1 µg per microneedle with coated and dissolving microneedles, although 
multiple microneedles can be used). A dissolving microneedle patch (similar to (Figure 
1.6, right) for the delivery of flu vaccine is being investigated in an ongoing phase I 
clinical trial (NCT02438423).  
 
Figure 1.6 – Three types of microneedles that can be used to penetrate the body’s superficial barrier (e.g., 
epidermis) and deliver drugs: (Left) hollow microneedles, similar in function to hypodermic needle, allows 
infusion of liquid formulations. (Middle) metal studs with dried drug deposited on surface. Upon 
penetration, the dried drug dissolves. (Right) dissolving polymeric studs with drug interspersed in polymer. 
Upon penetration, the polymer and drug dissolve. No sharps waste after delivery. 
1.6 Suprachoroidal Delivery using Microneedles 
Microneedles have been used to deliver drugs to different regions of the eye. 
Jiang et al. used coated metal microneedles (500-700 µm in length) to deliver small-
molecules, proteins, and DNA into the corneal stroma and sclera109. Sixty-nine percent 
































topical eye drops. Kim et al. was able to deliver bevacizumab using coated microneedles 
to the cornea for the prevention of corneal neovascularization114.  
Figure 1.7 – Hollow Metal Microneedle 
Representative image of ½” hypodermic 
needle (top), 33 G (left), 30 G (middle), 
and 27 G (right) microneedles. 
Figure 1.8 – SCS separation caused by microneedle 
injection. Composite images after saline was injected into 
the suprachoroidal space of an in vivo rabbit eye. Scale bar 
= 500 µm. From Chiang et al.115  
 
Jiang et al. also used a hollow microneedle to deliver drugs into the scleral 
stroma110. Small molecules and particles up to 1.0 µm in diameter were infused into the 
scleral stroma. However, it was only possible to infuse up to 35 µL, despite changing 
injection parameters. Patel et al. found that slightly longer microneedles that fully 
penetrated through the full thickness of the sclera could deposit drug into the 
suprachoroidal space8, 81. Fluid injected into this space would spread circumferentially 
within the suprachoroidal space, bathing the choroid with drug. Though drugs had been 
delivered into this space before using cannulation and/or sclerotomy, 2, 5, 36, 116-118 use of a 
microneedle simplified the procedure. The microneedle could be used to administer drug 
in a fashion similar to an intravitreal injection procedure, which is a regularly performed 
outpatient procedure8, 69. Success with injecting a particle suspension was dependent on 
needle length, needle gauge, infusion pressure, and particle size, and did not depend on 
intraocular pressure81.  
Preclinical animal studies have shown that suprachoroidal space drug delivery has 







results from Phase I/II clinical trials (e.g., NCT01789320) have also been promising7. 
Intraocular pressure immediately after injection increased with increasing injection 
volume, however, IOP returned to baseline within 1 h post-injection17, 120. These IOP 
changes are similar to those observed with intravitreal injections98, 101, 102, 121, 122, and are 
not expected to cause long term ocular damage. Some studies have examined the eye 
histologically. Einmahl et al. noted that suprachoroidal delivery of hyaluronic acid 
resulted in retinal atrophy118, however, no abnormalities were noted by Olsen et al. 
following suprachoroidal delivery of bevacizumab and hyaluronic acid9. Gu et al. 
observed the eye in vivo using indirect ophthalmoscopy and found evidence of choroidal 
dilation and hyperemia that resolved by 24 h120. They were unable to identify parameters 
that affected this finding in a systematic way. The same group found no changes in 
electroretinograms before and after injection, indicating suprachoroidal injection did not 
adversely affect retinal health119, 120.  
Immediately after injection into the suprachoroidal space, higher levels of small 
molecules and macromolecules where found in the choroidal, RPE, and retinal tissues, 
compared with intravitreal injections2, 5, 8, 9, 36, 81, 119, 120, 123-125. Furthermore, anterior 
segment tissues, including lens, aqueous humor, and cornea, were largely spared from 
drug. However, drug was cleared significantly faster with suprachoroidal delivery than 
intravitreal or subconjunctival injections5, 9, 126. The vitreous humor can serve as a depot 
that slowly releases drug to the retina and choroid9, 69, 93, 102. Gu et al. found that the 
suprachoroidal space collapsed to baseline levels within 1 h120. Faster clearance was 
observed with suprachoroidal delivery of bevacizumab, 4 kDa and 40 kDa FITC dextran 
than with intravitreal injections8, 9. Thus, molecular weight (and molecular size) did not 
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affect this trend, although macromolecules were cleared more slowly from the 
suprachoroidal space than small molecules. Controlled release systems consisting of 
triamcinolone in suspension were able to release triamcinolone within the suprachoroidal 
space for 1 mo or more2, 7, 119, 127. Drug properties had an effect on clearance of drug, 
possibly due to drug binding123. 
Clearance from the suprachoroidal space was reasoned to be by choroidal blood 
flow. Olsen et al. performed immunohistochemistry to visualize bevacizumab clearance 
and concluded it occurred through the choroid9. Abarca et al. used recently euthanized 
pigs eyes to study the role of choroidal perfusion in clearance126. The study concluded 
that choroidal perfusion resulted in faster clearance than no perfusion.  
Though fluid injected into the suprachoroidal space distributes circumferentially 
around the eye in the suprachoroidal space, it does not cover the entire space8, 120, 128. 
Similarly, since most ocular diseases do not affect the eye uniformly (e.g., macular 
degeneration affects the macula while sparing the peripheral retina64, 66, 67, retinitis 
pigmentosa affects the peripheral retina while sparing the macula74). Therefore, targeting 
to specific regions of the suprachoroidal space is of interest. Multiple studies have shown 
that increasing injection volume resulted in increasing coverage area. Gu et al. found that 
increasing injection volumes resulted in increasing suprachoroidal space cross-sectional 
area under optical coherence tomography120. Seiler et al. looked at the maximal 
suprachoroidal thickness with different injections volumes116. While the thickness 
resulting from the smallest injection volume tested was different than those from larger 
injection volumes116, there did not appear to be a linear trend, especially with intraocular 
pressure at physiological levels. Kim et al. demonstrated that the density of the 
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microparticles injected could be used to affect the distribution of particle17. Denser 
particles would sink via decreased buoyancy towards the back of the eye if the eye was 
oriented upright with respect to gravity. Seiler et al. studied the distribution of ultrasound 
contrast agent injected into the suprachoroidal space116, but the distribution of these less 
dense microparticles would not be expected to mimic neutral density microparticles. Kim 
et al. also studied the distribution of particles injected with liquid formulations of varying 
viscosities128. They found that formulations containing carboxymethyl cellulose were 
able to localize particles near the site of injection, and that liquid formulations containing 
hyaluronic acid spread to cover up to 100% of the suprachoroidal space.  
1.7 Aims 
This work seeks to further elucidate the pharmacokinetics (specifically, 
distribution and clearance) of particles suspended in liquid formulations injected into the 
suprachoroidal space using a microneedle. Successful completion of these aims will 
enable the rational design of injection techniques, formulations, and controlled release 
systems.  
Our central hypothesis is as follows. The formulation exerts a force that is able to 
separate the weak adhesions between the sclera and the choroid. The thickness and 
circumferential area covered can be modulated by formulation viscosity, as well as the 
injection volume. Particles suspended in the liquid formulation become trapped in the 
suprachoroidal space relative to small molecules, though the formulation viscosity can be 
used to counteract this entrapment. Anatomical barriers physically limit the 
suprachoroidal space, and can prevent particle deposition in regions of the eye. Due to the 
initial high pressure state post-injection, fluid movement is due to convective flow either 
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through leakage sites (e.g., out the injection site or out perivascular drainage routes). 
Once the pressure returns to baseline, fluid and molecules drain via intravascular 
clearance by the choroid. As fluid clears from the suprachoroidal space, the sclera and 
choroid are re-apposed and particles become entrapped in that position until degraded. 
We will test this central hypothesis in three aims, outlined below. 
1.7.1 Aim 1: Identify anatomical barriers that limit spread in the SCS 
Previous studies have demonstrated that the suprachoroidal space is bounded by 
the scleral spur and the optic nerve. These boundaries confine fluid and particles injected 
into the suprachoroidal space. We hypothesize there are additional anatomical barriers 
that limit the circumferential spread of particles in the suprachoroidal space. Possible 
candidates include the vortex veins and the posterior ciliary arteries. Identification of 
anatomical barriers will motivate the development of strategies that enable the entire 
suprachoroidal space to be covered.  
1.7.2 Aim 2: Study the distribution of particles and molecules in the SCS 
Though some studies have described the distribution of particles and molecules 
injected into the suprachoroidal space, they have not attempted to go beyond observation 
or study both in concert. The purpose of this study was to investigate the distribution of 
molecules and particles co-injected into the suprachoroidal space. We further hypothesize 
that particles become entrapped relative to fluids and small molecules that were co-
injected. We will determine the circumferential distribution of fluorescent species via 3D 
cryo-reconstruction, flat mounts of enucleated eyes, and in vivo fundus photography. 
Finally, we hypothesize that the viscosity of the liquid formulation prevents particle 
entrapment, and prolongs transport time. 
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1.7.3 Aim 3: Investigate kinetics of the SCS thickness 
Few studies have looked at the distention of the choroid off the sclera (aka, SCS 
thickness). We set out to determine the effect of injection volume and formulation of a 
microneedle injection into the suprachoroidal space on SCS thickness and closure 
kinetics. We hypothesize that injections of varying volumes of a low viscosity fluid has a 
minor effect on SCS thickness, whereas formulation injected has a major effect on the 
SCS thickness. We will determine the distribution of suprachoroidal space thickness 
using high-frequency ultrasound B-scan and a 3D cryo-reconstruction method. 
1.7.4 Aim 4: Determine the relative contribution of clearance routes and study the 
clearance kinetics of molecules from the SCS 
Previous studies have investigated clearance of select molecules from the 
suprachoroidal space. The purpose of this aim is to correlate collapse and clearance with 
distinct events so that we can better understand these kinetics. We hypothesize that there 
are two phases of clearance, the first is driven by high pressure, and the second phase is 
driven by concentration gradient. We will determine the collapse rate of the 
suprachoroidal space after injection with different liquid formulations using a high-
frequency ultrasound B-scan probe in an in vivo rabbit model. We will also investigate 
suprachoroidal space clearance of a wider range of molecular weights. Finally, we will 
also determine the route of clearance from the suprachoroidal space. These results will 





1.7.5 Aim 5: Develop controlled-release brimonidine microspheres in the SCS for 
the treatment of glaucoma 
Because glaucoma patients have a low compliance (~50%) in administering eye 
drops, there is a clinical need for a sustained-release drug delivery system for glaucoma. 
We hypothesize that a sustained-release polymeric microsphere drug delivery system 
injected into the anterior suprachoroidal (aka, supraciliary) space will produce a 
therapeutic effect for 1+ mo. Previous studies have shown that brimonidine lowers 
intraocular pressure in the albino New Zealand White rabbit. This will be the first 
demonstration that a controlled release system injected into the suprachoroidal space can 




2 CIRCUMFERENTIAL FLOW OF PARTICLES IN THE 
SUPRACHOROIDAL SPACE IS IMPEDED BY THE 
POSTERIOR CILIARY ARTERIES 
This work has been published in Experimental Eye Research129. 
2.1 Summary 
Microneedle injection into the suprachoroidal space (SCS) enables targeted drug 
delivery for treatment of posterior segment diseases (e.g., posterior uveitis). This study 
sought to identify and characterize anatomical barriers to circumferential spread of 
particles in the SCS of rabbit and human cadaver eyes. These barriers could make 
targeting specific regions within the SCS challenging. A hollow microneedle (33-gauge, 
750 µm long) was used to inject fluorescent particles into albino New Zealand White 
rabbit eyes ex vivo at six different positions around the limbus and a limited number of 
conditions in vivo. SCS injections were also performed in human cadaver eyes 8 mm and 
2 mm from the optic nerve (ON). Eyes were dissected and particle distribution was 
quantified. In rabbit eyes, injections made in the superior or inferior hemispheres (even 
when injected temporally immediately adjacent to the long posterior ciliary artery 
(LPCA)) did not significantly cross into the other hemisphere, apparently due to a barrier 
formed by the LPCA. The vortex veins had a minor effect on particle deposition, limited 
to only around the vortex vein root. In human eyes, the short posterior ciliary arteries 
(SPCAs) prevented circumferential spread towards the macula and ON. In conclusion, 
the rabbit LPCA and the human SPCA were anatomical barriers to particle spread within 
the SCS. Therefore, design of drug delivery protocols targeting the SCS need to account 
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for barriers formed by anatomical structures in order for injected drug to reach target 
tissues. 
2.2 Introduction 
Suprachoroidal delivery is being explored as a targeted ophthalmic drug delivery 
technique to treat posterior segment diseases that affect choroidal, retinal pigment 
epithelial, and/or retinal tissues 2, 5, 8, 81, 118, 119, 123, 125, 127, 130. The suprachoroidal space 
(SCS), which is a potential space between the sclera and choroid, is an attractive drug 
delivery site because it is directly adjacent to the diseased tissue in many posterior 
segment diseases, including age-related macular degeneration (AMD) and posterior 
uveitis 64, 97, 127. SCS delivery results in increased drug concentrations and bioavailability 
at the choroid while limiting drug concentrations elsewhere in the ocular globe compared 
with intravitreal injections 5, 8, 9, 81, 123.  
The SCS can be accessed with a hollow microneedle that has a length similar to 
the thickness of sclera 8, 81. The microneedle is designed to penetrate the sclera and 
conjunctiva (but not the chorioretina) and inject material that can flow circumferentially 
within the SCS, thus bathing the choroid in drug. The safety and tolerability of 
microneedle injections into the SCS has been studied in an open-label Phase I/II clinical 
trial (NCT01789320) where triamcinolone acetonide suspension was injected into the 
SCS to treat noninfectious posterior uveitis 7. In this clinical trial and supporting pre-
clinical studies, the microneedle injection procedure was performed in a manner similar 
to an intravitreal injection, except it used a much shorter needle and therefore injected 
into the SCS rather than the vitreous; the procedure was well tolerated in animal and 
human subjects 7, 8, 81.  
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Since the chorioretina is typically not uniformly diseased (e.g., AMD affects the 
macula while sparing the peripheral retina), targeting drugs to specific regions of the 
chorioretina (i.e., to optimally treat the diseased region of the chorioretina) is of 
importance. Thus, understanding and controlling the movement of drugs within the SCS 
is needed to deliver drugs to the diseased tissue using the SCS as a conduit. The purpose 
of this work is, therefore, to study the movement of particles injected into the SCS and, 
more specifically, to identify barriers that impede circumferential flow in the SCS, which 
might influence the ability to target specific regions of the SCS.  
Previous experiments show that fluid injected into SCS is limited by the scleral 
spur anteriorly and the optic nerve (ON) posteriorly 8, 17, 81. Anatomically, the sclera and 
the choroid are tightly bound at these two sites, as they delineate the physical extent of 
the SCS. We hypothesize that there are additional barriers that prevent circumferential 
flow in the SCS following microneedle injection. Other likely candidates include the 
posterior ciliary arteries and the vortex veins since the sclera and choroid are bound at 
these points 118. Although a previous study reported no anatomical barriers to spread of 
micro-bubbles within the SCS 116, in that study injections were carried out at the superior 
(12 o’clock) position near the limbus, which may not optimally assess the existence of 
barriers throughout the eye, as shown in the present study. 
2.3 Methods 
2.3.1 Microneedle injection and tissue processing 
Enucleated albino New Zealand White rabbit eyes (shipped overnight from Pel-
Freeze, Rogers, AR) were stored at -80°C upon arrival until use in ex vivo rabbit 
experiments. Frozen eyes were used to facilitate the testing of many parameters, a subset 
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of which were tested in an in vivo rabbit model. In all ex vivo eyes, no particles were 
detected in the vitreous, which suggests that the choroid had not degraded. When needed, 
frozen eyes were rapidly defrosted in a room-temperature water bath for ~30 min, and 
muscle, conjunctiva, and fascia were dissected from the ocular globe. The superior prime 
meridian of the eye (i.e., 12 o’clock) and the injection site were marked with a shallow 
cut in the adjacent cornea using a scalpel dipped in blue or red food coloring 
(McCormick, Hunt Valley, MD), respectively. 
All injections were performed at room temperature (~23°C). SCS injections were 
accomplished using a 33-gauge hollow microneedle with a length of ~750 µm (kindly 
provided by Clearside Biomedical, Alpharetta, GA) and a 250 µL glass chromatography 
syringe (National Scientific, Rockwood, TN). Injections were performed 3 mm posterior 
to the limbus, and occurred in 3 s. The fluid injected was 50 µL of 0.5% (w/v) 200 nm 
diameter red-fluorescent microspheres (580 nm excitation and 605 nm emission 
wavelength; FluoSpheres, Life Technologies, Carlsbad, CA) in Hank’s Balanced Salt 
Solution (HBSS, Mediatech, Manassas, VA), unless otherwise specified. After waiting 1 
min, the needle was withdrawn from sclera.  
To arrest fluid flow in SCS, each eye was rapidly frozen 1 min after injection by 
submersion in 100% ethanol chilled over dry ice. Eight approximately equally-spaced, 
full-thickness cuts were made in the sclera from the posterior pole to limbus using a 
scalpel. This yielded eight scleral flaps (a.k.a., “petals”) approximately equal in area. One 
cut was aligned with the injection site and one with the 12 o’clock position. The scleral 
flaps were splayed open to expose the frozen vitreous humor, lens and aqueous humor, 
which were removed with forceps and collected to verify no particles were in the 
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vitreous. Three replicates were performed in each condition unless otherwise stated. The 
following experiments were performed. 
2.3.1.1 Effect of injection site on spread in the SCS of rabbits 
We performed injections at six positions around the limbus of ex vivo rabbit eyes 
(Figure 2.1A): at the superior (12 o’clock) and inferior (6 o’clock) prime meridians; 
infratemporal (7.5 o’clock) and supratemporal (10.5 o’clock) locations; and temporally 
directly superior and inferior to the 90° meridian (9 o’clock). Injections were performed 
in the temporal hemisphere because, in humans, the macula is temporal to the ON, which 
we knew limited flow from previous studies 8, 17, 81. 
2.3.1.2 Effect of IOP on spread in the SCS of rabbits 
To change intraocular pressure (IOP), the eye was cannulated through the ON 
using a 25-gauge needle connected to a water column of predetermined height 17. We 
tested three pressures: unpressurized, 10-12 mmHg (normotensive IOP in rabbits), and 
22-25 mmHg (hypertensive IOP in rabbits). After confirming IOP using a rebound 
tonometer (iCare Tonovet, Helsinki, Finland), we performed an injection at either the 
temporal position (3 o’clock; directly above the temporal LPCA) or the superior position 
(12 o’clock) of that eye. 
2.3.1.3 Effect of injection volume on spread in the SCS of rabbits 
To determine if injection volume would change the flow patterns following a 
microneedle injection, injections of 50, 100, and 200 µL were performed. Before each 
experiment, the eye was pressurized to 10-12 mmHg. Injections were performed either at 
 40 
 
the superior position (12 o’clock) or the temporal position (9 o’clock) directly superior to 
the LPCA. 
2.3.1.4 Effect of particle size on spread in the SCS of rabbits 
To study the effect of particle size on spread, we injected one of three mixtures: 
0.5% (w/v) 200 nm red fluorescent particles, 0.5% (w/v) 20 nm red fluorescent particles, 
or 0.025% sulforhodamine B dye (559 Da; 565 nm excitation and 585 nm emission 
wavelength). The excitation/emission spectra of these three mixtures were comparable. 
The eyes were pressurized to 10-12 mmHg. Fifty microliters of one of the three 
formulations were injected at the superior position (12 o’clock) or the temporal position 
(9 o’clock), directly superior to the LPCA. 
2.3.1.5 Effect of bevel orientation on spread in the SCS of rabbits 
To study the effect of bevel orientation on spread, injections were performed at 
the superior position (12 o’clock) with the bevel either directed temporally or nasally. 
Before each experiment, the eye was pressurized to 10-12 mmHg.  
2.3.2 In vivo injection into the SCS of rabbits 
All in vivo experiments were carried out in albino New Zealand White rabbits 
(Charles River, Wilmington, MA) and were approved by the Georgia Institute of 
Technology Institutional Animal Care and Use Committee. Practices complied with the 
ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Both eyes 
were used in this study, since the growing body of evidence on SCS injections (pre-
clinical animal and human clinical data) indicates that SCS injections are well-tolerated 
and there have been no reports on vision loss associated with SCS injection.  
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Animals (N=3 per group) were anesthetized with a subcutaneous injection of 
ketamine and xylazine. A 50 µL injection of 200 nm fluorescent particles in HBSS was 
made either in the supratemporal position (10.5 o’clock) or in the temporal position (9 
o’clock), directly superior to the LPCA. A superior injection was infeasible as that would 
have required puncturing through the superior rectus muscle. In some cases, green 
fluorescent fundus images of the eye after suprachoroidal injection were obtained with a 
RetCam II with fluorescein angiography attachment (Clarity Medical Systems, 
Pleasanton, CA). In this case, a 50 µL injection of 200 nm green fluorescent particles was 
made in the supranasal quadrant. Animals were euthanized with an injection of 
pentobarbital through the ear vein after two days. The eyes were enucleated and 
processed as described above.  
2.3.3 Dissection of ocular globe of rabbits and humans  
To better visualize attachments between choroid and sclera, we dissected ex vivo 
rabbit eyes and human cadaveric posterior poles (Georgia Eye Bank, Atlanta, GA) under 
a stereoscope (Olympus SZX16, Tokyo, Japan) with a camera (Olympus DP71). The 
human donors had no history of ocular disease. 
2.3.4 Effect of injection site on spread in the SCS of cadaver eyes 
Based on findings from the dissections, we hypothesized that the short posterior 
ciliary arteries (SPCA) would impede particle spread. We tested this hypothesis by 
injecting particles within and without the SPCA ring. Although this was a different 
injection site than those used with previous injections (in this and previous studies) and 
also not clinically relevant, injections made at these positions would adequately test the 
barrier function of the SPCAs. 
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Human cadaveric ocular globes (Georgia Eye Bank, Atlanta, GA) with no history 
of posterior segment disease were obtained 1-3 days after death. We performed injections 
at two positions: (a) 2 mm from the ON and (b) 8 mm from the ON (N = 4 per group), 
which were on either side of the SPCAs 131. To process the eye, the cornea was removed 
and the eyes were cut with a scalpel through all the ocular tissue, starting anteriorly and 
leaving the ON and surrounding tissue untouched. Since the eyes were pigmented, the 
retina and choroid were removed prior to imaging. Other procedures are described above. 
2.3.5 Image acquisition and analysis, and statistics 
We took two photographs of each mounted eye using a Canon 60d dSLR digital 
camera (Canon, Melville, NY). Camera settings were held constant at an aperture of 1/2.8 
and shutter speed of 1/15 s. All images were captured in the same windowless room with 
the same light sources. The first image was taken with room light and no filter; the 
second image was taken with green light (Bluewind Multicolor RGB, HitLights, Baton 
Rouge, LA) and an optical bandpass filter (610 ± 10 nm; Edmunds Optics, Barrington, 
NJ) mounted on the camera. This lighting and filter were chosen to match the 
fluorescence properties of the fluorescent particles used. 
After the images were acquired, the red channel of the fluorescent images was 
thresholded to capture the coverage of the fluorescent particles (ImageJ, National 
Institutes of Health, Bethesda, MD). The measurement tool in ImageJ was then used to 
find, for each petal: (a) the area of each petal, (b) the average intensity and (c) standard 
deviation, and (d) the percentage of the area of each petal that was above the threshold. 
Alternatively, we used the measurement tool in ImageJ to find the percentage of 
thresholded area that was superior and inferior to the LPCAs. 
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Further analysis was performed using Matlab (Mathworks, Natick, MA) and 
Prism (Graphpad, La Jolla, CA). Values are presented as the mean ± standard error of the 
mean (SEM), unless otherwise specified. Unpaired Student’s t-test and two-way ANOVA 
analysis were performed to determine statistical significance (α = 0.05).  
2.4 Results 
2.4.1 Effect of injection site on spread in SCS of rabbits 
After injecting particles at different positions around the limbus, we identified the 
LPCA as a barrier to circumferential spread of particles in the SCS of rabbit eyes ex vivo 
(Figure 2.1). Injections at the superior (Figure 2.1B), supratemporal (Figure 2.1C), 
infratemporal (Figure 2.1F), and inferior (Figure 2.1G) positions resulted in similar 
particle distributions, where the spatial distributions of particles were roughly normal 
(i.e., not skewed) (see Figure 2.1, right column for quantification of particle per petal). 
Furthermore, the spatial distribution of particles was centered near the injection site. 
Vortex veins, typically located in the supratemporal and infratemporal quadrants, did not 





Figure 2.1 – SCS injections at different injection sites, shown in the right eyes ex vivo.  [A] Representative 
images showing spread of fluorescent particles in eyes at the tested injection sites. Eyes are all positioned 
in the same anatomical orientation – superior is on top and temporal is right. Injections were performed at 
the superior (12 o’clock, b); supratemporal (10.5 o’clock, b); temporal, directly superior (d) and inferior 
(e) to the long posterior ciliary artery (9 o’clock); infratemporal (7.5 o’clock, f); and inferior (6 o’clock, g) 
positions. [B-G] Quantification of the average concentration of particles in each scleral flap for the tested 
injection sites. Distribution of particles is shown after 50 µl of HBSS containing 200-nm particles was 
injected into SCS at different sites. Injection site indicated by white arrow in representative images, and 
hollow arrow in graphs. Sup. = superior (12 o’clock); Temp. = temporal (9 o’clock); Inf. = inferior (6 
o’clock); Nas. = nasal (3 o’clock). Since the eye is spherical, leftmost and rightmost bars are adjacent.  
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In contrast, injections at the temporal (9 o’clock) position (Figure 2.1D and E) 
had markedly different patterns of spread compared with the others (p < 0.0001, 2-way 
ANOVA). In particular, >95% of particles injected on one side of the 90° meridian did 
not cross to the other side (i.e., injection superior to the LCPA resulted in few particles in 
the inferior hemisphere, and vice versa). This resulted in a skewed distribution with the 
tail directed away from the 90° meridian (Figure 2.1 D and E, right column), which 
indicates an anatomical barrier that impedes flow near the 90° meridian.  
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Figure 2.2 – Percentage of particles above versus below LPCA. Data from images like those in Figure 2.1 
were re-analyzed to find the percentage of SCS area with fluorescent signal above threshold, indicating 
presence of injected particles. Injections were carried out in right eyes ex vivo using 50 µl of HBSS 
containing 200-nm particles. Data show mean±SEM from n=3 replicates.  
We reanalyzed the eyes presented in Figure 1 to further examine barrier function 
at the site of LPCA. We calculated percentage of area with fluorescent signal exceeding 
background threshold levels above and below LPCA for each injection site (Figure 2.2) 
and found they were significantly different (p = 0.0009, 2-way ANOVA), despite their 
close proximity. For each of the three injection sites above LPCA (i.e., Figure 2.2 B, C 
and D), 96±3% (mean±SD) of thresholded area was in the superior hemisphere of the 
eye. Likewise, in each of the three injections below LPCA (i.e., Figure 2.2 E, F and G), 
98+3% (mean±SD) of thresholded area was found in the inferior hemisphere. From these 
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data, we conclude that barriers at the site of LPCA impeded circumferential flow into the 
opposite hemisphere.  
2.4.2 Effect of IOP, injection volume, and particle size on spread in SCS 
The effects of IOP, injection volume and particle size on spread in the SCS were 
evaluated. We found no statistical difference in particle spread at the three different IOPs 
tested (unpressurized, normotensive IOP, and hypertensive IOP) (Figure 2.3A, p=0.85, 2-
way ANOVA).  
Varying injection volume did not result in a statistically significant difference in 
particle spread (Figure 2.3B, p = 0.59, 2-way ANOVA). It is important to note that the 
eye was able to accommodate the entire 200 µL volume when injected at the 12 o’clock 
position but not when the injection occurred temporally above the LPCA (i.e., there was 
leakage out the injection site, supporting the hypothesis that the LPCA formed a barrier 
to flow). Furthermore, particles injected at 12 o’clock had entirely covered the superior 
hemisphere and could be found partially in the inferior hemisphere. On the other hand, 
the 200 µL injection above the LPCA had a smaller coverage area compared to the 
injection at 12 o’clock. The presence of LPCA might have decreased the expandability of 
SCS enough so that 200 µL could not be injected temporally.  
No differences in particle spread were detected when particle size was varied 
(Figure 2.3C, p=0.28, 2-way ANOVA) with >90% of delivered compounds retained in 
the superior hemisphere. We conclude that particle size did not significantly affect 
particle spread circumferentially past LPCA. Moreover, since very little sulforhodamine 
B was found in the inferior hemisphere, LPCA appears to physically prevent fluid flow 
into the opposite hemisphere and did not just sieve particles. Indeed Gu et al. noted that 
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saline injected into the suprachoroidal space of guinea pigs did not cross the “horizontal 
midline” and was not found in the inferior hemisphere 120. 
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Figure 2.3 – Effect of IOP (A), injection volume (B), and particle size (C) on LPCA barrier function. The 
fraction of eyes in which particles were detected inferior to LPCA is shown above each tested condition. 
Data show mean±SEM from n=3-5 replicates. (A) Injections were carried out in left eyes ex vivo using 50 
µl of HBSS containing 200-nm particles. The percentage of SCS area with fluorescent signal above 
threshold is shown in unpressurized eyes, eyes at physiological IOP (10 - 12 mmHg), and eyes with 
hypertensive IOP (22 – 25 mmHg). (B) Injections were carried out in right eyes ex vivo using 50, 100 or 
200 µl of HBSS containing 200-nm particles. Pound sign (#) indicates that significant leakage out the 
injection site occurred. (C) Injections were carried out in right eyes ex vivo using 50 µl of HBSS containing 




2.4.3 Effect of bevel orientation on spread in SCS 
When the bevel was directed either temporally or nasally during injection, particle 
spread was indistinguishable (data not shown). This result was expected, since the needle 
length, including bevel, was designed to penetrate only conjunctiva and sclera.  
2.4.4 In vivo injection into SCS  
Guided by findings in the ex vivo eye, we performed injections in the rabbit eye in 
vivo at the supratemporal position or temporal position above LPCA, and found no 
statistical difference between these injection sites (p = 0.71, 2-way ANOVA). The 
supratemporal position was chosen instead of the superior position (as in the ex vivo eyes) 
because a superior injection would require puncturing the superior rectus muscle. In eyes 
injected supratemporally, 87±13% (mean±SD) of thresholded area was above LPCA and 
in eyes injected temporally, 92±12% (mean±SD) of thresholded area was above LPCA 
(Figure 2.4A-F). One of the eyes injected temporally had particles present in the inferior 
hemisphere (Figure 2.4F).  
We next visualized the rabbit fundus (Figure 2.4G) and imaged spread of green-
fluorescent particles (Figure 2.4H) after supranasal injection in the rabbit eye in vivo 
using an ophthalmic digital imaging system. Since these rabbits were albino, the choroid 
was readily visible, with the inner retinal vessels shadowing the choroid. The LPCA 
could be seen (Figure 2.4G, blue arrowheads) after penetrating through sclera anteriorly 
(rightmost arrowhead) and as it traversed deep to sclera, sending small branches through 
sclera. When visualized with fluorescein angiography, the injected green fluorescent 
particles were clearly seen in SCS. Fluorescence was shadowed by the inner retinal and 
choroidal vessels, confirming particles’ localization in SCS between choroid and sclera. 
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The microneedle injection (Figure 2.4H, white arrowhead) occurred in the supranasal 
quadrant and spread until flow was impeded by LPCA and its branches (blue arrowheads) 
anteriorly, as indicated by bright fluorescence superior to LPCA and dimmer 
fluorescence elsewhere. When we imaged the superior region of the eye, the area 
immediately adjacent (within 0.5 mm) to the vortex vein was devoid of fluorescent 
particles (Figure 2.4I). We hypothesize that vessels feeding into the vortex vein were 
sufficiently dense to prevent particle deposition or, alternatively, particles deposited were 
efficiently cleared. Thus, the vortex veins had a minor effect on particle deposition that 
was visible on fundus exam but not flat mounts.  
 
Figure 2.4 – Distribution of particles in SCS after injection into rabbit eyes in vivo.  (A-F) The path of 
LPCA (dotted line) and injection site (white arrow) are shown, based on examination of tissue using 
brightfield optics (not shown). Supratemporal (A, B, C) and temporal, above the LPCA, (D, E, F) injections 
are shown. One eye (F) had some particles present in the inferior hemisphere presumably by flowing 
anteriorly bypassing the LPCA. Temporal injections were carried out in left (D, E) and right (F) eyes in 
vivo using 50 µl of HBSS containing 200-nm particles. RetCam image after supranasal injection 
illuminated with white light (G) and fluorescein angiography attachment (H and I). Particles were not 
found near the root of the vortex vein (I). White arrow = injection site; ON = optic nerve; VS = visual 
streak; blue arrowheads = LPCA with its branches. 
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2.4.5 Dissections of ex vivo rabbit eyes and human eyes 
Previous studies have reported that branches of the LPCA pass through sclera via 
multiple tightly packed perforations 132, 133. To confirm this anatomy in this study, we 
dissected ex vivo rabbit eyes to better visualize the path of LPCA as it penetrated through 
sclera. During dissection, choroid easily separated off sclera for most of the globe, 
consistent with a potential space between these tissues, but was strongly attached to 
sclera where LPCA penetrated through sclera near and anterior to the equator (Figure 
2.5). The vortex vein did not tightly adhere sclera and choroid together, possibly due to 
tissue processing. We hypothesize that multiple sites of adhesion associated with 
penetration of branches of LPCA across SCS in the rabbit eye are responsible for LPCA’s 
barrier to circumferential flow.  
 
Figure 2.5 – Image of rabbit sclera showing LPCA perforations through sclera. The temporal LPCA is a 
branch of the ophthalmic artery that penetrates through sclera near the equator to supply choroid, ciliary 
body, and iris (Gray, 1918). In the rabbit, the LPCA branches before penetrating through sclera; these 
LPCA branches appeared to strongly adhere choroid to sclera during dissection. Dashed lines indicate the 
path of LPCA. Arrows indicate sites where LPCA branches perforated sclera. The representative image 




The literature indicates that in human eyes, the LPCA anatomy is different from 
rabbit eyes 132. Dissection in human cadaver eyes demonstrated that the LPCA penetrated 
through sclera more posteriorly (relative to the equator) than in the rabbit eye, and then 
travelled within SCS for at least 5 mm before anastomosing with the circulus arteriosus 
(Figure 2.6A). Notably, the two LPCAs penetrated into SCS at just one location and did 
not have multiple branches penetrating into SCS, as seen in the rabbit eye. It is possible 
that the presence of a section of LPCA running within SCS may be able to facilitate, 
rather than impede, distention of SCS during microneedle injection in humans, especially 
anterior to the equator.  
 
Figure 2.6 – Images of the posterior pole of a representative human cadaver eye showing LPCA and 
SPCAs.  (A) Choroid was lifted off sclera and folded over to show the LPCA, which penetrated more 
posteriorly than in the rabbit and traveled within SCS for at least 5 mm before anastomosing with the 
ciliary body. (B) Retina/choroid was removed to show SPCAs, which are vessels originating from the 
ophthalmic artery that penetrate sclera to form a ring around the optic nerve and macula (Gray, 1918). 
Images were taken with a brightfield stereoscope in a representative human cadaver eye after dissection. 
No SCS injection was performed. 
However, we found that the choroid was tightly attached to the sclera in a region 
surrounding the ON and roughly corresponding to sites of the SPCA penetration into the 
eye. The six-to-twelve SPCAs found in the human eyes formed an ellipsoid around the 
ON with a major radius of ~5 mm and minor radius of ~1 mm (Figure 6B), which is 
consistent with previous findings 131. Since retina had peeled off choroid, we were unable 
to locate the macula in relation to SPCA. However, it is likely that the macula was within 
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the ellipsoid demarcated by SPCAs 134. This suggests that in human eyes, flow within 
SCS may also be impeded, but not anteriorly by LPCAs, as seen in the rabbit eye, but 
more posteriorly by SPCAs in the human eye. This might affect the ability of an injection 
in the SCS to target the macula due to a possible barrier formed by the SPCAs.  
2.4.6 Microneedle injection into human cadaver eyes 
To test the hypothesis that the SPCAs impede flow in the human eye, we 
performed injections inside the SPCA ring (2 mm from the ON, Figure 2.7A) and outside 
the SPCA ring (8 mm from the ON, Figure 2.7B) in human cadaver eyes. The SPCAs 
could be found between the chosen injection sites at ~3 mm from the ON. Although these 
injection sites were not clinically relevant, they allowed us to assess the barrier function 
of the SPCAs; we reasoned that if the SPCAs formed a barrier when an injection was 
made immediately adjacent to the vessels, then an injection made near the limbus (i.e., 
>20 mm from the ON) would experience similarly impeded flow, provided particles 
could flow that far.  
The particle distributions of these conditions were statistically different (p = 
0.0035, 2-way ANOVA, Figure 2.7C). When injection occurred within the SPCA ring, 
66±8% (mean±SD) of particles were within 5 mm of the ON. When injection occurred 
outside the SPCA ring, 18 ± 7% (mean ± SD) of particles were found within 5 mm of the 
ON. These data indicated that the SPCAs provided a barrier to circumferential spread 




Figure 2.7 – Images of human cadaver eye after microneedle injection (A) 2 mm from the optic nerve (ON), 
and (B) 8 mm from the ON. Solid gray circle denotes location of ON, dashed line denotes location of 
SPCAs and white arrow denotes injection location. (C) Quantification of images following injection within 
the SPCA ring and without the SPCA ring. ** indicates p<0.005. 
2.5 Discussion 
The SCS is an attractive site of drug delivery targeted to the chorioretina 2, 5, 8, 81, 
118, 119, 123, 125, 127, 130. However, targeting within the SCS is important as well, since sites of 
disease are often localized to specific regions of the chorioretina, such as localization of 
AMD to the macula and localization of tumors at their sites of growth. This study 
addressed the possible existence of barriers to flow in the SCS due to its anatomy, more 
specifically due to sites where the posterior ciliary arteries, but not the vortex vein, cross 
the SCS and thereby limit its distention. This study showed that sites where the LPCA 
crosses the SCS in the rabbit eye and where the SCPA crosses the SCS in the human eye 
were associated with limited movement of particles in the SCS. The vortex veins had a 
minor effect on particle deposition, limited only to near the vortex vein root. In the rabbit 
eye, the LPCA barrier limited flow of particles between the upper and lower hemispheres 
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of the eye, which was similar to distribution of saline seen with guinea pigs 120. In the 
human eye, the SPCA barrier limited flow of particles posteriorly to the macula and ON.  
We believe that previous studies have not reported this barrier because they were 
not designed to look for it and, in some cases, used animal models with different anatomy 
8, 116. One studies mentions injected fluid not crossing the midline but does not offer an 
explanation as to why this is 120 . Other studies have shown that formulations designed to 
keep SCS open after injection allow particles to redistribute within SCS and cover both 
hemispheres of the eye 128, although re-analysis of particle spread indicates lower particle 
concentration overlaying LPCAs compared with elsewhere (data not shown).  
Vortex veins, another likely candidate that may have had barrier function in the 
SCS, did not have a large effect on particle distribution. Any effect by the vortex vein on 
particles spread was not apparent when viewed in flat mount, but was visible when 
imaged fundoscopically in vivo. We noted that few particles were deposited within 0.5 
mm of the vortex vein upon funduscopic exam. It is important to note that each vortex 
vein penetrates through sclera as a single large vessel, which does not form a large region 
of physical attachment between sclera and choroid 41. We posit that morphological 
differences between how branches of LPCAs penetrate sclera at multiple locations, 
whereas each vortex vein penetrates at just a single vessel, govern the ability of vessels to 
block circumferential flow.  
Results from our ex vivo studies agreed with in vivo rabbit studies, suggesting that 
particle distribution was insensitive to vital processes, such as blood flow, for the 
injection formulation tested (i.e., particles suspended in HBSS). Previous studies using 
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particles suspended in HBSS have indicated that particle spread occurs at the time of 
injection, after which the particles do not move 6, 8, 17, 81, 128.  
Dissection of the choroid from the sclera demonstrated that the choroid is strongly 
attached to the sclera where multiple branches of the LPCA penetrate through sclera to 
anastomose with the choroid. These branches of the LPCA may act like staples to secure 
sclera and choroid together, thus physically impeding fluid flow. We hypothesize that it 
is possible to bypass this barrier by (i) flowing anteriorly or posteriorly around 
attachment sites, (ii) distending the choroid between the vessels, or (iii) tearing the small 
vessels. Further studies are needed to test this hypothesis.  
Human eye dissection was consistent with prior studies 44, 131, 133, which indicated 
that the LPCA pierces the sclera more posteriorly and does not tightly adhere the sclera to 
the choroid, as compared to rabbit eyes. In contrast, SPCAs do tightly adhere choroid to 
sclera in a ring around the ON. This ring likely encompasses the macula, which may 
make SCS delivery to the macula and ON more difficult in humans. Consistent with these 
findings, Olsen et al. found that there were more and “stronger connections” between 
sclera and choroid in the macular region of porcine eyes 2, which is where the SPCAs 
penetrate through the sclera 135. 
Limitations of this study include the use of ex vivo rabbit eyes, inability to 
determine kinetics of particle movement, lack of blood flow in ex vivo experiments, and 
inability to study temporal effects on LPCA’s barrier function. Furthermore, the 
conclusion of anatomy affecting particle spread (expected to be driven by convective 
flow) cannot be applied to distribution of small molecules (expected to be driven by both 
convection and diffusion). These barriers may not affect drugs diffusing within the SCS 
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since they are on different length scales. Factors, such as physiochemical properties and 
clearance, are more likely to affect drug distribution 9, 123. More comprehensive testing of 
anatomical barriers present in the SCS of human eyes is warranted. 
In conclusion, we found that circumferential fluid flow in the SCS was impeded 
by the LPCA in rabbit eyes ex vivo and in vivo. It appeared that multiple tightly clustered 
vessels perforating through the sclera (such as those seen with branches of the LPCA in 
New Zealand White rabbits) result in strong attachment between sclera and choroid, and 
that these strong attachments form a physical barrier to circumferential flow. On the other 
hand, singular large vessels (e.g., vortex veins) had a minor effect on impeding 
circumferential particle spread. Human cadaver eyes exhibited a similar pattern of tightly 
clustered vascular perforations at the SPCAs near the ON, which impeded particle spread 
near the ON. This may make specifically targeting the SCS overlaying the macula and 
ON more difficult. Development of drug delivery and other applications requiring fluid 
flow in the SCS should take these anatomical barriers into account and either accept 
limitations they may impose or develop strategies to overcome or circumvent them. 
  
 
3 DISTRIBUTION OF PARTICLES AND MOLECULES IN THE 
SUPRACHOROIDAL SPACE AFTER MICRONEEDLE 
INJECTION  
3.1 Summary 
The purpose of this study was to determine the effect of injection volume, 
formulation composition, and time on the circumferential spread of particles and 
molecules in the suprachoroidal space (SCS) after microneedle injection into New 
Zealand White rabbit eyes ex vivo and in vivo.  
Microneedle injections of 25 to 150 µL of Hank’s Balanced Salt Solution (HBSS) 
containing 0.2 µm particles and fluorescein were performed in rabbit eyes ex vivo. Spread 
of the compounds within the SCS was visualized via flat mount and 3D cryo-
reconstruction. In the living rabbit, red-fluorescent microparticles and the following 
molecules were co-injected into the SCS: fluorescein, fluorescein isothiocyanate (FITC)-
labeled Discovisc, and FITC-labeled carboxymethyl cellulose (CMC) in HBSS. 
Microparticles of different diameters (0.02 – 2 µm) were also injected in HBSS. 
Fluorescent fundus images were acquired over time to determine area of particle and 
molecule spread, as well as their co-localization. 
We found that increasing injection volume increased area of particle and 
fluorescein spread in the SCS ex vivo. Particles occupied a smaller area than fluorescein, 
suggesting additional barriers to particle flow. In the living rabbit, injection of particles in 
viscous polymeric formulations led to initial localization of particles near the site of 
injection, followed by spreading of polymer and particles together until the formulation 
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polymers were cleared after 2 – 3 weeks for polymers that did not crosslink to form a gel. 
There was no significant effect of particle size on spreading in the SCS.  
We conclude that (i) the area of particle spread generally increased with 
increasing injection volume and was unaffected by particle size, (ii) particles suspended 
in low-viscosity liquid formulations were entrapped in the SCS after injection, whereas 
molecules were not, (iii) increased formulation viscosity delayed particle entrapment in 
the SCS, allowing movement subsequent to injection and (iv) when using polymeric 
formulations that crosslink, particles can be entrapped within the formulation at the site 
of injection.  
3.2 Introduction 
Ophthalmic drug delivery into the potential space between the sclera and the 
choroid (aka. suprachoroidal space or SCS), is a new drug delivery technique actively 
under pre-clinical and clinical investigation2, 7, 8, 81, 118, 119, 127, 136. Unlike traditional 
ophthalmic drug delivery techniques, such as topical eye drops and intravitreal injections, 
SCS injection enables targeted delivery to the choroid, retinal pigment epithelium, and 
retina with high bioavailiability8, 9, 81, 117-119, 123, 126, 130. Additional advantages of SCS 
delivery include increased bioavailability, dose sparing, and avoiding the visual axis. A 
hollow-bore needle with a length of ~1 mm or less (aka. microneedle) can be used to 
reliably access the SCS without piercing the chorioretina8, 81. Performing such an 
injection is similar to an intravitreal injection and has been performed in the outpatient 
clinic setting8, 81, 109. Ongoing clinical trials are assessing the safety and efficacy of 
microneedle injections for indications such as posterior noninfectious uveitis 
(NCT01789320 and NCT02595398)7.  
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When administering drugs via the SCS, it is important to control the area over 
which the drug formulations spread within the SCS. This targeting within the SCS may 
be used to treat diseased tissue while sparing non-diseased tissue. In some cases, it is 
desirable to have drug distributed over a large area of the SCS to broadly deliver drug to 
the chorioretina (e.g., to treat posterior uveitis7). In other cases, it may be desirable to 
localize the drug near the site of injection (e.g., to treat glaucoma)6, 115.  
Previous studies have used the two- dimensional (2D) circumferential spread of 
particles injected into the SCS as the primary metric of distribution6, 8, 17, 81, 128. Though 
many studies have investigated the distribution of particles8, 17, 81, 119, 128 and molecules5, 6, 
8, 9, 124 independently, to our knowledge, no study has examined the distribution of 
particles and molecules injected into the SCS simultaneously, or imaged the distribution 
of polymeric formulation excipients in the SCS. Because of the large differences in 
diffusivity between particles and molecules, distribution of particles and molecules are 
expected to be different.  
The purpose of this work was to investigate particle and molecule distribution 
following microneedle injection into the rabbit SCS. We hypothesize that (i) the area of 
particle spread generally increases with increasing injection volume, (ii) particles 
suspended in low-viscosity liquid formulations are entrapped in the SCS after injection, 
whereas molecules are not, (iii) increased formulation viscosity delays particle 
entrapment in the SCS, allowing movement subsequent to injection and (iv) at very high 
liquid formulation viscosity, particles can be entrapped within the formulation at the site 




3.3 Materials and Methods 
All reagents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO) 
unless otherwise specified. Red-fluorescent polystyrene particles (Excitation: 580 nm; 
Emission: 605 nm) and green-fluorescent polystyrene particles (Excitation: 505 nm; 
Emission: 515 nm) with diameters ranging from 0.02 – 2 µm were purchased from Life 
Technologies (Fluosphere, Carlsbad, CA). Eyes of pigmented Silver Fox and American 
Blue rabbits (Broad River Pastures, Elberton, GA) and albino New Zealand White rabbits 
(Pel Freeze, Rogers, AR) were obtained within 1 day after euthanasia until use. All in 
vivo experiments were carried out in albino New Zealand White rabbits (Charles River 
Laboratories, Wilmington, MA) and were approved by the Georgia Institute of 
Technology Institutional Animal Care and Use Committee. Practices complied with the 
ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Four 
replicates per experimental group were performed unless otherwise specified. 
3.3.1 Ex vivo injection procedure 
Extraocular tissues were carefully removed from the rabbit ocular globe. To 
simulate a physiological intraocular pressure (IOP) of 10-12 mmHg, a water column was 
raised to ~14 cm and connected to the eye via a 25-gauge needle penetrated through the 
optic nerve17. A microneedle (750 µm in length, 33-gauge; kindly provided by Clearside 
Biomedical, Alpharetta, GA) attached to a 250 µL glass chromatography syringe 
(National Scientific, Rockwood, TN) was used to make injections. Injections were 
performed 3 mm posterior to the limbus at the 12 o’clock position (superior) to be as far 
as possible from anatomical barriers created by the long posterior ciliary artery that 
impede circumferential flow129.  
 61 
 
Depending on the experimental condition, each injection consisted of 25 to 150 
µL of 0.5% (w/v) red-fluorescent particles (0.2 µm diameter; Excitation: 580 nm; 
Emission: 605 nm) and 0.025% (w/v) fluorescein suspended in Hank’s Balanced Salt 
Solution (HBSS; Gibco, Life Technologies). After each injection, the needle was held in 
place for 1 min to minimize reflux121. The eye was then frozen via submersion in 100% 
ethanol chilled over dry ice 3 min post-injection depending on experimental condition.  
3.3.2 Flat mount to characterize 2D circumferential spread 
After SCS injection and freezing, eyes were prepared to assess the 2D spread of 
particles and fluorescein, as described previously8, 128, 129. The frozen eye was sliced open 
from the limbus to the posterior pole to generate eight approximately equidistant scleral 
flaps. The resulting scleral flaps were splayed open and the frozen vitreous humor, lens, 
and aqueous humor were removed.  
A digital SLR camera (Canon 60D, Canon, Melville, NY) with a 100 mm lens 
(Canon) was used to acquire brightfield and fluorescence images. Camera parameters 
were held constant at shutter speed = 1/15 s and aperture = F/2.8. To acquire the area of 
fluorescein spread, a green optical band-pass filter (520 ± 10 nm; Edmunds Optics, 
Barrington, NJ) was placed on the lens, and the sample was illuminated by a lamp with 
the violet setting of a multicolor LED bulb (S Series RGB MR16/E26. HitLights, Baton 
Rouge, LA). To visualize the location of the red-fluorescent particles, a red filter (610 ± 
10 nm; Edmunds Optics) was placed on the lens, and the sample was illuminated with the 
same lamp switched to green light. The area of green and red fluorescence that was above 
threshold was calculated for each eye using ImageJ (National Institutes of Health, 
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Bethesda, MD). Thresholding was set manually based on visual inspection of background 
signal. 
3.3.3 3D cryo-reconstruction to determine 3D distribution of particles and 
fluorescein 
Rabbit eyes that received a microneedle injection of 25 to 150 µL containing 
0.5% w/v red-fluorescent particles (0.2 µm diameter) and 0.025% w/v fluorescein were 
processed using the 3D cryo-reconstruction procedure (detailed procedure in Section 
4.3.3 on page 87). Briefly, the eye was frozen in chilled ethanol after 3 or 15 min. The 
frozen pigmented eye was sliced with a cryostat, and fluorescence images of the cryo-
block were acquired every 300 µm. Imaging the block reduced apparent drift and 
simplified reconstruction compared with previous methods137, 138. To acquire the green 
fluorescence (from fluorescein), a green optical band-pass filter (520 ± 10 nm; Edmunds 
Optics) was placed on the lens, and the sample was illuminated with blue/violet LED 
light (HitLights). To visualize the location of the red fluorescent particles, a red filter 
(610 ± 10 nm; Edmunds Optics) was placed on the lens, and the sample was illuminated 
with green LED light (HitLights).  
The resulting image stack consisting of only the green or red fluorescence images 
was imported into a custom Matlab (Mathworks, Natick, MA) script. The eye was 
modeled as a sphere and discretized into 100x100 points. For each of these 100x100 
points, a ray originating from the centroid of the eye (determined manually by visual 
inspection) through each point was identified (Figure 4.1B). The intensity along each ray 
was used to find the location of the fluorescence in the SCS (Figure 4.1C). If the ray had 
a segment >25 µm in length with an intensity above threshold, we considered the point to 
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be occupied by the fluorescent species. This procedure was repeated for all 100x100 rays 
to yield a 2D map projection or a 3D surface plot (Figure 4.1D and E). The resulting 
100x100 array was viewed as a surface plot in Matlab, and the thresholded area was 
calculated as a percentage of total ocular globe minus the cornea. Thresholding was 
determined manually by visual inspection. 
3.3.4 Fluorescent tagging of excipient formulation 
To visualize spread of polymer formulation excipients, we fluorescently labeled 
polysaccharides that have been shown to significantly influence spread of particles within 
the SCS128 using previously described methods139. Carboxymethyl cellulose (CMC; 700 
kDa high viscosity, Sigma-Aldrich) has been shown to impede spread of particles, 
allowing for localized delivery of particles that stay near the injection site6, 128. On the 
other hand, Discovisc (Alcon Laboratories, Fort Worth, TX) and hyaluronic acid have 
been shown to promote spread up to 100% of SCS area by a slow process after 
injection128.  
To label CMC, 250 mg of CMC and 10 mg of fluorescein isothiocyanate (FITC) 
was added to 25 mL of 0.1 M NaOH in DI water. The solution was mixed in the dark at 
room temperature (22 °C) for 4.5 days. The solution was then transferred into a dialysis 
tube (30 kDa cutoff, Spectra/Por, Spectrum Laboratories, Rancho Dominguez, CA) in a 
DI water bath. The water bath was changed daily for 5 days to remove unreacted FITC. 
The contents of the dialysis tube were transferred into a 50 mL centrifuge tube and frozen 
prior to vacuum drying. Care was taken to minimize light exposure at all steps to 
minimize bleaching. A similar procedure was performed with Discovisc; 500 µL of 
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Discovisc and 1 mg of FITC were added to 2.5 mL of 0.1 NaOH. The other methods 
were the same as those used for FITC labeling of CMC.  
3.3.5 In vivo SCS injections and image acquisition 
Albino rabbits were anesthetized with isoflurane and treated with proparacaine 
eye drops (Bausch & Lomb, Rochester, NY). All injections were 50 µL in volume and 
performed 3 mm posterior to the limbus at the supranasal quadrant (4 mm nasal to the 
edge of the superior rectus extraocular muscle).  
To determine the effect of polymeric formulation on particle spread, the following 
injections (N=4 eyes per group) were performed: [i] 50 µL of 2% (w/v) red-fluorescent 
particles (0.2 µm diameter) and 0.025% fluorescein in HBSS; [ii] 50 µL of 2% (w/v) red-
fluorescent particles (0.2 µm diameter) and 5% FITC-CMC in HBSS; [iii] 50 µL of 2% 
(w/v) red-fluorescent particles (0.2 µm diameter) and 1x FITC-Discovisc re-constituted 
in HBSS.  
To determine if particles ranging from 0.02 µm to 2 µm co-localize, the following 
injections (N=4 eyes per group) were performed: [i] 50 µL of 1% (w/v) red-fluorescent 
particles (0.2 µm diameter) and 1% (w/v) green-fluorescent particles (0.02 µm in 
diameter) suspended in HBSS; [ii] 50 µL of 1% (w/v) red-fluorescent particles (0.2 µm 
diameter) and 1% (w/v) green-fluorescent particles (0.2 µm diameter) suspended in 
HBSS; [iii] 50 µL of 1% (w/v) red-fluorescent particles (0.2 µm diameter) and 1% (w/v) 
green-fluorescent particles (2 µm diameter) suspended in HBSS; and [iv] 50 µL of 1% 
(w/v) red-fluorescent particles (0.02 µm diameter) and 1% (w/v) red-fluorescent particles 
(2 µm diameter) suspended in unlabeled Discovisc. 
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At predetermined time points, the animals were imaged with a modified RetCam 
II system (Clarity Medical Systems, Pleasanton, CA). Prior to imaging, tropicamide 
(Akorn Pharmaceuticals, Lake Forest, IL), phenylephrine (Akorn Pharmaceuticals), and 
proparacaine (Akorn Pharmaceuticals) eye drops were given. The built-in fluorescein 
attachment was used to capture green fluorescence. For the red fluorescence, green light 
was generated by placing a 575±50 nm bandpass filter (Edmunds Optics) in line with the 
fiber optic line. A red-emission filter (610 ± 10 nm, Omega Optical, Brattleboro, VT) was 
placed over the camera to capture red fluorescence. Animals were euthanized with an 
injection of pentobarbital through the ear vein at the end of the experiment.  
Post-processing of the RetCam images was used to generate a collage for each 
imaging condition, since the camera did not have built-in image stitching algorithms. Co-
localization was determined using a previously described method140. Briefly, the 2D 
correlation coefficient of the red- and green-fluorescent images was calculated, and 
compared against the 2D correlation of 100 randomly assigned image pairs using a one-
sided unpaired t-test. A low p-value indicated statistically significant co-localization 
greater than chance, and a high p-value indicated no significant co-localization. 
3.3.6 Statistical analysis 
Image analysis was performed using Matlab and ImageJ. Statistical analysis was 
performed using Prism (Graphpad, La Jolla, CA). Values are presented as the mean ± 
standard error of the mean (SEM), unless otherwise specified. Two-way ANOVA and 






3.4.1 Distribution of particles and molecules immediately after injection into the 
SCS  
The first objective was to test the hypothesis that the circumferential area of 
particle coverage increases with increasing injection volume. We therefore calculated the 
percentage area of the SCS that had red and green fluorescence greater than threshold 
after injection of increasing volumes into the rabbit SCS ex vivo using flat mounts (Figure 
3.1) and 3D cryo-reconstruction (Figure 3.2) measurement methods.  
Consistent with the hypothesis, area covered by fluorescein and particles 
generally increased with increasing injection volume, although the rate of increase was 
larger at lower volumes (Figure 1). A linear fit to the data yielded a poor correlation (r2 = 
0.51 for particles and 0.67 for fluorescein), whereas an exponential fit was better (r2 = 
0.90 for particles), which is consistent with the observation that area initially increases 
and appears to approach a plateau value slightly below 50% area coverage for particles 
and slightly above 50% for fluorescein. We hypothesize that this apparent plateauing 
behavior is due to anatomical barriers that inhibit coverage in the inferior hemisphere, 





Figure 3.1 – Percentage area of SCS containing injected particles and fluorescein molecules, as 
determined by flat-mount measurement method.  (A) Representative red and green fluorescence flat-mount 
images to visualize the spread of particles (0.2 µm diameter) and fluorescein after microneedle injection in 
ex vivo rabbit eyes. Eyes frozen and processed 3 min after injection. (B) Quantification of percent area 





Figure 3.2 – Percentage area of SCS containing injected particles and fluorescein molecules, as 
determined by 3D cryo-reconstruction method.  Eyes frozen and processed 3 min post-injection. (A) 
Representative equatorial map projections of red fluorescence of 0.2 µm diameter particles and green 
fluorescence of fluorescein after microneedle injection in ex vivo rabbit eyes. Injection site indicated by 
yellow arrow. Note that like a Mercator map projection of Earth, there is distortion at the poles (anterior 
and posterior). (B) Quantification of percent area (mean±SEM, N=2-6) covered by red particles or 




Figure 3.3 – Parity plot comparing area calculated from flat mount and cryo-reconstruction methods. 
Pooled data had a slope of 0.91 ± 0.14 (mean ± SEM; r2 = 0.65), which was not statistically different from 
1 indicating methods agree. 
For all injection volumes, the fluorescein occupied a larger area than the red 
fluorescent particles (p<0.0001, ANOVA). The ratio of area covered by fluorescein 
versus particle was 2.05±0.24 (mean±SEM), which did not significantly depend on 
injection was found when comparing the percentage areas of eye covered by fluorescein 
versus particles. There was no discernible pattern in the ratio when comparing high- and 
low-volume injections. This difference in area could be explained by the higher 
diffusuvuty of fluorescein versus particles (which are assumed to transport only by 
convection). However, diffusion of fluorescein for 3 min after injection is expected to 
account for an area increase of only ~20% (based on a calculation assuming a fluorescein 
diffusivity of 4.3x10-6 cm2/s 141 and a covered SCS area of ~200 mm2 in the rabbit eye 
142). Because this small predicted increase is much less than the roughly two-fold 
measured increase, this results suggest, which is less than 2.05. This result suggests that 
there are additional factors at play in the SCS that limit movement of particles relative to 
small molecules (i.e., fluorescein). 




























P a rt ic le F lu o re s c e in
 70 
 
3.4.2 Distribution of particles and molecules over time after injection into the SCS 
in vivo 
We further investigated the role of formulation and time on particle distribution in 
the SCS. The distribution of red-fluorescent particles suspended with green fluorescently-
tagged formulation excipients in HBSS after injection into the SCS of live rabbits was 
imaged using red and green fluorescence simultaneously. Fluorescence was imaged using 
RetCam imaging, which was preferred to other non-contact fundus imaging methods, 
since it enabled visualization of the posterior pole as well as the far periphery (i.e., the 
injection site). We then calculated the percentage of the SCS area in the composite 
images that had red/green fluorescence values at least 0.1% of the starting concentration, 
which we used as a proxy of true coverage; and determined the incidence of co-
localization of the red and green fluorescence greater than chance. 
To study the distribution of red-fluorescent particles and green-fluorescent 
fluorescein molecules injected in HBSS (Figure 3.4), we measured the SCS area over 
which the particles and fluorescein spread for 21 days after injection in vivo. The particle 
area coverage was constant at all time points from 3 min to 14 d post-injection (p=0.99, 
Sidak’s multiple comparison test), with a small decrease in area at 21 d. In contrast, the 
fluorescein area increased from 3 min to 1 h post-injection before being cleared by 2 d. 
At the 3 min and 1 h time points, fluorescein covered a larger area than the red particles 
(p<0.01, Sidak’s multiple comparison test). Moreover, the time point at which the 
maximum fluorescein coverage was measured was later than the red particle maximum. 
Statistical analysis showed that the particles co-localized with fluorescein immediately 
after injection, but not at later time points. Taken together with the ex vivo data, we 
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conclude that particles suspended in HBSS became immobilized immediately post-
injection even though fluorescein was able to move within the SCS well after the 
injection.  
We next investigated how the addition of viscous formulation excipients affected 
particle distribution over time. When the formulation consisted of red particles suspended 
in 5% FITC-CMC in HBSS (Figure 3.5), particle area coverage increased from 3 min 
until 2 d post-injection (p<0.01, Sidak’s multiple comparison test). Then, from 2 d to 35 
d, there was no significant change in particle distribution in the SCS (p=0.61, Sidak’s 
multiple comparison test). The co-injected FITC-labeled CMC initially followed a pattern 
similar to the particles, increasing in area for the first two days (p<0.005, Sidak’s 
multiple comparison test). However, from 2 d until 21 d, the area of FITC-CMC 
decreased (p<0.005, Sidak’s multiple comparison), and from 21 d until 35 d, there was 
essentially no detectable FITC-CMC in the SCS. The FITC-CMC never occupied an area 
larger than the red particles (p>0.07, Sidak’s multiple comparison test). The maximum 
red particle coverage and maximum FITC-CMC coverage occurred at the same time 
point, i.e., 2 d post injection. The last time point of co-localization was at 4 d. This 
suggests that the particles and FITC-CMC were transported together during the injection 
and for up to 2 days thereafter, after which the particles remained immobilized and the 
FITC-CMC was cleared. 
When the formulation consisted of red particles suspended in FITC-Discovisc 
(Figure 3.6), particle area coverage changed over time. Particle coverage was constant 
from 3 min to 1 h (p=0.98, Sidak’s multiple comparison test), and increased by 2 d 
(p<0.05, Sidak’s multiple comparison test). There was no significant change in particle 
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coverage from 2 d to 21 d (p>0.24, Sidak’s multiple comparison test). The co-injected 
FITC-labeled Discovisc molecules initially followed a pattern similar to the particles, 
increasing in area for the first two days (p<0.005, Sidak’s multiple comparison test). 
However, from 2 d until 7 d, the area of FITC-Discovisc decreased (p<0.005, Sidak’s 
multiple comparison), and from 7 d until 21 d, there was essentially no detectable FITC-
Discovisc in the SCS. The FITC-Discovisc never occupied an area larger than the red 
particles (p>0.05, Sidak’s multiple comparison test). The maximum red particle coverage 
and maximum FITC-Discovisc coverage occurred at the same time point, i.e., 2 d post 
injection. The last time point of co-localization was at 2 d. This suggests behavior similar 
to that seen with FITC-CMC, where the particles and FITC-Discovisc were transported 
together during the injection and for up to 2 days thereafter, after which the particles 
remained immobilized and the FITC-Discovisc was cleared, although the FITC-Discovisc 
was cleared faster than the FITC-CMC and, on an absolute scale, the area coverage of 
FITC-Discovisc and co-injected particles was roughly twice as large as the area coverage 





Figure 3.4 – Spread of particles and fluorescein molecules in the SCS after injection of HBSS formulation 
in vivo.  (A) Representative fluorescent fundus collages after microneedle injection of red-fluorescent 
particles (0.2 µm diameter) and fluorescein in HBSS in the supranasal position in vivo (injection site 
indicated by white arrow). The same animal was imaged for the duration of the experiment. Sup.=superior. 
Nas.=nasal. (B) Quantification of area covered (mean±SEM, N=3) by red-fluorescent particles and 




Figure 3.5 – Spread of particles and fluorescein molecules in the SCS after injection in FITC-CMC 
formulation in vivo.  (A) Representative fluorescent fundus collages after microneedle injection of red-
fluorescent particles (0.2 µm diameter) and FITC-CMC in HBSS in the supranasal position (injection site 
indicated by white arrow). The same animal was imaged for the duration of each experiment. Sup. = 
superior. Nas.= nasal. (B) Quantification of area covered (mean±SEM, N=2-4) by red fluorescent particles 




Figure 3.6 – Spread of particles and fluorescein molecules in the SCS after injection in FITC-Discovisc 
formulation in vivo.  (A) Representative fluorescent fundus collages after microneedle injection of red-
fluorescent particles (0.2 µm diameter) and FITC-Discovisc reconstituted in HBSS in the supranasal 
position (injection site denoted by white arrow). The same animal was imaged for the duration of each 
experiment. Sup.=superior. Nas.=nasal. (C) Quantification of area covered (mean±SEM, N=2-4) by red 
fluorescent particles and FITC-Discovisc in HBSS. * represents time points where red particle and FITC-
Discovisc signals co-localize. 
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Considering all of these data (Figure 3.4 – Figure 3.6), the spread of particles 
immediately after injection depended on formulation composition, such that spreading 
went from smallest to largest with: FITC-CMC (8.5%) < FITC-Discovisc (26%) < HBSS 
(30%). At 14 d, the rank list for particle coverage for the tested excipients was FITC-
CMC (20%) < HBSS (27%) < FITC-Discovisc (46%). The maximum area coverage was 
achieved at 3 min when formulated only in HBSS, and at 2 d for FITC-CMC and FITC-
Discovisc. The particles injected with a low-viscosity formulation (i.e. HBSS only) did 
not experience a change in area coverage over time. On the other hand, particles injected 
with viscous formulations (FITC-CMC and FITC-Discovisc) experienced an increase in 
coverage of two-fold when comparing coverages at 3 min and 14 d post-injection. Thus, 
we can conclude that the viscous formulations prolonged particle transport time 
compared with the low-viscosity formulation. There was a strong association between 
transport time compared with viscosity (Figure 3.7). Initial viscosity of the formulation 
was a poor predictor of final spread of particles, possibly due to physical crosslinking of 
CMC143 that effectively increased viscosity after injection and thereby limited spreading 
(Figure 3.8).  
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Figure 3.7 – Plot of transport time (mean±SEM) vs. formulation viscosity. Transport time defined as 
greater of (a) time in which co-localization stops, and (b) time in which particle area stops increasing. 
Linear regression fits data well (r2=0.90)  
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Figure 3.8 – Plot of SCS area coverage (mean±SEM) vs. formulation viscosity. SCS area coverage 
determined from RetCam II collages. Linear regression did not fit data well (r2=0.44) 
Fluorescein in HBSS occupied 66% of the visible SCS, which was the largest area 
of all the fluorescent species injected. In comparison, peak FITC-CMC spreading was 
20% of SCS area, and occurred at 2 d. Peak FITC-Discovisc coverage was 63% and 
occurred at 2 d. Total clearance of the fluorescently-tagged formulation excipients 
occurred by 2 d for HBSS, 21 d for FITC-CMC, and 14 d for FITC-Discovisc.  
Co-localization of particles and the formulation excipients was seen up until 3 
min for HBSS, 4 d for FITC-CMC, and 3 min for FITC-Discovisc. 
3.4.3 Effect of particle size on particle distribution over time after injection into 
the SCS in vivo 
To determine the effect of particle size on distribution, particles of different sizes 
(20 nm – 2 μm) were suspended in HBSS and Discovisc, and co-injected into the rabbit 
SCS in vivo. Injections ysed pairwise combinations of red- and green-fluorescent 
particles of different sizes to determine whether the particles co-localized in the SCS. In 
all cases, the pairs of co-injected particles all co-localized for at least 4 d post-injection 
(Figure 9). With all HBSS conditions, particle area did not change with time (p>0.06, 2-
 78 
 
way ANOVA). For particles in Discovisc, the particle area increased until 2 d for both 
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Figure 9 – Quantification of area covered (mean±SEM, N=3-4) after SCS injection with (A) 2 nm red- and 
200 nm green-fluorescent particles in HBSS, (B) 200 nm red- and 200 nm green-fluorescent particles in 
HBSS, (C) 200 nm red- and 2 µm green- fluorescent particles in HBSS, and (D) 20 nm red- and 2 µm 
green-fluorescent particles in Discovisc over time in vivo. The same animal was imaged for the duration of 
each experiment. * represents time points where red- and green-fluorescent particles signals co-localize. 
3.5 Discussion 
Traditional ophthalmic drug delivery techniques, namely topical eye drops and 
intravitreal injections, do not precisely target diseased tissues in posterior segment 
indications. Compared with these conventional routes of administration, suprachoroidal 
delivery enables targeted drug delivery to the choroid, retina, ciliary body, and sclera 
with higher bioavailability5, 6, 8, 9, 81, 115, and can be performed in the outpatient clinic 
setting7, 8, 81. The extent and distribution of posterior-segment diseases are typically not 
uniform. For example, glaucoma treatment requires localization near the ciliary body, 
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which is near the site of microneedle injection6, 115; while noninfectious posterior uveitis 
requires spreading throughout the SCS7. Deposition within the suprachoroidal space can 
be geographically controlled so as to target diseased tissues while sparing non-diseased 
tissues17, 118, 124, 128, 129. This work investigated the distribution of particles and molecules 
injected into the rabbit SCS over time as a function of injection volume and formulation. 
3.5.1 Distribution of particles and molecules injected into the SCS 
One goal of this work was to study the distribution of particles and molecules co-
injected into the SCS of rabbits. We found that, as injection volume increased, 
circumferential area of SCS containing particles and molecules also generally increased. 
However, we were not able to conclude if area increased linearly with injection volume 
or followed an exponential or other relationships. Thus, increasing injection volume was 
a reasonable strategy to increase coverage, but may limit particle spreading across certain 
anatomical barriers129. For example, in rabbits and guinea pigs, anatomical barriers 
prevented particle spread into the inferior hemisphere when injections were made 
superior to the long posterior artery 120, 129. To address this limitation, Kim et al. showed 
that it is possible to achieve particle spread >50% (and up to 100%) by optimizing the 
injection formulation128.  
3.5.2 Distribution of particles relative to molecules 
Another goal of this study was to determine the relative distributions of particles 
and molecules co-injected into the SCS. We found that, with HBSS as the formulation, 
the area covered by fluorescein was larger than the area covered by particles for all 
injection volumes tested. On average, the fluorescein occupied an area twice as large as 
that occupied by particles ex vivo and in vivo. The discrepancy in area covered could be 
 80 
 
due to either barriers in the SCS that preferentially limit movement of particles or 
increased diffusion of fluorescein in the SCS post-injection relative to the particles. 
Because the contribution of fluorescein diffusion was estimated to increase coverage by 
only ~20%, entrapment of particles is the more likely explanation.  
Because molecules distributed to cover a larger area than particles in the SCS, the 
delivery of molecules may be preferred if the goal is to achieve full coverage of the SCS. 
However, the use of particles (e.g., containing drug molecules for slow release over time7, 
115) may be preferable to injecting free drug molecules, which are usually cleared from 
the SCS within a day6, 8, 9, 120.  
3.5.3 Effect of formulation on distribution of particles  
For the purposes of our in vivo formulation excipient experiments, we defined 
transport time as the greater of (a) the time at which particle area stopped changing and 
(b) the time in which co-localization of particles and formulation excipients stopped. The 
data showed that there was a strong association between transport time and viscosity of 
the liquid formulation, where increased viscosity facilitated longer transport time (i.e., for 
days after the injection). In contrast, viscosity of the formulation had a much weaker 
association with area coverage, probably because certain viscous formulations like CMC 
may become physically cross-linked, effectively increasing viscosity after injection and 
thereby limiting spread.  
3.5.4 Effect of particle size on distribution of particles  
Finally, particles with diameters ranging from 0.02 to 2 µm co-localized within 
the SCS independent of particle size. Furthermore, the size of the particles did not 
influence transport time. Particles of different sizes may be preferred for different 
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applications, such as micron-scale particles to serve as slow-releasing drug delivery 
systems, nanoscale virus particles as gene delivery vectors, and micron-sized cells as cell-
based therapies. This study shows that particles spanning two orders of magnitude in size 
distributed on the SCS to a similar extent with similar kinetics, which should simplify 
design of particle delivery to the SCS. Of course, other particle parameters may also play 
a role, such as particle density, shape, surface properties and composition. 
3.5.5 Study limitations 
Limitations of the study include use of ex vivo rabbit eyes, and shortcomings of 
equipment and measurement methods. There are physiological and anatomical 
differences between rabbit and human eyes. These species differences may or may not 
alter suprachoroidal distribution. For example, as we showed previously129, there are 
different anatomical barriers in rabbits versus humans that affect circumferential particle 
spread. Human clinical trials will be needed to investigate suprachoroidal distribution, as 
it applies to human health. This study used ex vivo eyes for some studies, which may not 
be fully representative of living animals. However, the use of ex vivo eyes made certain 
measurements possible; for example, using ex vivo (and enucleated) eyes allowed rapid 
freezing of the eye to stop particle and molecule movement. The distribution of 
molecules and particles suspended in HBSS was studied in both ex vivo and in vivo rabbit 
eyes, and the results were similar, at least initially post-injection.  
The RetCam II fluorescent fundus imaging system did not have the ability to 
automatically stitch image fields together. Instead, collages were used, and this may have 
introduced errors in the actual coverage of fluorescence (e.g., two neighboring images in 
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the collage may overlap). However, the RetCam allowed visualization into the far 
periphery, which would be difficult with other non-contact fundus imaging modalities. 
3.5.6 Conclusion 
In conclusion, we studied the distribution of particles and molecules co-injected 
into the SCS of rabbits. We found that as injection volume increased, the area the injected 
fluid in the SCS generally increased. Particles did not spread to cover as large an area as 
fluorescein molecules, suggesting barriers to particle movement in the SCS. With high-
viscosity formulations, the transport time of particles was significantly extended (to 2 d), 
and particles were often co-localized with viscous polymer excipients during spreading. 
These studies will aid in the development of formulations that can be injected via 




4 THICKNESS AND CLOSURE KINETICS OF THE 
SUPRACHOROIDAL SPACE FOLLOWING MICRONEEDLE 
INJECTION OF LIQUID FORMULATIONS  
4.1 Summary 
The purpose of this study was to determine the effect of injection volume and 
formulation of a microneedle injection into the suprachoroidal space (SCS) on SCS 
thickness and closure kinetics. Microneedle injections containing 25 – 150 µL of Hank’s 
Balanced Salt Solution (HBSS) were performed in the rabbit SCS ex vivo. Distribution of 
SCS thickness was measured by ultrasonography and 3D cryo-reconstruction. 
Microneedle injections were performed in the rabbit SCS in vivo using HBSS only; 
Discovisc; and 1, 3, and 5% carboxymethyl cellulose (CMC) in HBSS. Ultrasonography 
was used to track SCS thickness over time. We found that increasing HBSS injection 
volume increased the area of expanded SCS, but did not increase SCS thickness ex vivo. 
With SCS injections in vivo, the SCS initially expanded to thicknesses of 0.43±0.06 mm 
with HBSS, 1.5±0.4 mm with Discovisc, and 0.69 – 2.1 mm with 1 – 5% CMC. After 
injection with HBSS, Discovisc and 1% CMC solution, the SCS collapsed to baseline 
with time constants of 19 min, 6 h and 2.4 d, respectively. In contrast, injections with 3 – 
5% CMC solution resulted in SCS expansion to 2.3 – 2.8 mm over the course of 2.8 - 9.1 
h after which the SCS collapsed to baseline with time constants of 4.5 – 9.2 d. Thus, we 
concluded that with low-viscosity formulations, increasing injection volume has a 
negligible effect on SCS thickness. Increasing injection fluid viscosity had a major effect 
on SCS thickness. SCS expansion is hypothesized to be controlled by a balance between 
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the viscous forces of the liquid formulation and the resistive biomechanical forces of the 
tissue. 
4.2 Introduction 
The suprachoroidal space (SCS) is a potential space found between the sclera and 
choroid. Due to its close proximity to the ciliary body, choroid, retina, and sclera, this 
space has recently drawn attention as a site for targeted drug delivery2, 7, 8, 81, 118, 119, 125, 127, 
placement of glaucoma drainage devices144-147, and implantation of retinal prostheses148. 
As a site of drug administration, delivery into the SCS is noted for high bioavailability at 
targeted tissues in posterior segment diseases, as well as fast clearance by the choroidal 
vasculature8, 9. Access to the SCS is possible via surgical procedures of varying 
complexity2, 117, 118, 124, 126, 130, 149 and microneedle injections that offer greater simplicity 8, 
81. A hollow microneedle with a length similar to the thickness of the sclera can be used 
to reliably access the SCS while preventing penetration deeper into the eye8, 81. 
Microneedle injections can be performed by ophthalmologists in the outpatient clinic 
setting, similar to the intravitreal injection procedure. The safety and efficacy of these 
microneedle injections have been demonstrated in a recent open-label Phase I/II clinical 
trial (NCT01789320) where triamcinolone acetonide suspension was injected into the 
SCS to treat posterior uveitis7; a Phase III clinical trial is ongoing (NCT02595398) to 
further study the efficacy of the SCS injection. 
Although many studies have investigated the circumferential spread of particles 8, 
17, 81, 119, 120, 128, 129 and molecules5, 9, 116, 120, 125 within the SCS, few have studied the third 
dimension: the distensibility of the choroid off the sclera, a.k.a. the SCS thickness. Seiler 
et al. measured the maximum suprachoroidal space thickness over the injection site in ex 
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vivo porcine and canine eyes, and found that there was no difference in thickness with 
three injection volumes, especially once the eyes were inflated to a physiological 
intraocular pressure116. They also determined the 3D distribution of microbubbles in the 
porcine eye116, however, the microbubbles are not expected to distribute the same as 
neutral-density materials17. Patel et al. used a fluorophotometer to assess the SCS 
thickness along the visual axis in rabbits8, 81. Gu et al. used optical coherence tomography 
to study the SCS thickness along the visual axis in guinea pigs120. Since the injection 
occurs in the far periphery (near the limbus), the SCS thickness at the posterior pole may 
not be representative of the entire globe. Kadam et al. showed that the physiochemical 
properties of molecules injected into the SCS affected affinity to certain ocular layers, 
which may indirectly affect measured SCS thickness123.  
These prior studies made measurements of SCS thickness at individual locations 
at individual time points using individual liquid formulations. To provide a more 
comprehensive understanding the distribution of SCS thicknesses and the factors that 
affect SCS thickness after microneedle injection, this study measured SCS thickness at 
multiple locations at multiple time points using multiple different liquid formulations of 
multiple different volumes. More specifically, this work evaluated the effect of increasing 
injection volume and liquid formulation viscosity on SCS thickness at the time of 
injection and over time after the injection.  
We used two companion approaches to report on the distribution of the SCS 
thickness throughout the entire ocular globe (i.e., ultrasonography and 3D cryo-
reconstruction). We hypothesize that for a given liquid formulation, the SCS thickness 
expands to a constant value independent of the volume of fluid injected; that increasing 
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viscosity of the liquid formulation increases the SCS thickness; that SCS thickness may 
continue to expand after injection of concentrated carboxymethyl cellulose (CMC) 
solutions that form physically crosslinked hydrogels that swell; and that SCS thickness 
collapses to baseline over time after SCS injection.  
4.3 Materials and Methods 
All reagents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO) 
unless otherwise specified. Red fluorescent polystyrene particles (excitation: 580 nm; 
emission: 605 nm) with diameters of 200 nm were purchased from Life Technologies 
(Fluospheres, Carlsbad, CA). Eyes of pigmented Silver Fox and American Blue rabbits 
(Broad River Pastures, Elberton, GA) and albino New Zealand White rabbits (Pel Freeze, 
Rogers, AR) were obtained within 1 d after slaughter and stored in a -80°C freezer 
immediately upon arrival. All in vivo experiments were carried out in albino New 
Zealand White rabbits (Charles River Laboratories, Wilmington, MA) and were approved 
by the Georgia Institute of Technology Institutional Animal Care and Use Committee. 
Practices complied with the ARVO Statement for the Use of Animals in Ophthalmic and 
Vision Research. Four replicates per group were performed unless otherwise specified. 
4.3.1 Ex vivo injection procedure 
The conjunctiva, fascia, and extraocular muscles were carefully dissected off the 
rabbit eye. The eye was pressurized to a physiological intraocular pressure (IOP) of 10-12 
mmHg by penetrating a 25 gauge needle through the optic nerve, which was connected to 
a water reservoir raised to ~14 cm above the eye17. A 750 µm-long, 33-gauge hollow 
microneedle (Clearside Biomedical, Alpharetta, GA) attached to a 250 µL glass 
chromatography syringe (National Scientific, Rockwood, TN) was used to make 
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injections. All injections were performed 3 mm posterior to the limbus at the 12 o’clock 
position (superior) to be as far as possible from anatomical barriers that impede 
circumferential flow129. Depending on the experimental condition, each injection 
consisted of 25, 50, 75, 100, or 150 µL of 0.5% (w/v) red-fluorescent particles suspended 
in Hank’s Balanced Salt Solution (HBSS; Gibco, Life Technologies, Carlsbad, CA). 
After each injection, the needle was held in place for 1 min to prevent reflux121.  
4.3.2 Ultrasound imaging to determine SCS thickness 
A high-frequency ultrasound (U/S) probe (UBM Plus, Accutome, Malvern, PA), 
with a minimum axial resolution of 15 µm, was used to generate 2D cross-sectional 
images of the SCS in rabbit eyes ex vivo after injecting volumes ranging from 25 to 150 
µL. An U/S probe cover (Clearscan, Eye-Surgical-Instruments, Plymouth, MN) was 
attached to the UBM Plus to facilitate U/S image acquisition. Three minutes after 
injection, the U/S probe was used to acquire eight sagittal views around the eye (12, 1.5, 
3, 4.5, 6, 7.5, 9, and 10.5 o’clock). Post-processing of the U/S B scans was performed to 
find the thickness from the outer sclera to the inner retina at 1, 5, and 9 mm posterior to 
the scleral spur. The mean, median, and standard deviation for each eye were calculated.  
4.3.3 3D cryo-reconstruction to determine 3D distribution of particles and 
fluorescein 
Microneedle injections of 25 – 150 µL containing red-fluorescent particles were 
performed in pigmented rabbit eyes, as described above. The eyes were frozen 3 min 
post-injection using ethanol chilled to -80°C. Frozen eyes were put into cryomolds loaded 
with Optical Cutting Temperature embedding medium (OCT; Tissue-Tek, Sakura 
Finetek, Tokyo, Japan) and India Ink (Higgins Ink, Leeds, MA). The cryomolds were 
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then half-submerged in liquid nitrogen until the OCT was solid. The eye was removed 
from the plastic mold for sectioning. The pigmentation in the eye and the India Ink in the 
OCT prevented fluorescence from out of plane during imaging (see below). 
Each cryomold was connected to the mount of a cryostat (CryoStar NX70 
cryostat, Thermo Fisher Scientific, Waltham, MA or Leica CM 3050 cryostat, Wetzlar, 
Germany). A digital SLR camera (Canon 60D, Canon Inc., Melville, NY) with 100 mm 
prime lens was positioned on a tripod such that the camera was along the longitudinal 
axis of the cryo-block (to minimize apparent motion of the sample as it was cut and any 
keystoning effect). Camera parameters were held constant at shutter speed = 1/15 s and 
aperture = F/2.8. The camera was placed close enough such that the sample occupied 
>80% of the image sensor.  
One red fluorescent images of the cryo-block was obtained every 300 µm by 
slicing the sample with the cryostat (Figure 4.1). Since the cryo-block was locked in 
place for each image and the camera was stationary, determining the orientation of one 
image relative to other images was simplified compared with other reconstruction 
methods137, 138. To visualize the location of the red-fluorescent particles, a red filter was 
placed on the lens, and the sample was illuminated with green LED light (HitLights, 
Baton Rouge, LA). Care was taken not to shift the camera when connecting the filter. 
After every 300 µm of tissue was removed by the cryostat, the procedure was repeated 




Figure 4.1 – Diagram of 3D cryo-reconstruction methods. Microneedle injection of particles suspended in 
HBSS is made in the suprachoroidal space (SCS). (A) Eye is cryo-sectioned. Every 300 µm, fluorescence 
images of the block are taken. (B) Image stack is uploaded to Matlab script. The centroid of the eye is 
identified manually by visual inspection, and 100 x 100 rays originating from the centroid are calculated. 
(C) The intensity along each ray is used to calculate the SCS thickness. (D and E) The SCS thicknesses for 
each of the 10,000 rays are calculated and displayed as either a (D) spherical representation or (E) 2D 
equatorial map representation. Similar to a Mercator projection of Earth, the regions near the anterior and 
posterior pole in (E) are greatly distorted. Injection site indicated with yellow arrow. 
Image stacks consisting of red fluorescence images were imported into a custom 
Matlab (Mathworks, Natick, MA) script. The image stack was preprocessed by spatially 
transforming each image so the four corners of the mold matched up, using the Matlab 
functions ‘cp2tform’ and ‘imtransform’. The spatial transformation accounted for angular 
deviations (e.g., roll around the longitudinal axis of the sample), linear deviations (e.g., 
shifting the camera), apparent changes in sample size due to changes in distance from 
sample to camera (i.e., as the sample was cut), and perspective deviations (i.e., viewing 
the sample from off the longitudinal axis).  
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The eye was modeled as a sphere and discretized into an array of 100 x 100 
pixels. For each of these 10,000 pixels, a ray originating from the centroid of the eye 
through each point was identified (Figure 4.1B). The intensity along each ray was used to 
map the SCS thickness, as determined by the distribution of red particles, in the SCS 
(Figure 4.1C). The SCS thickness was determined by finding the distance between the 
first appearance and first disappearance of red fluorescence, as determined with an 
absolute intensity threshold and the first derivative of the intensity (to ensure an edge). 
This procedure was repeated for all 10,000 rays to yield a 2D map projection or a 3D 
surface plot (Figure 4.1D and E). Note that only SCS thickness per ray was calculated, 
not particle concentration.  
A low-pass filter was used on the 100 x 100 array to remove aberrant signals. The 
resulting array was viewed as a surface plot in Matlab. Key parameters from each sample 
included distribution of thickness (5th, 25th, 50th, 75th, and 95th percentile, mean, and 
standard deviation) excluding thicknesses < 25 µm, thresholded area, and thresholded 
volume.  
4.3.4 Mechanical testing of sclera-choroid attachments 
To assess the mechanical properties of attachments between the sclera and 
choroid, a peel test (modification of ASTM D1876 method150) was performed on 
sclera/chorioretina strips with and without microneedle injection of HBSS into the SCS 
(N=8 per condition). Albino rabbit eyes ex vivo were used for this experiment.  
Either the superior and inferior hemisphere was randomly assigned to receive a 
microneedle injection of 100 µL HBSS. After injection, two sagittal strips – one with no 
injection and one with SCS injection – from the same eye, approximately 10 mm in width 
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and 14 mm in length, were cut from the eye. The actual width was measured with a 
caliper. A scalpel blade was gently run along the edges of the strip to ensure the edges 
were clean. The ciliary body was cut posterior to the scleral spur so the choroid could be 
separated off the sclera. A 5 mm biopsy punch was used to make a hole through the 
cornea. The strip was mounted on a force displacement station (ESM301 motorized 
stand, Mark-10 Corp., Copiaque, NY) with a 50 gF force sensor (Series 5 Force Gauge, 
Mark-10 Corp.). A hook attached to the force sensor was threaded through the hole in the 
cornea, and the ciliary body was clamped to a stationary platform. The force 
displacement station was programmed to pull (i.e., peel) the sclera from the choroid at a 
rate of 60 mm/min. The force readings were collected in real time by the MESUR Lite 
gauge software. The average force per width of sclera/choroid tissue strip was calculated.  
4.3.5 SCS collapse rate with different liquid formulations 
The rabbit was anesthetized with isoflurane. Topical proparacaine was given to 
further anesthetize the eye. To study the effect of viscosity on SCS collapse time, one of 
the following formulations was injected: [i] 50 µL of HBSS; [ii] 50 µL of Discovisc 
(Alcon Laboratories, Fort Worth, TX); [iii] 50 µL of 1% carboxymethyl cellulose (CMC; 
700 kDa high viscosity) dissolved in HBSS; [iv] 50 µL of 3% CMC in HBSS; [v] 50 µL 
of 5% CMC in HBSS; and [vi] 25 µL of 5% CMC in HBSS. High-frequency ultrasound 
B-scan was used to determine the rate of SCS collapse. Eight sagittal views over the pars 
plana were acquired: (a) supranasal, over the injection site; (b) superior; (c) nasal; (d) 
supratemporal; (e) temporal; (f) infratemporal; (g) inferior; and (h) infranasal. Image 
acquisition for these formulations occurred for up to 28 d in vivo. 
 92 
 
Off-line post processing was performed on the U/S views to measure the SCS 
thickness. The U/S probe used has a minimum axial resolution of 15 μm. For each U/S 
view, a line segment 5 mm posterior to the scleral spur and perpendicular to the sclera 
was created (Figure 4.2). The line started at the outer surface of the sclera and ended at 
the inner surface of the retina. The sclera and chorioretina were included in the 
measurement to ensure the line was perpendicular. SCS thickness was then calculated by 
subtracting the tissue thickness from the measured line length. Curve fitting was done to 
determine the rate of SCS collapse.  
 
Figure 4.2 – Calculation of SCS thickness in ultrasound B scans. A line segment perpendicular to the 
sclera and choroid, from the outer sclera to the inner retina, is found. The conjunctiva is excluded from the 
measurement. The tissue thickness is found and subtracted out, resulting in the SCS thickness.  
4.3.6 Determination of SCS clearance kinetics by fundus imaging 
To study the effect of viscosity on fluorescein movement in the SCS, a 50 µL 
microneedle injection of the following formulations were tested: [i] 0.025% (w/v) 
fluorescein sodium (25% AK-Fluor, Akorn, Lake Forest, IL diluted with HBSS); and [ii] 
0.025% fluorescein sodium (25% AK-Fluor, diluted with HBSS) and 5% CMC in HBSS. 
The approximate clearance rate of injected fluorescent material from the SCS was 
found by taking fluorescence fundus images over time in the rabbit eye in vivo. Topical 
eye drops of tropicamide and phenylephrine (Akorn, Lake Forest, IL) were administered 
prior to each imaging session to dilate the eye. A RetCam II (Clarity Medical Systems, 
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Pleasanton, CA) with the 130° lens attachment and the built-in fluorescein angiography 
module was used to acquire the images. Multiple images were taken with the blue light 
output from the RetCam II set at 0.0009, 1.6, and 2.4 W/m2. In an attempt to capture the 
entire interior surface of the ocular globe, nine images were captured: central, supranasal, 
superior, supratemporal, temporal, infratemporal, inferior, infranasal, and nasal. This 
allowed imaging into the far periphery. Imaging was done immediately after injection, at 
1 h, every 3 h for 12 h, and every two days post-injection.  
The total clearance time, which we defined as the first time point in which 
fluorescence was not detectable by visual observation, was determined for all eyes 
injected. 
4.4 Results  
4.4.1 Effect of injection volume on SCS thickness: cryo-reconstruction 
measurement 
We measured the thickness of the SCS and investigated its distribution in rabbit 
eyes after microneedle injection ex vivo using a 3D cryo-reconstruction method. 2D 
mapping of the spread of particles (Figure 4.3A) in the SCS after injection of different 
volumes of fluid indicated that the area of spreading increased with injection volume.  
Quantification of the SCS thickness throughout the area of spreading produced 
histograms (Figure 4.3B) of the SCS thickness for each injection volume. Sites where 
SCS thickness was less than 25 µm were considered to have “unopened” SCS and were 
therefore not included in the analysis. All particle thickness histograms showed a 
characteristic spike at ~160 µm (i.e., the average mode value among the histograms 
collected at all conditions shown in Figure 4.3 is 160±25 µm (mean±SEM), and there 
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were very few portions of the SCS open to smaller thicknesses. This peak value of SCS 
thickness did not significantly change as a function of injection volume (p=0.43, one-way 
ANOVA). This indicates that if the SCS is opened up, it readily expands to a thickness of 





Figure 4.3 – Distribution of SCS thickness after injection of particles suspended in HBSS into the SCS of 
the rabbit eye ex vivo. Ex vivo rabbit eyes were frozen 1 min after SCS injection and analyzed by 3D cryo-
reconstruction. (A) Representative thickness maps of 200 nm particles, where brighter white color indicates 
thicker SCS spreading. Yellow arrow indicates site of injection, at the 12 o’clock superior position. Each 
2D map is an equatorial projection oriented such that anterior (i.e., cornea) is up and posterior (i.e., optic 
nerve) is down. As with 2D map projections of globes, the area represented by pixels at the upper and 
lower poles are distorted. (B) Data from these thickness maps are presented as histograms for different 
injection volumes (indicated on the left side of the figure). Y-axis is counts with every 100 counts marked. 
(C) Box and whiskers represent 5th, 25th, 50th (median), 75th, and 95th percentile of SCS thickness after 
injection (N=3-7 replicates per condition). 
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The median value of SCS thickness was found to be 330±30 µm, which was 
significantly different from the mode value (p<0.001, unpaired t-test) indicating few 
points where the thickness was less than 150 µm. The median SCS thickness was 
independent of injection volume (p=0.15, F test for zero slope), as shown in Figure 4.3C. 
This finding is notable, because injection of larger volumes of fluid can increase the area 
of fluid spread in the SCS and/or the thickness of the SCS. These data indicate that the 
SCS expands to a maximum thickness, and that injection of additional fluid increases 
area of spreading in direct proportion to the volume injected. To further test this 
hypothesis, we plotted area of spreading versus injection volume and found they 
increased in direct proportion to each other (Figure 4.4).  





















Figure 4.4 – Area of SCS coverage with increasing injection volume. Injection volumes ranging from 25 – 
150 µL were performed in ex vivo rabbit eyes and the area of circumferential coverage was determined by 
3D cryo-reconstruction. Values represent mean±SEM. Linear regression performed on data indicated that 
area was directly related to injection volume (R2 = 0.92).  
Finally, the mean values of SCS thickness were found to be 340±40 µm among all 
the conditions tested. The mean values had a slight dependence on injection volume 
(p=0.04, F test for zero slope). The 5th, 25th, median, and 75th percentile SCS thickness 
was approximately constant for injection volumes greater than 25 µL, but the 95th 
percentile increased with injection volume. The fact that there was a spread of SCS 
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thicknesses to values up to a few-fold larger than the median value indicates that SCS 
thickness can be spread well beyond ~ 300 µm in some cases. These sites of greater SCS 
thickness occurred in patches (see bright spots on Figure 4.3A) that were often located 
near the site of injection.  
4.4.2 Effect of injection volume on SCS thickness: ultrasound B-scan measurement 
To validate the SCS thickness measurements calculated by the cryo-
reconstruction method, we conducted additional experiments to measure SCS thickness 
by ultrasound B-scan in the rabbit eye ex vivo (Figure 4.5). This U/S measurement 
yielded a median SCS thickness of 160±20 µm, which was independent of injection 
volume (p=0.67, F test for zero slope) and was about half the value obtained by the cryo-
reconstruction method (i.e., 330±30 µm). The two methods both showed that SCS 
thickness values were independent of injection volume and had a median value of 
roughly 150 – 350 µm. Since the eyes used in the U/S measurement were at room 
temperature and measured in real time shortly after injection and the eyes used in 3D 
cryo-reconstruction were frozen shortly after injection and measured later, still in the 
frozen state, the observed differences in thickness may be due to differences in timing, 
temperature, solid vs. liquid state tissue fluids or artifacts due to freezing. Furthermore, 
the U/S measurement was not able to assess the SCS thickness at the posterior pole, 




Figure 4.5 – SCS thickness measured with ultrasound B-scan in the rabbit eye ex vivo.  (A) Representative 
ultrasound B scans. (B) Quantification of median SCS thickness ± SEM based on ultrasound (U/S) and 
cryo-reconstruction methods (N=3-7 replicates). Lines on the graph indicate best fits by linear regression. 




4.4.3 Measurement of force of adhesion between sclera and choroid  
We investigated further why median SCS thickness was constant over the range 
of injection conditions studied. The presence of lamellae that attach the sclera to the 
choroid might explain this constant thickness, as they may limit expansion of the SCS 
beyond a certain thickness. The literature suggests that such lamellae exist1, 37, 149. We 
therefore performed a peel test (modified ATSM 1876, Figure 4.6A) on 
scleral/chorioretinal strips from rabbit eyes that had either received or not received a SCS 
injection of HBSS ex vivo. We found that eyes with previous injection in the SCS 
required only 51% of the force to separate the sclera from the choroid compared with 
eyes having no SCS injection (p<0.005, unpaired t-test, Figure 4.6B). This suggests that 
the process of SCS injection weakens the adhesion strength between the sclera and 
choroid, possibly due to reorganizing, weakening, breaking or otherwise altering fibers 
adhering the sclera to the choroid. Since the force to separate the tissue does not become 
zero after injection, adhesive forces between the sclera and choroid, possibly involving 
connective fibers, may play a role in limiting SCS expansion.  
 
Figure 4.6 – Modified ATSM 1876 peel test performed on scleral/chorioretinal (Sc-Ch-Re) strips from eyes 
that had either received (gray bar) or not received (black bar) a 100 µL SCS injection of HBSS ex vivo.(A) 
A diagram of the experimental setup is shown. (B) Mean ± SEM of the force to separate sclera from 
choroid per width of tissue strip is shown (N=8 replicates). P<0.005 = **, unpaired t-test. 
To further interpret these findings, we examined histological sections for 
anatomical structures within the SCS of rabbit eyes that had either received or not 
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received a SCS injection of HBSS in the live rabbit. With no injection, the sclera and 
choroid were tightly apposed (Figure 4.7A). After injection, the sclera and choroid were 
no longer tightly adhered (Figure 4.7B), even more than one month after injection (Figure 
4.7C). Furthermore, there was evidence of structures that appear to be fibrils connecting 
the sclera and choroid (Figure 4.7B and C). It cannot be determined at this time if these 
fibrils were intact or not. In companion experiments, the SCS thickness measured in vivo 
by U/S 30 min or longer post-injection was found to be indistinguishable from pre-
injection thickness (i.e., zero), suggesting that processes in the living rabbit (e.g., 
intraocular pressure) were able to minimize the SCS thickness in vivo but were unable to 
maintain it after death. This finding further supports the hypothesis that there has been a 
loss in adhesion strength, possibly due to changes to the SCS lamellae. 
 
Figure 4.7 – Representative histological images showing SCS fibrils.  (A) In eyes with no injection, the 
sclera and choroid are tightly adhered. (B) In eyes 30 min after HBSS injection, the sclera and choroid are 
no longer closely adherent. There are SCS fibrils visible, especially when image is transformed to black & 
white (insets). (C) In eyes 1+ mo after HBSS injection, the sclera and choroid are still not adherent. There 
are SCS fibrils visible, especially when image istransformed to black & white (insets). When animals were 
viewed under U/S in vivo, no SCS expansion was visible. Sc = sclera; C = choroid; F = SCS fibril. Scale 
bar = 1 mm. 
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4.4.4 Effect of liquid formulation on SCS thickness and collapse time  
We next evaluated the effect of liquid formulation on SCS thickness, as well as 
the SCS collapse rate over time in the living rabbit (Figure 4.8A). We chose solutions of 
carboxymethyl cellulose (CMC) at different concentrations in HBSS and the commercial 
viscoelastic product, Discovisc® as liquid formulations for this study, because these 
liquid formulations were previously shown to distribute differently in the SCS, compared 
with HBSS128.  
The initial SCS thickness over the injection site varied greatly with choice of 
liquid formulation from 0.43±0.06 mm with HBSS to 2.1±0.1 mm with 5% CMC in 
HBSS (Figure 4.8B and Figure 4.9). The value for HBSS found here in the living rabbit 
eye is larger than what was found above in the rabbit eye ex vivo. This could be because 
the in vivo measurement was made at the injection site, which was the site of maximum 
SCS thickness, whereas the ex vivo measurement was reported as the average SCS 
thickness through the expanded SCS. Use of Discovisc, which had previously been 
reported to initially remain near the site of injection in the SCS128, had a SCS thickness of 
1.5±0.4 mm, which was significantly larger than the value for HBSS (p<0.01, Sidak’s 
multiple comparison test). SCS injection of solutions containing 1%, 3% and 5% CMC in 
HBSS (viscous solutions that have also been reported to localize at the injection site128) 
had initial SCS thicknesses of 0.7±0.1 mm, 1.6±0.2 mm and 2.1±0.1 mm, respectively 
(Figure 4.8B). These data indicate that changing the formulation (to increase viscosity) 
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Figure 4.8 – Quantification of median SCS thickness after injection of different liquid formulations as a 
function of time.  (A) Time course of SCS thickness after injection with six liquid formulations. Inset shows 
first 24 h. (B) SCS thickness measured immediately post-injection (θ0) and the maximum SCS thickness 
reached (θmax) when using different liquid formulations. (C) The time constants associated with SCS 
expansion and collapse when using different liquid formulations. All values are mean±SEM (N=4 




Figure 4.9 – Representative ultrasound B-scan images of the SCS after 50 µL injection of (A) HBSS and 
(B) 5% CMC solution. C = conjunctiva; Sc = sclera; SCS = suprachoroidal space; Ch-Re = choroid-
retina. Arrows indicate SCS thickness. 
We next monitored SCS thickness over time at eight positions around the globe 
for all the formulations tested (Figure 4.10A). After injection of HBSS, the SCS thickness 
over the injection site achieved its peak value immediately after injection and then 
decreased according to a roughly first-order exponential decay, i.e., there was no 
significant difference between SCS thickness immediately post-injection (θ0) and the 
maximal SCS thickness (θmax) (p > 0.99, Sidak’s multiple comparison test, Figure 5B). 
Measurements at other locations around the globe behaved similarly.  
There was also no difference between initial and maximal SCS thickness over the 
injection site for Discovisc and 1% CMC (p≥0.97, Sidak’s multiple comparison test). 
However, the SCS thickness measured at the other sites behaved differently, which is 
consistent with a previous study128. With Discovisc, the decrease in SCS thickness at the 
injection site over time was accompanied by a concomitant increase in SCS thickness at 
adjacent sites in the SCS (Figure 4.10A, 4 h). By 2 d, the SCS thickness throughout the 
entire eye had returned to baseline. In contrast, 1% CMC only expanded the SCS at or 
near the injection site for the entire time course (data not shown). Because Kim et al.128 
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had shown that Discovisc was able to facilitate the distribution of particles throughout the 
SCS and that CMC was able to localize particles near the injection site, we hypothesize 
that the expansion of a region of SCS was necessary for particle deposition in that region.  
With 3% CMC and 5% CMC solutions, θ0 over the injection site was different 
than θmax (p<0.01, 2-way ANOVA) because the SCS thickness initially increased over the 
course of hours after the injection. This expansion of the SCS could be explained by an 
osmotic and hydration effect of the CMC within the SCS, which could draw in water 
from the surrounding tissue to dilute the CMC and cause swelling of the gel. Besides the 
swelling, the behavior of the SCS thickness at other positions (Figure 4.10B) was similar 
to those found with 1% CMC. 
To describe the timecourse of SCS thickness changes after injection over the 
injection site, we used a 2nd order exponential equation that could account for both the 
observed expansion and collapse of the SCS:  
 θ(𝑡) = −𝐴𝑒−𝑡 𝜏𝑒𝑥𝑝⁄ + 𝐵𝑒−𝑡 𝜏𝑐𝑜𝑙⁄ ,  Eq. 4.1 
where t is the time post-injection, θ(t) is the SCS thickness as a function of time, A and B 
are thickness constants, τexp is the expansion time constant, and τcol is the collapse time 
constant (Figure 4.8C). This equation described the data from all the liquid formulations 
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Figure 4.10 – Time course of SCS thickness following microneedle injection of (A) 50 µL Discovisc and (B) 
50 µL 5% carboxymethyl cellulose in HBSS. Injection was performed supranasal and U/S B scans were 
acquired at eight positions around the ocular globe. Each time point represents the mean of 3-5 replicates. 
X-axis divisions at Inf. = inferior; Nas. = nasal; Sup. = superior; Temp. = temporal. SCS thickness (y-axis) 




Using this equation, we calculated the characteristic times associated with each of 
the liquid formulations. As expected, the liquid formulations that did not cause further 
expansion of the SCS after injection (i.e., HBSS, Discovisc, and 1% CMC), the 
calculated τexp values were all on the order of seconds (Figure 4.8C, left). In contrast, τexp 
values for the 3% CMC and 5% CMC liquid formulations ranged from 2.8 to 9.1 h, and 
there was no significant difference among these τexp values (p=0.77, F test).  
There were significant differences in τcol values among the liquid formulations 
tested (Figure 4.8C, right). With HBSS as the liquid formulation, τcol was 19±3 min. With 
the Discovisc liquid formulation, τcol was 6±2 h, which was significantly different than 
the HBSS value (p<0.005, F test). With all of the CMC liquid formulations, τcol ranged 
from 2.4 – 9.2 days, which were different than HBSS (p<0.0001, F test) but not different 
from each other (p=0.47, F test). It is notable that collapse of SCS containing 1% CMC 
solution (that did not swell after injection) and SCS containing 5% CMC solution (which 
did swell after injection) had comparable τcol values, which suggests that dissociation of 
the crosslinks found in CMC gels143 is the rate limiting step to CMC clearance from the 
SCS resulting in collapse. 
4.4.5 Effect of liquid formulation on clearance of fluorescent molecules from the 
SCS 
We investigated the effect of liquid formulation viscosity on the timescale of 
clearance of fluorescein from the SCS. Using fundus microscopy, we identified how long 
it took for there to be no visual evidence of fluorescein in the SCS. Total clearance of 
fluorescein injected into the SCS in HBSS was 0.33±0.05 d, which was significantly 
faster than the clearance of fluorescein injected in 5% CMC solution, which was 2.7±0.7 
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d (p<0.0005, unpaired t-test, Figure 4.11). This can probably be explained by the long-
lived presence of viscous CMC gel in the SCS (as evidenced by the SCS remaining open 
for many days, Figure 4.8 and Figure 4.10), which can slow diffusion of fluorescein out 
of the SCS. 
























) * * *
 
Figure 4.11 – The total clearance time of fluorescein from the SCS after injection in HBSS or 5% CMC 
solution. Total clearance time is defined as the first time point at which fluorescein was not detectable 
under fluorescent fundus exam. All values are mean±SEM (N=3-6 replicates). p<0.0005 = ***, unpaired t-
test.  
4.5 Discussion  
4.5.1 SCS thickness is independent of injection volume 
This study examined the effects of injection volume and liquid formulation on the 
thickness and closure kinetics of the SCS following microneedle injection. We found that 
the SCS was spread to a roughly constant thickness, independent of injection volume. 
The observation was made in the rabbit eye ex vivo using two different measurement 
methods: 3D cryo-reconstruction and U/S B-scan imaging. This result was not 
necessarily expected. Injection of an increasing volume of fluid into the SCS could be 
accommodated by an increase in SCS thickness, SCS area, or a combination of both. Our 
data indicate that the SCS readily expands to a certain thickness, after which additional 
fluid fills the SCS by expanding the SCS area containing fluid without expanding the 
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SCS thickness further. This explanation was supported by demonstration that the area of 
fluid in the SCS increased in direct proportion with the volume injected.  
We and others hypothesized that the constant SCS thickness could be due to 
fibrils running between the sclera and choroid that resist expansion of the thickness of 
this space1, 125. Results from a modified peel test to determine the strength of adhesion 
between sclera and choroid showed that a fluid injection into the SCS as a pretreatment 
reduced, but did not eliminate, the force needed to subsequently separate the tissues. This 
could be explained by a partial weakening of the adhesions between sclera and choroid, 
possibly due to reorganizing, weakening, breaking or otherwise altering the fibrils with 
an injection. We also imaged evidence of these fibrils in the SCS, which was consistent 
with previous reports1, 37.  
Previous studies were inconclusive regarding the relationship between SCS 
thickness and injection volume. Seiler et al. concluded that, in ex vivo canine and porcine 
eyes, there was a difference between the maximum thickness achieved with the smallest 
injection volume tested (250 µL), and higher injection volumes tested (500, 800 and 1000 
µL)116. However, no difference in maximum thickness was seen once the eyes were 
inflated to physiological intraocular pressures116. Moreover, the Seiler study assessed 
maximum thickness, rather than median thickness reported here, and it used much larger 
volumes of fluid, which are much greater than those used in current clinical trials7.  
Gu et al. found that, in guinea pigs, the cross-sectional area of the SCS increased 
with increasing injection volume120. However, as seen in Figure 4.5A of this study, not all 
the SCS was expanded, especially at small injection volumes. Thus, increases in cross-
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sectional area could be attributed to either expanding previously-unexpanded SCS (i.e., to 
enlarge the area of SCS expansion), or increases in SCS thickness.  
4.5.2 SCS thickness depends strongly on injection liquid formulation  
We found that liquid formulation had a major effect on SCS thickness, possibly 
related to fluid viscosity. While HBSS spread over large areas of the SCS, Discovisc and 
CMC solutions were largely retained near the site of injection initially, probably due to 
their high viscosity. This might be explained by the viscous forces resisting spread of the 
injected fluid in the SCS leading to the fluid further expanding the SCS near the site of 
injection in order to accommodate the injected fluid volume. Interestingly, in some cases 
(i.e., 3% CMC and 5% CMC solutions), SCS thickness continued to expand for hours 
after the injection, probably due to the diffusion of water into the hydrogel, which 
resulted in swelling it.  
At later times, SCS thickness decreased and ultimately returned to baseline within 
hours for HBSS and within days to weeks for the viscous solutions. These slow kinetics 
were probably controlled by clearance of the polymer components of the hydrogels from 
the SCS, which was significantly slower for CMC, which forms a physically crosslinked 
gel143.  
4.5.3 SCS thickness controlled by balance between viscous forces of the liquid 
formulation and biomechanical forces of the tissue 
We propose that SCS thickness is controlled by a balance between the viscous 
forces of the liquid formulation and the biomechanical forces inherent to the tissue (such 
as the viscoelastic properties of the sclera and choroid, as well as the viscoelastic and 
failure mechanics of the SCS fibrils). A cartoon of this is presented in Figure 4.12. When 
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fluid first enters the SCS, it can expand the thickness of the SCS at the site of injection 
and/or it can expand the area of the SCS that it occupies. We propose that what 
determines how the SCS expands to accommodate the fluid is based on whether there is 
less physical resistance to increasing thickness or to increasing area. Increasing thickness 
will require overcoming biomechanical forces (e.g., from fibrils connecting sclera to 
choroid) and elastic restoring forces of the sclera and choroid tissues151 13, 151, 152. 
Intraocular pressure differences between the SCS and adjacent tissues may also play a 
role34. Increasing area will require overcoming the viscous forces opposing flow of fluid 
circumferentially in the SCS.  
We further propose that the required force increases with increasing SCS 
expansion in thickness, while the required force of viscous flow within the SCS is a 
function of fluid viscosity and SCS thickness. We hypothesize that when the SCS is fully 
collapsed, the force required to expand the thickness of the SCS is less than the force to 
flow liquid through the adjacent collapsed SCS to expand the area. As more fluid is 
forced into the SCS, the SCS thickness continues to expand until the force required for 
further expansion of thickness of SCS exceeds the force required to flow fluid out into 
adjacent SCS. This switch occurs due to two factors: (i) as the SCS thickness increases, 
the force required to further increase thickness escalates and (ii) as the SCS thickness 
increases, the viscous forces to flow into adjacent SCS decrease because flow through 
wider channels exhibits less resistance to flow.  
When injecting HBSS (with a low viscosity comparable to water) into SCS of the 
rabbit, the force balance switches when the SCS is expanded to 150 – 350 µm in the 
rabbit eye ex vivo and to 400 – 500 µm in the rabbit eye in vivo; we can call this thickness 
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the “equilibrium thickness,” because it represents the thickness when the force needed to 
expand thickness equals the forces needed to expand area of the SCS. In this way, SCS 
expansion readily expands to the equilibrium thickness, because increasing SCS area 
requires less force than further increasing SCS thickness. A distribution of equilibrium 
thicknesses is expected, as seen in Figure 4.12, due to variation in the mechanical 
properties of the SCS. 
When injecting Discovisc or CMC, which have higher viscosity than HBSS (e.g., 
>170,000 cP for 1.7% CMC (700 kDa) in HBSS128, 143), the force balance should be 
altered. The force to expand SCS thickness may only be marginally affected by the 
increase in viscosity, because the main resistance to expansion is from the ocular tissues, 
not from viscous flow. In contrast, the force to expand SCS area may be significantly 
affected, because expansion of area requires flow of fluid into narrow channels of SCS 
that becomes increasingly difficult as viscosity increases. Thus, the equilibrium thickness 
of the SCS increases, because expansion of SCS area requires greater force.  
In the case of 3% CMC and 5% CMC solutions, there is an additional force in 
play. After the fluid has been injected and the SCS expanded to its equilibrium value, 
diffusive forces pulling fluid into the CMC gel formed in the SCS cause the gel to 
expand. Because the gel has physical crosslinks, it cannot easily flow through SCS to 
expand area, but instead expands in place, which primarily expands SCS thickness. In 
this case, a new force balance is set up between the expansive swelling force of the gel 
and the resistive biomechanical forces of the ocular tissue. This results in a new 




Figure 4.12 – Schematic of SCS expansion after injection of fluid.  (1) The SCS is closed before injection. 
(2) Upon injection the SCS expands to an equilibrium thickness (θeq) determined by a balance between 
viscous forces of the liquid formulation and the resistive biomechanical forces of the tissue. This thickness 
is smaller for low-viscosity fluids (θeq in 2a) than for high-viscosity fluids (θeq’ in 2b), due to increased 
resistance to flow. (3) As the injection proceeds, the area of expanded SCS increases to accommodate the 
additional fluid, but the SCS thickness remains constant. (4) After injection is complete, no further growth 
of the SCS usually occurs (4a, 4b(i)), but a gel that continues to swell could further increase SCS thickness 
(θeq” in 4b(ii)) 
4.5.4 Additional comments  
The ability to modulate SCS thickness could have implications on emerging SCS 
technologies, such as targeted drug delivery, placement of glaucoma drainage devices, 
and suprachoroidal retinal prostheses. For example, increasing liquid formulation 
viscosity has a dual effect of expanding the SCS and localizing the circumferential spread 
at the site of injection. This might be useful in treating localized diseases, such as placing 
anti-glaucoma agents in the anterior SCS near their site of action in the ciliary body6, 115 
or localizing anti-cancer agents in the SCS adjacent to intraocular tumors. In another 
application, SCS injections of sodium hyaluronate have been made as an alternative to 
scleral buckling for the treatment of retinal detachment153, 154. As shown in the present 
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study, greater distension and localization are achievable with CMC, which continues to 
expand after injection, compared with hyaluronic acid (i.e., a major component of 
Discovisc), which does not. Perhaps use of CMC as a liquid formulation may yield better 
results. Finally, microneedle injection of a viscous liquid formulation could be made prior 
to surgical implantation of suprachoroidal devices. This could transiently weaken sclera – 
choroid adhesion (e.g., stretch or break SCS fibrils), allowing for easier implantation. 
There was a difference between the ex vivo and in vivo SCS thickness. Ex vivo 
eyes were chosen to remove the confounding effect of fluid clearance from the eye that 
occurs in vivo. Intraocular pressure changes in post mortem eyes were significantly faster 
than eyes in the living rabbit, indicating faster normalization of ocular volume, 
presumably by clearance of fluid. This difference in behavior could be explained by loss 
of tissue integrity (e.g., loss in the biomechanical strength of sclera or SCS fibrils), the 
absence of living process (e.g., choroidal perfusion, intraocular pressure), or 
consequences of these effects (e.g., increased trans-scleral and perivascular drainage).  
Increasing formulation viscosity had a modest effect on the residence time of 
small molecules dissolved in the formulation. This effect could be explained by 
decreased diffusivity through the viscous formulation compared with less viscous 
formulations. Controlled-release polymeric systems115 may be more suitable if the goal is 
drug delivery for one month or longer. 
Limitations of the study include use of ex vivo rabbit eyes in some experiments. 
Species differences between rabbit and human eyes may affect the translation of these 
findings to clinical medicine. Further experiments in human eyes are warranted. The U/S 
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was only able to image the far periphery, not the posterior aspect of the eye. This may 
bias the SCS thickness measurements but should not change the general trends observed. 
4.6 Conclusions 
In conclusion, microneedle injection of fluid into the SCS results in distension of 
the choroid off the sclera, which expands the thickness of the SCS. Liquid formulation 
injected into the SCS had a major effect on SCS thickness, where highly viscous fluids 
expanded SCS thickness more than low-viscosity HBSS. Surprisingly, increasing 
injection volume of HBSS had no significant effect on SCS thickness, such that injection 
of increasing volume of fluid was accommodated by increasing area of fluid spread in the 
SCS while maintaining constant SCS thickness. Expansion of SCS thickness in vivo 
ranged from 0.43±0.06 mm after injection of HBSS and 0.7 – 2.8 mm after injection of 
viscous formulations. Injection of CMC solutions led to further expansion of SCS 
thickness over the course of hours after the injection was completed, which could be 
explained by swelling of CMC gel in the SCS. Clearance of HBSS from the SCS 
occurred within 1 h and clearance of Discovisc and CMC took days to weeks.  
These observations could be explained by SCS expansion controlled by a balance 
between the viscous forces of the injected liquid formulation (which increase with fluid 
viscosity) and the biomechanical forces that hold the sclera and choroid together (which 
are unaffected by fluid viscosity or fluid volume). There is evidence that the forces that 
limit expansion of SCS thickness may be in part related to fibrils that bind the sclera and 
choroid and that may need to stretch and/or break to accommodate SCS expansion. These 
findings that affect the extent and duration of expanded SCS thickness and area, may be 
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used to improve control over targeted drug delivery and placement of devices in the SCS 
for therapeutic applications.  
  
 
5 CLEARANCE KINETICS AND CLEARANCE ROUTES OF 
MOLECULES FROM THE SUPRACHOROIDAL SPACE AFTER 
MICRONEEDLE INJECTION 
5.1 Summary 
The purpose of this work was to determine clearance kinetics and routes of 
clearance of molecules injected into the suprachoroidal space (SCS) of live New Zealand 
White rabbits. 
The SCS collapse rate was determined by ultrasonography after microneedle 
injection of Hank’s Balanced Salt Solution (HBSS). Fluorescent fundus images were 
acquired to determine clearance rates of fluorescent molecules ranging in molecular mass 
from 323 Da to 2 MDa and 20-nm green-fluorescent polymeric particles. A microneedle 
injection containing fluorescein in HBSS was performed, and samples were taken over 
time to determine amount of fluorescein on the scleral surface at the injection site, on the 
anterior surface and on the posterior surface, including sites where vortex veins 
penetrated through sclera. Blood was also sampled from the vortex vein. Clearance 
transport was modeled theoretically and compared to data.  
We found that after injection of 50 µL of HBSS solutions, intraocular pressure 
(IOP) spiked and then returned to baseline over a characteristic time of ~5 min. There 
was no significant difference between pressure in the SCS and the vitreous humor. After 
injection, SCS expanded and then collapsed over a characteristic time of ~20 min, which 
provides a measure of the time scale of fluid clearance from the SCS. Characteristic time 
of clearance of molecules from the SCS ranged from 4 h to 26 h, in proportion to 
molecular mass. Total clearance time from the SCS (i.e., below detection limit) ranged 
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from 22 h for fluorescein to 21 d for 2 MDa FITC-dextran. Nanoparticles were not 
cleared from the SCS at all. One hour after fluorescein injection, 57% was still present in 
the eye, 14% had transported through the sclera, 6% had been cleared by the choroidal 
vasculature, and 3.8% had refluxed out the injection site or via perivascular leakage 
pathways. These data generally agreed with predictions from a two-dimensional model of 
clearance transport.  
In conclusion, clearance of molecules from the SCS occurred in three regimes: (i) 
on a time scale on the order of 10 min, fluid and molecules were cleared from the SCS by 
pressure-driven reflux out leakage sites across the sclera (i.e., injection site and 
perivascular drainage) and remaining molecules were transported out of the SCS into the 
choroid and sclera, (ii) on a time scale of 1 – 10 h, molecules were cleared from the 
choroid by blood flow and (iii) on a time scale of days up to weeks, molecules were 
cleared from the sclera by diffusion as well as IOP-driven convection. Clearance kinetics 
were strongly dependent on molecular size, where 2 MDa FITC-dextran was cleared 
significantly slower than smaller molecules.  
5.2 Introduction 
Suprachoroidal drug delivery is an emerging route of administration that targets 
diseased tissues in posterior segment diseases, such as age-related macular degeneration 
and uveitis2, 7, 81, 119. Since the suprachoroidal space (SCS) is bounded by the ciliary body, 
choroid, and sclera, significantly higher bioavailability at these tissues can be achieved 
with SCS delivery compared with eye drops or intravitreal (IVT) injections5, 8, 123, 124, 126. 
Due to higher bioavailability, significant dose sparing can be achieved with drugs that 
have their site of action at these tissues6, 9. Fewer ocular side effects are expected due to 
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dose sparing and also because drugs are compartmentalized away from non-target tissues 
(e.g., lens). Furthermore, a short needle, with a length matched to the thickness of the 
sclera (aka, a microneedle), can be used in an outpatient procedure similar to an IVT 
injection7, 8. Indeed, the safety and tolerability of a microneedle injection has been 
demonstrated in a Phase I/II clinical trial (NCT01789320) where triamcinolone acetonide 
was injected into the SCS to treat non-infectious posterior uveitis7. Other indications are 
also actively being pursued. 
When comparing the pharmacokinetics of molecules in the SCS against IVT 
injections, higher levels of injected molecules have been found in the chorioretina with 
significantly faster clearance. Olsen et al. reported that 12 h after SCS injection, higher 
levels of bevacizumab were found in the chorioretina compared with IVT injection9. 
However, at 7 days, bevacizumab was undetectable in the SCS group, but remained 
relatively high in the IVT group. Patel et al. observed a clearance half-life of 3.6 – 7.9 h 
for various macromolecules injected into the SCS8, 81. Tyagi et al. reported that sodium 
fluorescein concentration in the chorioretina was 25-fold higher after SCS injection 
compared with IVT injection; however, 2 h after injection, fluorescein levels in the 
chorioretina were higher in the IVT injection group than in the SCS group124. Similarly, 
Wang et al. found that the elimination half-life of ketorolac was longer with intravitreal 
injections than SCS delivery (3.1 hr vs. 1.2 hr)5. Interestingly, Wang et al. reported a 
lower Cmax in the chorioretina for the SCS group than the IVT group. Gu et al. found that 
the SCS collapsed to baseline levels within 1 h120. To our knowledge, no studies have 
systematically investigated factors that affect clearance from the SCS. 
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Although prior studies have investigated the pharmacokinetics of SCS delivery, 
only limited information exists about different routes of clearance from the SCS and their 
relative contributions to clearance. Moseley et al. found that the clearance of Xenon and 
radioactive water injected intravitreally was due to choroidal blood flow11, 155. Indeed, 
Olsen et al. and Tyagi et al. hypothesized that molecules injected into the SCS are rapidly 
cleared by choroidal blood flow9, 123. Abarca et al. demonstrated significantly faster 
clearance of fluorescein from the SCS with choroidal perfusion than without in a 
postmortem porcine model126. Classical experiments performed by Bill et al. in 
elucidating the uveoscleral outflow pathway showed that microspheres injected into the 
anterior chamber were found trapped in the SCS where blood vessels penetrated through 
the sclera41, 43. These particles were able to exit the eye through perivascular drainage 
routes. Since SCS injections expand the SCS and generate a significant pressure gradient 
out of the SCS, we believe the mechanisms elucidated by either Moseley et al. or Bill et 
al. do not provide the complete picture. 
The purpose of this work is to measure clearance kinetics and to identify the 
dominant routes of clearance from the rabbit SCS after microneedle injection. We 
hypothesize that clearance of fluid and dissolved molecules injected into the SCS occurs 
initially through leakage sites across the sclera (i.e., injection site and perivascular 
drainage) and then by trans-scleral transport. Later, clearance from the SCS is by 
diffusion into and clearance by the choriocapillaries. 
5.3 Methods 
All reagents and chemicals were purchased from Sigma-Adrich (St. Louis, MO) 
unless otherwise specified. All experiments were performed in albino New Zealand 
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White rabbits (Charles River, Wilmington, MA) and were approved by the Georgia 
Institute of Technology Institutional Animal Care and Use Committee. Practices 
complied with the ARVO Statement for the Use of Animals in Ophthalmic and Vision 
Research.  
5.3.1 Microneedle injection 
The rabbit was anesthetized with isoflurane and an eye drop of proparacaine 
(Bausch & Lomb, Rochester, NY) was given as a topical anesthetic prior to injection. For 
all experiments, a 50 µL injection was performed in each eye with a 33-gauge 
microneedle approximately 750 µm in length (Clearside Biomedical, Alpharetta, GA) 
and a 1 mL syringe. All injections were made in the supranasal quadrant 3 mm posterior 
to the limbus and 4 mm nasal to the superior rectus muscle. Four eyes were used in each 
group unless otherwise specified. The 50 µL injection occurred in 3 s. After injection, the 
needle was kept in place for 1 min to limit reflux at the injection site.  
5.3.2 Determination of SCS collapse rate by ultrasonography 
High-frequency ultrasound B-scan (U/S; UBM Plus, Accutome, Malvern, PA) 
was used to determine the rate of SCS collapse after a microneedle injection of 50 µL 
Hank’s Balanced Salt Solution (HBSS; Mediatech, Manassas, VA) into the SCS. Three 
sagittal views were acquired: (a) supranasal, over the injection site; (b) superior, 45° 
lateral to the injection site; and (c) nasal, 45° nasal to the injection site. Image acquisition 
occurred every minute for 10 min, and then every 2 min for 1 h.  
Off-line post processing was performed on the U/S views to determine the SCS 
thickness. For each U/S image, a line segment 5 mm posterior to the scleral spur and 
perpendicular to the sclera was found. The line started at the outer surface of the sclera 
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and ended at the inner surface of the retina, which were readily identifiable on the U/S 
images. The sclera and chorioretina were included in the measurement to ensure the line 
was perpendicular. SCS thickness was determined as the length of the line segment minus 
the thickness of the sclera and chorioretina. The characteristic time of SCS collapse was 
determined by modeling SCS thickness versus time as an exponential decay.  
5.3.3 Fluorescent labeling of monoclonal antibody 
Bevacizumab (Avastin, Genentech, South San Francisco, CA) was fluorescently 
labeled with fluorescein isothiocyanate (FITC) using previously described methods40. 
Briefly, 40 mg FITC was added to a 1.0 mL sodium bicarbonate (pH = 9) solution, and 3 
mL of bevacizumab solution (25 mg/mL) was added to the FITC solution and stirred in 
the dark for 2 h at room temperature. The solution was dialyzed against phosphate 
buffered saline (PBS) using dialysis tubing with a cutoff of 30 kDa (Spectra/Cor, 
Spectrum Laboratories, Rancho Dominguez, TX). The PBS was changed daily for 5 days 
to remove unreacted FITC. 
5.3.4 Determination of SCS clearance kinetics by fundus imaging 
To study the effect of molecular radius on clearance from the SCS, a 50 µL 
microneedle injection of the following formulations were tested: [i] 0.025% (w/v) 
fluorescein sodium in HBSS; [ii] 0.5% (w/v) 70 kDa FITC–dextran in HBSS; [iii] 00.5% 
(w/v) 500 kDa FITC-dextran in HBSS; [iv] (w/v) 2 MDa FITC–dextran in HBSS; [v] 
1.5% (w/v) FITC–bevacizumab in HBSS; and [vi] 1% (w/v) 20 nm green-fluorescent 
particles (Excitation: 505 nm, Emission: 515 nm; FluoSpheres, Life Technologies, 
Carlsbad, CA) in HBSS.  
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The clearance rate of injected fluorescent material from the SCS was estimated by 
taking fluorescence fundus images over time. Topical eye drops of tropicamide and 
phenylephrine (Akorn, Lake Forest, IL) were administered prior to each imaging session 
to dilate the eye. A RetCam II (Clarity Medical Systems, Pleasanton, CA) with the 130° 
lens attachment and the built-in fluorescein angiography module was used to acquire the 
images. Multiple images were taken with the blue light output from the RetCam II set at 
0.0009, 1.6, or 2.4 W/m2. In an attempt to capture the entire interior surface of the ocular 
globe, nine images were captured: central, supranasal, superior, supratemporal, temporal, 
infratemporal, inferior, infranasal, and nasal. This allowed imaging into the far periphery. 
Imaging was done 3 min after injection, at 1 h, every 3 h for 12 h, and every other day 
post-injection for up to 28 days.  
The relative concentration of the injected fluorescent molecules was estimated for 
each eye at each time point by comparing the average fluorescence intensity with aliquots 
of known concentrations imaged using the same lighting conditions for calibration. The 
characteristic times of SCS clearance rate and total clearance time were determined by 
modeling these processes as exponential decays in fluorescein concentration in the SCS 
over time. 
5.3.5 Intraocular pressure measurements 
A custom-designed pressure measurement system was used to measure pressure 
in the vitreous humor (VH) and in the SCS after either an IVT or SCS injection. The 
animal was terminally anesthetized with a subcutaneous injection of a ketamine and 
xylazine cocktail. A 33 gauge, 0.5 inch hypodermic needle was penetrated through the 
pars plana into the VH, and a 33 gauge microneedle was penetrated through the sclera 3 
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mm posterior to the limbus to access the SCS. Both needles were connected 
by polyethylene tubing (I.D. 1.14 mm, Becton Dickinson and Company, Sparks, MD) to 
a T-junction (i.e., to switch between the SCS and VH) that was in fluid communication 
with a second T-junction. The second T-junction allowed switching between either a 1 
mL syringe (to inject HBSS into either the SCS or the VH) or a pressure transducer 
(Honeywell 142PC01, Morris Plains, NJ). The pressure transducer was zeroed to the 
height of the eye, and the height difference of the needle openings was also found (<10 
mm height difference). A custom Labview (National Instruments, Austin, TX) script was 
used to record the pressure trace. 
A 50 µL SCS or IVT injection (N=4 per injection site) was made either in the 
SCS or the VH, respectively. The pressure in the SCS and VH was measured by 
switching the T-junction between the two sites every few minutes. The pressure was 
monitored until the pressures had reached their original baseline values from before the 
injection (i.e., ~15 mmHg). After the measurements, the animal was euthanized with a 
lethal dose of pentobarbital injected intravenously. A second set of SCS and IVT 
injections was made in the animal postmortem. In the postmortem measurements, 
pressure was only measured in the tissue space (i.e., SCS or VH) where the injection was 
made. 
The characteristic times of elevated pressure in the SCS and VH were determined 
by modeling these processes as exponential decays in pressure over time.  
5.3.6 Collection of fluorescein by different clearance routes 
For this terminal experiment, the rabbit (N=4 eyes per group) was anesthetized 
with a subcutaneous injection of ketamine and xylazine before microneedle injection; 
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additional injections were given every 30 min to maintain anesthesia. A subcutaneous 
injection of 60 mL saline was also given on the rump to counteract fluid loss. The amount 
of fluorescein exiting the eye by four routes was determined by collecting samples over 
time from the [i] sclera anterior to the equator; [ii] anterior sclera with injection site 
plugged; [iii] sclera posterior to the equator; and [iv] posterior sclera with vortex vein 
transected.  
Prior to the microneedle injection, the conjunctiva in the supranasal quadrant was 
carefully dissected off the sclera. A 50 µL microneedle injection was performed 
supranasally 4 mm nasal to the superior rectus muscle and 3 mm posterior to the limbus. 
In the [i] anterior sclera and [iii] posterior sclera conditions, samples were collected every 
minute for 10 min, and every 2 min for 1 h by swabbing the space with a 1 cm x 1 cm 
paper tissue (Kimwipe, Kimberley-Clark, Irving, TX) for the entirety of time between 
each time point (i.e., one or two minutes). Care was taken to swab only anterior or 
posterior to the equator, depending on the condition. The tissue was then placed in 1 mL 
of HBSS until analysis.  
To determine the amount of fluorescein leaving [ii] the anterior sclera with 
injection site plugged, a similar experiment was performed. Immediately post-injection, 
the site of injection was plugged by carefully applying cyanoacrylate glue (Loctite 4013, 
Düsseldorf, Germany) with a 30 gauge needle to the microneedle hub to seal the gap 
between the microneedle and surrounding scleral tissue. After the microneedle injection 
occurred, the microneedle was left in the eye. Other methods were the same as above. 
For the eyes that had a vortex vein cut [iv], the superior vortex vein was 
transected prior to injection. Heparin (5 mL of 10,000 IU/mL; Hospira, Lake Forest, IL) 
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was given intravenously prior to the start of the experiment to prevent coagulation. The 
vortex vein was found under the nasal edge of the superior rectus muscle. The rectus 
muscle was lifted off the ocular surface to expose the vortex vein. The vortex vein was 
confirmed by verifying its path, i.e., originating from within the sclera and traveling 
posteriorly along the ocular surface towards the optic nerve. A transfer pipette was used 
to collect the blood exiting the vortex vein every 1 min post-injection for 10 min, and 
every 2 min for 1 h. The volume of collected blood collected was recorded and HBSS 
was added to reach a final volume of 2 mL per sample for analysis.  
Immediately after the last time point, all animals were euthanized with an 
injection of pentobarbital through the marginal ear vein. The eyes were enucleated to 
measure the amount of fluorescein remaining in the vitreous humor and within the tissue 
(including the SCS). An incision in the cornea was made so the aqueous humor, vitreous 
humor, and lens could be drained from the ocular globe and collected. The remaining 
ocular tissues (with undisturbed SCS) were collected. The Kimwipe paper tissue and 
ocular tissue samples were placed in HBSS at 4 °C for 2 days to allow the fluorescein to 
diffuse out and equilibrate with the HBSS. It is possible that fluorescein bound to the 
Kimwipe tissue paper but it should have done so equally for all conditions tested. The 
amount of fluorescein in all samples was measured using a multiplate reader (Synergy 
H4, BioTek, Winooski, VY) with parameters set to excitation = 494 nm and emission = 
521 nm.  
Further analysis was performed using Matlab (MathWorks, Natick, MA) and 
Prism (Graphpad, La Jolla, CA) software. The characteristic times of clearance rate via 
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each route were determined by modeling these processes as exponential decays in 
fluorescein concentration over time. 
5.3.7 Data and Statistical Analysis 
Prism and Matlab software were used to perform data and statistical analysis. 
Data were fit to exponential decays to find relevant parameters (e.g., time constant) using 
the formula 𝑦(𝑡) = 𝑌0𝑒
(−𝑡 𝜏⁄ ), where t is the time post-injection, y(t) is the SCS thickness 
or fluorescent-molecule fluorescence at time t, Yo is the maximum SCS thickness or 
fluorescent-molecule fluorescence, and τ is the characteristic time constant of SCS 
collapse or fluorescent molecule clearance, respectively. Other data were fit to an 
exponential approach function, N(𝑡) = 𝑁0(1 − 𝑒
(−𝑡 𝜏⁄ )), where t is the time post-
injection, N(t) is cumulative amount of fluorescein collected at time t, No is the maximum 
amount of fluorescein, and τ is the characteristic time constant. 
All values are reported either as mean ± standard error of the mean (mean±SEM), 
or mean and 95% confidence interval (mean [95% CI]), unless otherwise specified. One-
way ANOVA analysis was performed to determine statistical significance (α=0.05) 
among multiple conditions. F test was used to compare parameters generated by curve 
fits.  
5.4 Results 
5.4.1 SCS collapse rate as a measure of fluid clearance rate from the SCS 
We determined the SCS collapse rate in live rabbits after microneedle injection of 
HBSS into the SCS (Figure 5.1). Under typical conditions before injection, the sclera and 
choroid in rabbits were apposed since the SCS is normally collapsed (Figure 5.1A, pre). 
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Upon microneedle injection, fluid was introduced into the SCS, which caused the choroid 
to distend off the sclera. This created a gap between the sclera and choroid when viewed 
under ultrasound B scan (Figure 5.1A, 1 min), which we tracked over time and used as a 
proxy for SCS collapse rate and fluid clearance rate. Since the SCS expansion due to 
HBSS can be measured directly, no tracers or contrast agents were added to the fluid.  
 
Figure 5.1 – SCS thickness over time determined by ultrasound B-scan images acquired during supranasal 
injection of 50 µL HBSS into the SCS of the live rabbit.  (A) Representative B-scans of time course. C/Sc = 
conjunctiva/sclera interface; SCS = expanded suprachoroidal space; Ch/Re = choroid/retina interface. 
Scale bar represents 1 mm. (B) Quantification of SCS thickness (mean only, N = 2-6 replicates) 2 mm 
posterior to scleral spur at three locations. The SEM for all time points ranged from 0.00 to 0.21 mm with a 
mean of 0.06 mm. Reported time constants (τcol) were derived from exponential-decay curve fitting. 
After a 50 µL injection in the supranasal position, we tracked collapse of the SCS 
as a function of time directly over the injection site and also superiorly and nasally 
(Figure 5.1B). The data were fit to an exponential decay (r2=0.62-0.71). One minute after 
the injection, the SCS thickness over the injection site was 470 ± 60 µm (mean±SEM). 
The collapse time constant (τcol) was 19 min [15; 27 min 95% confidence interval]. The 
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SCS expansion was indistinguishable from pre-injection thickness by 40 min post-
injection. There was no significant difference in the curve fits for the measurements made 
supranasal or nasal (p=0.89, F test). Collapse rate of the superior SCS (τ = 5.5 min [3.9; 
9.4 min]) was significantly faster than the other two positions measured (p<0.05, F test). 
This could be due to nearby perivascular drainage routes, but more experiments are 
warranted to explore this hypothesis. 
5.4.2 Clearance rate of fluorescent molecules from the SCS 
We determined the clearance rates of different-sized fluorescent molecules and a 
fluorescent nanoparticle injected as solutions into the SCS of live rabbits. The molecules 
ranged in molecular weight from 332 Da (fluorescein) to 2 MDa (FITC-dextran), which 
corresponds to effective molecular diameters of roughly 1 nm38 to 54 nm156, 157, 
respectively. The nanoparticle measured 20 nm in diameter. Bright-field and fluorescence 
fundus images were acquired for each fluorescent molecule tested over time (Figure 5.2). 
Since the rabbits were albino, the eyes were unpigmented, which made the choroidal 
vessels readily visible beneath the inner retinal vessels (Figure 5.2, pre (brightfield)). 
Furthermore, there was no detectable green autofluorescence with the light level used 
(Figure 5.2, pre).  
After injection, the fluorescent molecules and nanoparticles were visible in the 
SCS (Figure 5.2, 3 min and 14 d); localization in the SCS (i.e., behind the choroid) was 
confirmed by the shadowing of the choroidal vessels over the green fluorescence. Three 
minutes after injection, fluorescein in HBSS and 2 MDa FITC-dextran in HBSS 
distributed similarly in the SCS, occupying 56±6% and 58±7% of the visible SCS 
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respectively (p=0.95, Dunnett’s test). Both fluorescein and 2 MDa FITC-dextran covered 
larger areas of SCS than the nanoparticles (28±6%; p<0.05, Dunnett’s test). 
We further determined the rate of clearance by determining (i) the total clearance 
time and (ii) the clearance time constant (τclearance) calculated using a curve fit derived 
from the normalized concentration of fluorescein over time. We defined total clearance 
time as the first time point post-injection where fluorescence was not detected in the 
fundus images. Representative time courses for fluorescein (Figure 5.2, upper row and 
Figure 5.3A) and 2 MDa FITC-dextran (Figure 5.2, middle row and Figure 5.3B) show 
the rates of clearance and the calculated total clearance time. In the representative images 
in Figure 5.3A and B, the fluorescein is not visible by 1 d, whereas the 2 MDa FITC-
dextran was not totally cleared until 21 d.  
The fluorescence was tracked via fundus examinations with a series of lighting 
conditions, and used to estimate relative concentration of the fluorescent molecules over 
time in the SCS. For each fluorescent molecule, the data were fit to an exponential decay 
(r2 > 0.84; Figure 5.3C). The time constants from the curve fits are shown in Figure 5.3D 
(closed squares), along with the total clearance time (Figure 5.3D, open circles) for all the 




Figure 5.2 – Representative brightfield and fluorescent fundus images of the live rabbit eye before, 3 min 
post- and 14 days post-injection of 50 µL of fluorescein, 2 MDa FITC-dextran, or 20 nm polystyrene 
particles. Three minutes post-injection, the fluorescein and 2 MDa FITC-dextran were distributed 
approximately equally. The microspheres occupied less area than the other formulations. The 2 MDa 
FITC-dextran is still visible 14 days post-injection The particles were visible for at least 2 mo (data not 
shown). Inset depicts fundus image taken under brighter light setting, enabling visualization of regions with 
lower level of fluorescence. All eyes oriented such that up is superior (sup.) and nasal is left (nas.). Fundus 
field of view is 130°. 
Clearance time constant was linearly dependent on molecular diameter (Figure 
5.3D, r2=0.87), varying from 4.3 ±  0.4 h for fluorescein and 26 ± 9.8 h for 2 MDa FITC-
dextran. Total clearance time could also be fit to a line (Figure 5.3D, r2=0.43), but 
appears to show nonlinearity at high molecular size. While clearance time constant had a 
similar value to total clearance time for the smaller molecules, total clearance time was 
bigger for the larger molecules, suggested a biphasic clearance rate for which a fraction 
of the larger molecules persist in the SCS for a long time. The nanoparticle was not 
cleared from the SCS for the duration of the study (> 2 months). Despite differences in 
molecular weight and chemical structure between FITC-dextran and FITC-bevacizumab, 
clearance times were similar due to comparable hydrodynamic diameter of 70 kDa FITC-
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dextran (~12 nm38) and FITC-bevacizumab (~11 nm158), further indicating the dominant 
role of molecular diameter in determining SCS clearance. 
 
Figure 5.3 – Analysis of rates of clearance from the SCS after 50 µL SCS injection with molecules ranging 
from 1 – 60 nm in diameter and a 20 nm polystyrene particle.  (A) Representative fundus collages after 
injection with fluorescein in HBSS. (B) Representative fundus collages after injection with 2 MDa FITC-
dextran in HBSS. (C) Quantification of fluorescein/FITC- concentration with curve fit to an exponential 
decay. (D) Clearance time constant from (τclearance, from curve fit in C) and total clearance time plotted 





5.4.2.1 Intravitreal and SCS pressure measurements 
We measured pressure in the VH and suprachoroidal spaces after IVT or SCS 
injection using a custom-designed setup. The VH pressure trace after IVT injection was 
consistent with prior literature, showing a roughly exponential decay in pressure that 
returned to within 10% of baseline value within 15 min17, 98. After SCS injection, the VH 
pressure followed a similar timecourse, returning to within 10% of baseline value by 15 
min too. The VH and SCS pressure traces were within ±1 mmHg of each other 
throughout the length of the experiment.  
Each data set was fit to an exponential decay, from which a pressure-decay time 
constant (τpressure) was calculated (Figure 5.4). Although the pressure-decay time 
constants after SCS injection (~3 min) appear to be smaller than after IVT injection (~5.5 
min), there was no significant difference between any of the four time constants derived 
from the VH and SCS pressure curve fits after IVT or SCS injection in vivo (p=0.98, 2-
way ANOVA). Thus, we conclude that the time course of pressure decay in the eye is the 
same after IVT or SCS injection. We also conclude that there is no significant pressure 
different between the VH and SCS after IVT or SCS injection.  
Injections made postmortem in the companion eye resulted in significantly faster 
depressurization (~ 1 min) than injections in vivo (p<0.05, 2-way ANOVA). Since the 
eye was not enucleated and tissue degradation had likely not yet happened, we believe 
the main difference between the in vivo eye and the postmortem eye is the lack of living 
processes, such as choroidal perfusion. Our data suggest that these living processes have 
a major effect on SCS clearance. With no blood flow through the vortex veins, they are 
likely collapsed upon SCS injection, and therefore, SCS clearance through perivascular 
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drainage routes is expected to be greater postmortem than in vivo, which may explain the 
faster decay in IOP in the postmortem eye. Another possible explanation is that blood 
volume was expelled from the eye upon SCS injection (as there was no resistance to 
venous flow). 
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Figure 5.4 – Pressure measurement in vivo and postmortem after SCS injection of 50 µL HBSS. Pressure-
decay time constants derived from fitting data to an exponential decay. No difference in time constants 
from SCS or VH pressure traces after SCS or IVT injections in vivo. In vivo time constants were different 
than postmortem time constants. All values are mean±SEM (N=4 replicates). 
5.4.3 Route of clearance after SCS injection 
To determine the contributions of different routes of clearance, we collected 
fluorescein from multiple collection sites after SCS injection in vivo (Figure 5.5). 
Fluorescein was collected over the course of 1 h from four sites: [i] sclera anterior to the 
equator; [ii] anterior sclera with injection site plugged; [iii] sclera posterior to the 
equator; and [iv] posterior sclera with vortex vein transected. The cumulative fluorescein 
from these collection sites was determined as a function of time (Figure 5B). The amount 
of fluorescein leaving through the injection site (Figure 5.5B, upper right) was found by 
subtracting site [i] from site [ii]. And the amount of fluorescein leaving through the blood 
(Figure 5.5B, lower right) was found by subtracting site [iv] from site [iii]. Though the 
physiological data is inherently noisy and performing calculations on the data might yield 
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errors, it should nevertheless yield an order of magnitude estimate of the underlying 
processes (which can be compared to a 2D model of transport below).  
The cumulative amount of fluorescein collected at 1 h, as well as the residual 
amounts in the ocular tissues, was calculated and expressed as a function of the total 
fluorescein injected into the SCS (Figure 5.5C). One hour post-injection, 46±18% was 
still within the tissue (e.g., in the sclera, choroid, SCS, etc.); 15±0.3% had passed 
transsclerally to the subconjunctival space (anterior and posterior combined); and 6.3±4% 
was found in the blood. We calculated that 1.3±4% exited via the injection site and 
2.5±0.3% exited via perivascular drainage around the vortex vein. We were unable to 
account for 28% of the fluorescein, though we assume it to be roughly equally distributed 
in the collection sites due to difficulty to achieve efficient fluorescein collection during 
dynamic transport to the scleral surfaces, and the expected efficiency of fluorescein 




Figure 5.5 – Fluorescein collected from four routes out of the SCS after 50 µL SCS injection of fluorescein 
in HBSS.  (A) Representative series of images of eye with the injection site plugged. (B) Cumulative 
fluorescein collected by swabbing anterior sclera after plugging injection site (B upper left), collected by 
swabbing posterior sclera (B lower left), calculated by comparing amount collected from anterior sclera 
with and without plugging injection site (B upper right), and calculated by comparing amount collected 
from posterior subconjunctiva with and without transecting vortex vein (B lower right). All values are 
mean±SEM (N=4 replicates) (C) Quantification of total fluorescein distribution in and out of the eye after 
SCS injection based on data in (B) and analysis of residual fluorescein content in the eye after enucleation.  
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5.5 Discussion  
Microneedle injections enable targeted access to the SCS and can be performed 
with an out-patient procedure similar to intravitreal injections. Due to the high 
bioavailability at the sclera, choroid, ciliary body, and retina achieved with 
suprachoroidal drug delivery, this route of administration is well suited for targeting 
tissues diseased in posterior segment diseases. Ongoing clinical trials are testing the 
safety and efficacy of microneedle injections for the treatment of posterior noninfectious 
uveitis, as well as other indications. Although drug delivery via the SCS is receiving 
increasing attention, little is known about how molecules and fluid are cleared from the 
SCS in terms of clearance kinetics and routes of clearance.  
In this study, we investigated the clearance kinetics of molecules injected into the 
SCS of live rabbits using a microneedle. Previous studies demonstrated decay of IOP 
after SCS injection on a time scale of minutes17, which is expected to correlate with the 
time scale of fluid clearance from the SCS, and reported clearance of various molecules 
from the SCS on a time scale of hours5, 8, 9, 120, 124, 125, both which we corroborated in this 
study. Previous studies have also found that the clearance times after suprachoroidal 
delivery were significantly faster than after IVT injections102. We also found that the 
complete collapse of the SCS occurred by 40 min, which is consistent with previous 
studies120. During the first hour post-injection, approximately half of injected fluorescein 
was cleared from the ocular globe, with approximately half still remaining. The 





5.5.1 Modeling clearance from the SCS 
We developed a two-dimensional model (2D) of small-molecule transport after 
microneedle injection into the SCS to corroborate our experimental results. A Cartesian 
coordinate system was used such that the x-direction was a ‘radial’ measure into and out 
of the eye and the y-direction was the ‘circumferential’ measure; at small distances (like 
the one used in the model), the curvature of the eye was ignored. The convection-
diffusion equation (Eq. 5.1)159 describes the rate of change in the amount of molecule in a 
control volume, and attributes changes in concentration due to diffusion (first term), 




= ∇ ∙ (∇𝐷𝑐) − ∇ ∙ (𝑣𝑓𝑐) − 𝐵𝑐 Eq. 5.1 
where c is the concentration of molecule, t is the time, D is the diffusion coefficient of the 
molecule through tissue, vf is the velocity of flow, and B is a reaction or clearance 
coefficient.  
Due to the complex ocular anatomy across different tissues, an analytic solution 
of the above was not found. Instead, this model utilized a modified random walk 
algorithm160 to study the position and disposition of molecules by displacing the molecule 
at each time point in 2D based on the characteristic diffusional length a molecule would 
move in that time period, as well as additional rules as defined below. We defined the 
regions in the eye corresponding with the choroid, SCS, and sclera, which were set as 0.1, 
0.05, and 0.3mm thick, respectively161 (Figure 5.6A(i)).  
Rules governing molecule movement at each time point (Δt) of the random walk 
algorithm was set as follows. The diffusivity within the choroid and sclera (both of which 
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are limited largely by the proteoglycan extracellular matrix162) was set to 5x10-11 m2/s 
(diffusion coefficient of fluorescein in sclera163, corresponding to a characteristic 
diffusional length of 0.1 mm in 1 min. The diffusivity in the SCS was 5x10-10 m2/s 
(diffusion coefficient of fluorescein in water141) corresponding to a characteristic 
diffusional length of 0.34 mm in 1 min.  
Furthermore, we defined additional behaviors for regions in the model 
corresponding to ocular anatomy and physiology, in particular (region i) the choroid, 
(region ii) the sclera, and (region iii) a drainage pathway through the sclera analogous to 
the injection site (Figure 5.6A(i)). The choroid (region i) was subdivided into an inner 
and outer region, corresponding to the choriocapillaris and Haller’s/Sattler’s layers164, 
respectively. The choriocapillaris31 (as opposed to Haller’s and Sattler’s layers) possessed 
fenestrae capable of clearing molecules, which we modeled with a clearance rate B, 
whereas we assumed that no clearance occurred in Haller’s and Sattler’s layers.  
The sclera (region ii) was able to bind fluorescein (and prevent diffusion or 




  Eq. 5.2 
where Cb is the concentration of bound fluorescein, Cf is the concentration of free 
fluorescein, Bmax is the apparent maximum binding capacity of the sclera (experimental 
determined to be 1440 μM by Lin et al.163) and KD is the apparent equilibrium 
dissociation constant (experimentally determined to be 110 μM by Lin et al.163). Since the 
scleral binding of molecules was hypothesized to be mediated by collagen38, no binding 
to the choroid was included in the model.  
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In addition, the sclera had convective flow directed outwards due to the pressure 










  Eq. 5.3 
where Kh is the hydraulic conductivity of the flow pathway medium (10
-18 m2 for rabbit 
sclera)35, 165, 166, µ is the viscosity of the fluid (7x10-4 Pa s for water at 37°C)167, P is the 
pressure and x is position in the radial direction. We only considered pressure changes in 
the radial direction and not in the circumferential direction. Because there was no (or 
very little34) pressure differential between the vitreous humor and the SCS, there should 
be little pressure-driven flow into the choroid. The significant pressure drop was 
therefore between the SCS and the extraocular environment across the sclera. We could 
assume the pressure drops linearly across the sclera, i.e., across a representative distance 
of 300 µm 161. We could use the experimental data (Figure 5.4) to describe the pressure 
drop over time as an exponential decay with a maximum of 100 mmHg and a time 
constant of ~5 min.  
There was also convective flow via the drainage pathway (region iii), which had a 
y-dimension equivalent to the outer diameter of a microneedle (i.e., 0.25 mm), and had a 
convective flow two orders of magnitude greater than that in the rest of sclera. 
5.5.1.1 Modeling predictions of clearance from SCS 
At time t=0, 1000 molecules were randomly ‘injected’ into the SCS (Figure 
5.6A(ii)). At each subsequent time point (time step Δt=1 min), molecules were moved 
following the rules described above depending on each molecule’s location at the 
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previous time point (Figure 5.6A). The location and fate of each molecule was recorded 
(i.e., in the eye, outside the sclera, or cleared via choroid).  
After 5 min (Figure 5.6A(iii)), molecules were cleared from the SCS. A fraction 
of the molecules were rapidly convected across the sclera via leakage pathways at the site 
of injection and via perivascular routes (treated in the simulation as a single shunt 
pathway through the center of the sclera, as depicted in (Figure 5.6A(i)). The remaining 
molecules were transported into the choroid or the sclera as the SCS collapsed (in the 
simulation, the SCS did not collapse). Transport into the choroid was exclusively by 
diffusion, since no pressure gradient from the SCS across the choroid was expected. 
Transport into the sclera (i.e., not via leakage pathways) was through a combination of 
diffusion as well as convection driven by the decaying pressure gradient across the sclera. 
Molecules that entered the choroid were eventually cleared by choroidal vasculature. 
Molecules that entered the sclera were eventually cleared across the outer scleral surface.  
Within 15 min after injection (Figure 5.6A(iv)), molecules penetrated deeper into 
the choroid and sclera, and began to be cleared from these tissues. At 1 h (Figure 
5.6A(v)), most molecules within the choroid had been cleared into the bloodstream, while 
molecules in the sclera continued to be cleared. The rate of clearance from the choroid 
was determined by the rate of diffusion of molecules to capillaries and the odds of being 
taken up by a capillary (i.e., the B term). At 4 and 12 h (Figure 5.6A(vi) and Figure 
5.6A(vii)), transported across the sclera continues. The rate of clearance from the sclera 
was determined by the rate of transport to the outer scleral surface by diffusion, as well as 
convection driven by the normal IOP of the eye (i.e., 15 mmHg in the rabbit). Our model, 
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as well as previous literature168, predicted that both of these driving forces may play a 
role in the sclera.  
By 24 h (Figure 5.6A(viii), the clearance process was largely complete. It was 
worth noting that this modeling result was for the low-molecular weight compound 
fluorescein (Figure 5.6A – C). We predict that molecules that do not bind, e.g., ethacrynic 
acid163 (Figure 5.6D) or have higher molecular weight, e.g., 70 kDa dextran (Figure 5.6E) 
were cleared similarly, but with different kinetics, especially for diffusion-based 
processes.  
The snapshots shown in Figure 5.6A were supplemented with continuous time 
course results over the course of one hour (Figure 5.6B) and one day (Figure 5.6C). 
Within 10 min, most molecules were removed from the SCS, a fraction of the molecules 
were cleared from the eye via transscleral leakage pathways and the remaining molecules 
were transported into choroid and sclera. Over the course of hours, molecules were 
slowly cleared from the choroid and sclera. Molecules in the choroid were cleared more 
quickly (i.e., within 1 h, because of the shorter diffusional distances to choroidal 
capillaries that remove molecules via blood flow). Molecules in the sclera were steadily 





Figure 5.6 - Results from 2D model of molecule transport in the SCS. Transport after SCS injection with 
(A-C) ‘fluorescein’; (D) molecule with no binding, “ethacrynic acid”; and (E) high-molecular weight 
molecule, “70 kDa dextran”. (A) Cross-sectional view of eye showing position of molecules (blue dots) and 
molecules that were cleared in blood (red dots) at different times post injection. Ch=choroid; SCS=suprac 
horoidal space; Sc=sclera. Percentage of particles found in the eye, in the SCS, on the exterior surface of 
the sclera, and in the blood via the choroid (B)within 1 h after injection and (C) within 24 h after injection. 
Summarized fate of (D) small molecule that does not bind sclera and (E) large molecule, 70 kDa dextran.  
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The model suggested that the sclera accounted for more clearance than the 
choroid. This could be explained as follows. After injection into the SCS, a molecule 
experienced isotropic transport (recall that there was no pressure differential in the eye 
interior to the sclera) and was thus able to diffuse either circumferentially within the SCS 
or radially (towards the choroid or towards the sclera) at similar rates. Circumferential 
diffusion did not affect clearance very much, but radial transport played a major role in a 
molecule’s eventual clearance route. If the molecule diffused into the sclera, there was 
sufficient diffusive transport and convective flow due to physiological IOP across the 
sclera to ensure clearance of the molecules across the thickness of the sclera. 
Alternatively, if the molecule diffused into the choroid, the molecule had a probability of 
clearing as it diffused through the choroid. If the molecule within the choroid did not 
clear immediately (which is unlikely considering B = 0.05 min-1) it could diffuse towards 
the sclera and consequently become driven trans-sclerally. About one-third of molecules 
that diffused into the choroid initially were eventually cleared through the sclera. 
Exponential curve fits were generated from the model results in Figure 5.6C. The 
percentage of molecules found in the eye was fit to a 1st order exponential decay, which 
yielded a time constant of 3.38 h [3.34, 3.41; 95% confidence interval] (r2=0.98). The 
cumulative percentage of molecules that had entered the blood via the choroid was fit to a 
1st order exponential approach function with a time constant of 0.93 h [0.92, .94] 
(r2=0.99). The cumulative percentage of molecules that had exited the eye via trans-
scleral transport routes was fit to a 1nd order exponential approach with time constants of 
3.84 h [3.80, 3.87] (r2=0.99).  
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Since the time constants of molecule clearance from the eye and the time constant 
of trans-scleral clearance were on the same order of magnitude of hours (with 
intravascular clearance being significantly faster), the model suggested that trans-scleral 
diffusion was the dominant route of clearance. The model generated a clearance time 
constant similar to the time constant of 4.3 h that we found based on fundus imaging 
(Figure 5.2).  
Guided by the experimental data in the context of model predictions, the 
characteristic times of key transport phenomena following SCS injection were 
summarized in Table 5.1.  
Table 5.1 - Characteristic times of transport phenomena in the eye 
Characteristic time 
(order of magnitude) 
Transport phenomena in eye 
1 min 
 SCS loaded with molecules and fluid during 
injection 
10 min 
 Fluid and molecules cleared from SCS by 
convection through leakage pathways 
 Remaining molecules transported into choroid 
and sclera 
 SCS collapses 
 IOP drops to baseline 
1 h  Molecules cleared by choroidal blood flow 
1 - 10 h 
 Molecules cleared from sclera by diffusion and 
convection 
We also modeled the behavior of a small molecule that did not bind to sclera163 and a 
large molecule38, which were summarized in Figure 5.6 D and E respectively. To model a 
small molecule that did not bind sclera, we used experimentally derived values for 
ethacrynic acid163; in particular, we increased the diffusivity to 5x10-6 cm2/s163 and 
decreased Bmax to 5 μM
163 (other parameters kept the same as the fluorescein condition). 
The model predicted that half-life of “ethacrynic acid” in the eye to be 4.8 min with 
complete clearance by 25 min (Figure 5.6D). These values were similar to the SCS 
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collapse time (which could be viewed as a proxy for clearance of water from the SCS). 
Comparison of these characteristic times to those for fluorescein showed the dramatic 
effect that binding could have on clearance rates.  
The clearance of a large macromolecule was modeled by using values experimentally 
determined for 70 kDa FITC-dextran38. In particular, we decreased the diffusivity to 
5x10-8 cm2/s (by assuming the experimental derived scleral permeability of 1.5x10-6 
cm/s38 was at steady state across the thickness of the sclera), decreased the choroidal 
clearance rate to 0.005 min-1 (since larger molecules should have more difficulty passing 
through the fenestrae of the choriocapillaris31), and decreased the binding affinity Bmax to 
1000 μM38 while keeping the other parameters the same as the fluorescein condition. The 
model predicted that the half-life of this macromolecule to be 5.2 h and the total 
clearance time to be 3.8 d. Both values were within two-fold of the values we found 
experimentally. For all three model molecules tested, the dominant route of clearance was 
via trans-scleral transport with a lesser contribution from intravascular clearance. 
5.5.1.2 Sensitivity analysis of model predictions 
To provide greater insight into the transport phenomena, we performed sensitivity 
analysis on the model to determine the relative contributions of different parameters to 
the overall clearance in the eye (Figure 5.7). In general, the model predicted that small 
changes (within 1 order of magnitude) in parameter values did not significantly change 
the model results. The rank order of parameter sensitivity was, from most sensitive to 
least: diffusivity of the molecule in the SCS and in the tissue (Figure 5.7A), scleral 
binding capacity (Figure 5.7B) and equilibrium dissociation constant (Figure 5.7C), 
vascular clearance rate (Figure 5.7D), scleral hydraulic permeability (Figure 5.7E), size 
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of leakage sites (Figure 5.7F), τpressure (the rate at which elevated IOP dissipated, Figure 
5.7G), and baseline physiological IOP (Figure 5.7H). Since the model suggested that the 
rate limiting step in SCS clearance was the trans-scleral transport, it stood to reason that 
the parameters that modified the trans-scleral transport rate affected the clearance time 
constant and total clearance time the most. Nevertheless, as evidenced by the graphs in 
Figure 5.7, the clearance time constant was a linear combination of the trans-scleral and 
vascular clearance time constants. 
Diffusivity (D) had the greatest effect on clearance times (Figure 5.7A); for 
example, reducing D (the diffusivities of fluorescein) by one order of magnitude to one-
tenth the diffusivity of fluorescein (0.1xD) resulted in a doubling of the clearance time 
constant. Intuitively, changes in diffusivity will have a significant effect on clearance 
time since the characteristic time for a molecule to move across the sclera (300 μm in the 
radial dimension) increases with the diffusivity. As seen in Figure 5.7A and in our 
experimental results (Figure 5.3D), the model correctly predicted nonlinearity in the 
clearance time at 0.01x D. Experimental data suggested that the nonlinearity occurs at 
>500 kDa, which should be ~0.01x D based on the Stokes-Einstein equation.  
Scleral binding of molecules (as modulated by Bmax and KD; Figure 5.7B and C, 
respectively) also had a major effect on clearance times. Intuitively, increasing scleral 
binding effectively behaved like a decreased diffusivity by drastically slowly molecule 
transport. However, scleral binding affected molecule transport on short time scales 
(before saturating the sclera) whereas diffusivity equally affected transport at all times. 
Unlike the results seen with changing D, changes in Bmax and KD had a biphasic effect 
whereby small changes resulted in almost no change in clearance time but a large change 
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caused a disproportionate increase in clearance time. This could be due to changes in the 
binding saturation point of the sclera.  
The choroidal clearance rate had a moderate effect on characteristic clearance 
time constant and a minor effect on total clearance time (Figure 5.7D). At high clearance 
rates by choroidal vasculature, the choroidal perfusion contributed at most 50% of total 
clearance of molecules from the eye. We reasoned that this 50% makes sense since 
molecules leaving the SCS have an approximately 50% chance to enter the choroid (as 
opposed to the sclera). With clearance rates set to low or nonexistent (time constants 
excluded in Figure 5.7D), most or all molecules left via trans-scleral pathways, which set 
an upper limit on the clearance time (i.e., it takes ~25 h for all molecules to leave the eye 
trans-sclerally).  
The scleral hydraulic permeability (Figure 5.7D) and size of the leakage pathways 
(Figure 5.7E), had a moderate effect on clearance time. These parameters were indirectly 
related to trans-scleral transport. Parameters that increased the convective flow rate 
(τpressure and physiological baseline IOP) had a modest effect on clearance time. This 





Figure 5.7 – Sensitivity analysis of parameters used in two-dimensional model of molecule transport from 
the SCS. Parameters were varied at least one order of magnitude from the value used in the model (value 
used in base condition highlighted in gray). The clearance time constant (black square) and time to clear 
99% (open squares) of molecules are plotted against each variable. In addition, the time constants for 
intravascular clearance (τblood, triangle) and trans-scleral transport (τsclera, open circle) were also found. 




Of the parameters tested, diffusivity and size of the leakage site could be changed 
by optimizing formulation or microneedle injection technique, respectively and thereby 
modulate clearance rate. Diffusivity was the most sensitive variable and changes by an 
order of magnitude could change the clearance time constant from 5 min to 18 h. The 
Stoke-Einstein equation indicated that diffusivity could be modulated by changes in 
formulation viscosity and the molecular radius (which is in turn a function of molecular 
weight). In addition, using a smaller-bore microneedle did have a moderate effect on the 
clearance times. On the other hand, changes in physiological parameters (e.g., 
physiological IOP, scleral hydraulic conductivity, and clearance rate) did not drastically 
change the behavior of the model, and clearance changed by less than 2-fold with up to 
10-fold changes in the parameter value. Thus, the model may be applicable to other 
species, like humans.  
5.5.1.3 Additional comments on the model 
A limitation of the model was that it only investigated in two dimensional 
transport using Cartesian coordinates, although the actual clearance process occurred in 
three dimensions in spherical coordinates. This limited the ability of the model to predict 
distribution. To simplify the model, variation in SCS area and thickness were not 
accounted for, as these additional considerations would complicate the model with 
dynamic boundary conditions. Many other simplifying assumptions were also employed, 
such as no convective flow simulating the process of injection, no aqueous turnover via 
uveoscleral outflow16, and no influences of biomechanical tissue properties. Despite these 
limitations, model predictions were in general agreement with experimental data.  
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Previous studies had hypothesized that clearance from the SCS is predominantly 
due to either choroidal perfusion9, 124, 126 or perivascular leakage routes43. However, as 
shown in the present study, a combination of routes was utilized in clearing the SCS. 
Some studies showed that molecular clearance into the choroid was important9, 126. Other 
studies demonstrated the importance of perivascular drainage routes43. Furthermore, 
periocular injections into the subconjunctival space revealed that transscleral diffusion 
was possible, albeit in the opposite direction of transport in this study35, 36, 40, 104, 125.  
To our knowledge, this was the first study to provide experimental and 
computational evidence of the relative contributions of different routes of clearance from 
the suprachoroidal space. In particular, we identified pressure-driven flow through 
leakage routes (e.g., perivascular leakage routes and reflux out the injection site) and 
transscleral transport; and diffusion-mediated transport across the sclera and into the 
choroid for intravascular clearance. We also identified the time scales and relative 
contributions of each of these routes of clearance for the first time.  
5.5.2 Effect of molecular size on residence time  
We found experimentally and computationally that increasing molecular radius 
had a major effect on clearance time. Fluorescein (~1 nm in diameter38) was cleared by 
24 h, while 2 MDa FITC-dextran (~50 nm in diameter156) was not fully cleared until 21 d. 
The prolonged residence time did not increase as a linear function of molecular mass, but 
was dramatically longer above a threshold of ~106 Da. The difficulty for very large 
macromolecules to pass through the fenestrae of the choriocapillaris and through the 
extracellular matrix of the sclera is the likely explanation for this behavior.  
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As shown in this study, the bulk of clearance occurs via diffusion across the 
sclera, as well as through the choroid into choriocapillaris. The physiological upper limit 
of pore size of the choriocapillaris is estimated to be ~6 nm31. Thus, the hydrodynamic 
radius of 2 MDa FITC dextran is much larger than the choriocapillaris pore size. Because 
macromolecules are not rigid and are constantly changing shape, even 2 MDa FITC-
dextran is eventually able to adopt a conformation that allows passage through the 
fenestra of a choriocapillary. On the other hand, small polystyrene microspheres (20 nm 
in diameter), which are rigid and are not able to adopt different conformations, were still 
visible upon fundus examination 2 months after injection8, 128. Diffusion across sclera is 
the other main mechanism for clearance. Experimental studies and theoretical analysis 
have shown that scleral permeability decreases as a steep function of molecular mass91, 
169. 
5.5.3 Implications for drug delivery 
The findings in this study may be instructive for controlling drug delivery via the 
SCS. The observation that pressure-driven flow occurs through leakage sites indicates the 
importance of minimizing leaking from the site of injection (e.g., by keeping the 
microneedle in place after injection). It also suggests that there are diminishing returns on 
increasing injection volume; larger volumes lead to larger IOP which lead to more loss of 
fluid through pressure-driven flow through leakage pathways.  
Most molecules injected in the SCS are cleared into the systemic circulation via 
the choriocapillaris or transsclerally into the subconjunctival space. Drugs cleared via the 
choroid can interact with possible drug targets in that tissue, and possibly diffuse across 
the retinal pigment epithelium into the retina, where additional drug targets are also 
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located. Drugs cleared across the sclera (or via leakage pathways) do not enter the 
choroid or retina, and therefore do not reach targets in those tissues. 
Residence time in the SCS depends on what is injected. It has previously been 
reported that molecules are cleared from the SCS within one day and that particles are not 
cleared at all5, 8, 9, 81, 120, 125. This study corroborated those findings, which suggest that 
extending the residence time of drugs in the SCS requires their incorporation into 
particulate controlled release systems115. However, this study also suggests a new 
approach, which involves the use of drug molecules of very high molecular mass, 
possibly by conjugation to a large polymer, incorporation into a biodegradable polymer, 
use of a prodrug or other strategies46, 170-172.  
5.5.4 Limitations 
There were several limitations to this study. There are anatomical and 
physiological differences between rabbit and human eyes. Human clinical trials will be 
needed if these findings are to be applied to human medicine. However, sensitivity 
analysis indicates that changes in hydraulic conductivity and scleral thickness did not 
have major effects on the results of the model. Another possible concern is that we have 
an incomplete mass balance from the fluorescein collection experiments (i.e., 28% 
unaccounted for in Figure 5). While we assume that incomplete capture was equally due 
to all the collection routes, it is possible this collection was biased (i.e., unequal loss of 
fluorescein from the different routes, especially the intravascular route that was most 
difficult to collect). Since this study was performed with fluorescent tracer molecules and 





In summary, we used live New Zealand White rabbits to study molecular 
clearance from the SCS after microneedle injection. We identified that clearance occurs 
in three regimes. (i) There was immediate loss of fluorescein from pressure-driven 
leakage at the injection site and via perivascular routes associated with vortex veins on a 
time scale of minutes which accounted for a few percent of clearance from the SCS under 
the conditions of this study. The remaining molecules were transported out of the SCS 
and into the sclera or the choroid where they formed depots. (ii) Concentration-driven 
diffusion into the choroid and subsequent clearance of the choroidal depot by 
choriocapillaries took place on a time scale of an hour. (iii) Diffusion and physiological 
IOP-mediated convection across the sclera cleared the remaining fluorescein from the eye 
over the course of hours. These experimental data were supported by a two-dimensional 
model of small-molecule transport in the eye. Increasing the molecular radius of injected 
molecules significantly slowed the rate of clearance. These experiments will guide 
development of strategies to better control drug delivery via the SCS. 
  
 
6 SUSTAINED REDUCTION OF INTRAOCULAR PRESSURE BY 
SUPRACILIARY DELIVERY OF BRIMONIDINE-LOADED 
POLY(LACTIC ACID) MICROSPHERES FOR THE 
TREATMENT OF GLAUCOMA 
This work has been published in Journal of Controlled Release115. 
6.1 Summary 
Although effective drugs that lower intraocular pressure (IOP) in the management 
of glaucoma exist, their efficacy is limited by poor patient adherence to the prescribed 
eye drop regimen. To replace the need for eye drops, in this study we tested the 
hypothesis that IOP can be reduced for one month after a single targeted injection using a 
microneedle for administration of a glaucoma medication (i.e., brimonidine) formulated 
for sustained release in the supraciliary space of the eye adjacent to the drug’s site of 
action at the ciliary body. To test this hypothesis, brimonidine-loaded microspheres were 
formulated using poly (lactic acid) (PLA) to release brimonidine at a constant rate for 35 
days and microneedles were designed to penetrate through the sclera, without penetrating 
into the choroid/retina, in order to target injection into the supraciliary space. A single 
administration of these microspheres using a hollow microneedle was performed in the 
eye of New Zealand White rabbits and was found to reduce IOP initially by 6 mm Hg and 
then by progressively smaller amounts for more than one month. All administrations 
were well tolerated without significant adverse events, although histological examination 
showed a foreign-body reaction to the microspheres. This study demonstrates, for the first 
time, that the highly-targeted delivery of brimonidine-loaded microspheres into the 
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supraciliary space using a microneedle is able to reduce IOP for one month as an 
alternative to daily eye drops. 
 
Figure 6.1 – Graphical description of rationale to target ciliary body. Higher bioavailability achievable 
with supraciliary injection of briomindine-loaded microspheres compared with topical eye drops. 
6.2 Introduction 
Primary open-angle glaucoma is a leading cause of blindness in the United States, 
affecting nearly 2 million individuals with an annual cost of $2.9 billion 50, 51. Glaucoma 
is the most common form of optic neuropathy, where loss of retinal ganglion cell axons 
permanently disrupts transmission of visual information from the retina to the brain 1, 49, 
50. Over decades, patients experience a painless and gradual loss of vision starting from 
the periphery and eventually claiming central vision 1, 53. Intraocular pressure (IOP) is the 
only modifiable risk factor 52, 173 and reducing IOP prevents the progression of glaucoma-
related vision loss 53, 54.  
IOP is mediated by the balance of aqueous humor production and aqueous humor 
removal 13. Aqueous humor is a clear liquid that is secreted by the ciliary body. Clearance 
of aqueous humor occurs through either the trabecular meshwork into the episcleral veins 
or the uveoscleral outflow pathway into the suprachoroidal space 13, 16. Medical and 
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surgical therapy for glaucoma seeks to control IOP by reducing production of aqueous 
humor and/or increasing clearance of aqueous humor 4, 53. Topical eye drops, such as 
timolol, latanoprost, and brimonidine, are commonly-used FDA-approved medical 
therapies for glaucoma patients. Brimonidine is an α2-adrenergic agonist that both 
decreases aqueous humor secretion by the ciliary body and increases aqueous humor 
clearance 174. Because topical eye drops can have low bioavailability through the cornea 
(<5%), some regimens call for multiple eye drops per day to ensure sufficient drug 
dosing (e.g., brimonidine eye drops are prescribed three times per day) 4, 175.  
6.2.1 The need for improved patient adherence with administration of IOP-
lowering drugs 
Patient adherence to topical eye drops is low, estimated to be only 41% to 76% 4, 
55-58, 176. Due to the chronic nature of glaucoma and the rigorous administration schedule, 
it can be difficult for patients to administer their eye drops on a regular basis. Since any 
loss of vision is permanent, increasing patient adherence to the regimen will preserve 
functional vision and decrease progression to blindness 4.  
Patient adherence to the eye drop regimen can be increased through methods, 
such as memory tools that remind patients, and improved formulations that do not require 
refrigeration or require simpler administration regimens 4. But perhaps the most attractive 
method to improve eye drop adherence is through the use of controlled-release drug 
delivery systems that obviate the need for the patient to take eye drops at all. While 
brimonidine-loaded drug delivery systems for the management of glaucoma have been 
studied before 177-180, we seek to determine the efficacy of a targeted controlled-release 
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system delivered using a microneedle adjacent to brimonidine’s site of action in the 
ciliary body. 
6.2.2 Injections targeting the supraciliary spacing using microneedles 
The supraciliary space is the anterior-most region of the suprachoroidal space. 
The suprachoroidal space is a potential space in the eye found between the sclera (the 
fibrous collagenous layer that contains the eye) and the choroid (the rich vascular 
network that supplies nutrients to the outer retina). The suprachoroidal space has been 
explored as a site for ophthalmic drug delivery in preclinical and recent clinical studies 
(e.g., NCT01789320 and NCT02255032) 2, 5, 7-9, 17, 36, 81, 97, 116-118, 123, 124, 126, 127, motivated 
by higher bioavailability compared with topical eye drops 8, 81 and the ability to target 
drug delivery to the choroid that lines the suprachoroidal space, the adjacent retina or, 
most recently, the ciliary body that forms its most anterior boundary.  
Injections are targeted to the suprachoroidal (and supraciliary) space using 
individual hollow microneedles with a length matched to the thickness of the sclera and 
conjunctiva that enable access to the suprachoroidal space with a procedure comparable 
to an intravitreal injection, which is a method of ophthalmic drug delivery regularly 
performed in the outpatient clinic setting 8, 81, 88. Microneedle injections in the 
suprachoroidal space were originally designed as a treatment for posterior-segment 
diseases. This study seeks to treat glaucoma, which is currently treated with therapies 
targeted at the anterior-segment, by targeting drug delivery to the supraciliary space 6. 
In our initial study, a bolus microneedle injection of glaucoma drugs (including 
brimonidine) into the supraciliary space was able to reduce IOP with significant dose 
sparing compared with topical eye drops 6. Furthermore, fewer ocular side effects are 
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expected since the drug is compartmentalized in the suprachoroidal space away from 
other non-target tissues (e.g., lens, cornea, etc).  
In this study, we hypothesize that IOP can be reduced for one month after a single 
microneedle injection of brimonidine formulated for sustained release using PLA into the 
supraciliary space of the eye. Brimonidine was chosen because it is an FDA-approved 
IOP-lowering agent currently prescribed to glaucoma patients 174, 175, 181 and is 
pharmacologically active in the rabbit 6, 177-180. Due to increased bioavailability, a 
microneedle injection into the supraciliary space should reduce the dose needed, 
compared with topical eye drops, thereby allowing a relatively small injection to contain 
sufficient drug for extended therapy. The successful implementation of this technique 
could enable a sustained-release treatment for glaucoma patients without the need to 
administer topical eye drops.  
6.3 Materials and Methods 
6.3.1 Materials 
Brimonidine tartrate, poly-lactic acid (PLA) with an inherent viscosity (i.v.) of 
0.20 dL/g (free acid terminated, RESOMER® 202H), and polyvinyl alcohol (PVA, 80% 
hydrolyzed, MW ~9,000-10,000) were purchased from Sigma Aldrich (St. Louis, MO). 
PLGA (75:25, i.v. = 1.13 dL/g, ester terminated) was purchased from Durect (Cupertino, 
CA). All solvents used were HPLC grade and were purchased from Fisher Scientific 





6.3.2 Removal of low molecular weight acids from PLA 
PLA (~5 g) was dissolved in 10 mL CH2Cl2 at room temperature and then added 
to a stirring ddH2O bath maintained at 60°C. After evaporating CH2Cl2 for 3 h the 
aqueous phase containing water-soluble, low molecular weight acids was removed while 
the water-insoluble, higher MW polymer remained as a solid in the vessel as a result of 
the organic solvent evaporation. The resulting higher MW polymer was dried under 
vacuum and stored at -20°C until use 182. 
6.3.3 Microsphere preparation 
Microspheres were prepared using oil-in-water (o/w) emulsion solvent-
evaporation methods. First, brimonidine and the selected polymer(s) (Table 6.1) were 
dissolved in 1 mL CH2Cl2. Two mL 5.0% (w/v) PVA was added and vortexed to create 
the o/w emulsion, which was then poured into a stirring bath of 0.5% (w/v) PVA to allow 
for CH2Cl2 evaporation and microsphere hardening. After 3 h, the hardened microspheres 
were screened to 20-45 µm using sieves, washed with ddH2O, then lyophilized and stored 
at -20°C for future use. 








800PLA PLA 800 6.00% 






50 : 50 Blend 
PLGA : PLA 
500 10.00% 
6.3.4 Scanning electron microscopy 
Prior to imaging, lyophilized microspheres were mounted using double-sided 
carbon tape and coated with a thin layer of gold under vacuum. Scanning electron 
 
 160 
microcopy (SEM) images were then taken using a Hitachi S3200N scanning electron 
microscope (Hitachi, Japan). Images were obtained using EDAX software. 
6.3.5 Determination of brimonidine loading and encapsulation efficiency 
Prepared microspheres (~5 mg) were dissolved in 1 mL acetonitrile. The resulting 
solution was filtered and analyzed for brimonidine content by ultra-performance liquid 
chromatography (UPLC), as described below. Percentage loading and encapsulation 






𝑡𝑜𝑡𝑎𝑙 𝑚𝑎𝑠𝑠 𝑜𝑓 𝑚𝑖𝑐𝑟𝑜𝑠𝑝ℎ𝑒𝑟𝑒𝑠
𝑥 100 Eq. 6.1 
% 𝑒𝑛𝑐𝑎𝑝𝑠𝑢𝑙𝑎𝑡𝑖𝑜𝑛 𝑒𝑓𝑓𝑖𝑐𝑖𝑒𝑛𝑐𝑦 (𝐸𝐸) =
𝑎𝑐𝑡𝑢𝑎𝑙 𝑙𝑜𝑎𝑑𝑖𝑛𝑔
𝑡ℎ𝑒𝑜𝑟𝑒𝑡𝑖𝑐𝑎𝑙 𝑙𝑜𝑎𝑑𝑖𝑛𝑔
 𝑥 100 Eq. 6.2 
6.3.6 In vitro release kinetics of brimonidine 
Microspheres (~5 mg) were suspended in 1 mL phosphate-buffered saline + 
0.02% Tween 80 (PBST, pH 7.4) at 37°C under mild agitation. As brimonidine tartrate is 
highly water soluble183, 1 mL of release media was sufficient to ensure sink conditions 
for the duration of release. Microspheres were separated from media at each time point 
by centrifugation at 8,000 rpm for 5 min. Then, release media was completely removed 
and replaced at 1, 3, 5 and 7 days and weekly thereafter for 7 weeks. Release media was 
assayed for brimonidine content by UPLC, as described below. 
6.3.7 Brimonidine quantification 
Brimonidine content in loading solutions and release media was determined using 
a UPLC system (Waters, Milford, MA). The mobile phase was composed of 40 : 60 
(acetonitrile : ddH2O) and the flow rate was set to 0.5 mL/min. Samples and standards 
prepared in either acetonitrile or PBST were injected (8 µL) onto a C18 (Acquity BEH 
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C18, 1.7 µm, 2.1 x 100 mm) column maintained at 30°C. Brimonidine was detected at 
254 nm.  
6.3.8 Microneedle fabrication 
A 27-gauge (OD = 0.41 mm; ID = 0.21 mm) hypodermic needle (Becton 
Dickinson, Franklin Lakes, NJ) was used as the starting material. The needle was 
shortened to ~1.5 mm in length by cutting the needle using a cordless rotary tool (Dremel 
800, Robert Bosch Tool Corporation, Mount Prospect, IL). The bevel was produced by 
grinding the shortened needle at a 60° angle against the sanding band attachment of the 
rotary tool. A constant stream of water was flowed through the needle bore to prevent 
heat buildup and the metal from melting. This was done under a stereoscope to ensure the 
needle length was 750 ± 50 µm. If the needle was too long, the process was repeated; if 
the needle was too short, the plastic hub was carefully removed with a razor. Each needle 
was inspected for needle length, absence of metal shavings, and sharpness. If needed, the 
needle was filed with sandpaper and/or electropolished (ESMA E399, South Holland, 
IL), as previously described 8. 
6.3.9 In vivo experimental treatment groups  
All in vivo experiments were carried out in albino New Zealand White rabbits 
(Charles River, Wilmington, MA) and were approved by the Georgia Institute of 
Technology Institutional Animal Care and Use Committee. Practices complied with the 
ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Although 
bioavailability and distribution of brimonidine is affected by presence of pigment in the 
eye, albino rabbits were used to facilitate visualization of microspheres and since an 
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albino rabbit animal model was used in a previous study 6, 184. The treatment groups are 
listed in the Table 6.2. 
Table 6.2 – Summary of in vivo experimental treatment groups 
Treatment 
Group 
Fluid Carrier Description 
SC-HBSS 50 µL of HBSS Supraciliary delivery of saline 
SC-CMC 
50 µL of 5% (w/v) 
CMC in HBSS 
Supraciliary delivery of CMC 
SC-blank 
50 µL of 5% (w/v) 
CMC in HBSS 
Supraciliary delivery of blank microspheres 
SC-low dose 
50 µL of 5% (w/v) 
CMC in HBSS 
Supraciliary delivery of brimonidine-loaded 
microspheres (20-45 µm) [low dose] 
SC-high 
dose 
100 µL of 5% (w/v) 
CMC in HBSS 
Supraciliary delivery of brimonidine-loaded 
microspheres (20-45 µm) [high dose] 
Top N/A Topical delivery of brimonidine 
Before the injection procedure, animals were anesthetized with a subcutaneous 
injection of ketamine and xylazine. An eye drop of proparacaine (Akorn, Lake Forest, IL) 
was given 5 min prior to the injection. The eye was proptosed to facilitate injection. A 
hollow microneedle with a length of 750 µm (see Figure 6.3) and a 250 µL glass 
chromatography syringe (National Scientific, Rockwood, TN) were used to make 
injections 3 mm posterior to the limbus.  
To ensure delivery near the ciliary body, the total injection volume was divided 
into multiple injections of 10-20 µL each. Injections were spaced approximately equally 
around the limbus while avoiding the extraocular muscles. To inject a total volume of 50 
µL, three injections of 16.7 µL each were made supranasal, supratemporal, and 
infranasal. To inject 100 µL, five injections of 20 µL each were made; the same 3 
injection sites, as in the 50 µL dose, were used with an additional 2 injections 
infratemporal and temporal. The fluid carrier was 5% (w/v) carboxymethyl cellulose 
(CMC; average Mw 700 kDa; Sigma-Aldrich) in Hank’s buffered salt solution (HBSS; 
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Mediatech, Manassas, VA). For all groups, only one eye per rabbit received treatment; 
the contralateral eye did not receive any treatment during the study. 
For the supraciliary delivery of HBSS group (SC-HBSS), a total of 100 µL of 
HBSS was injected into the supraciliary space. For the supraciliary delivery of CMC 
group (SC-CMC), 50 µL of 5% (w/v) CMC in HBSS was injected. For the supraciliary 
delivery of blank microspheres group (SC-blank), 50 µL of 30% blank microspheres 
(w/v) and 5% (w/v) CMC in HBSS was injected. For the low-dose delivery of 
brimonidine-loaded microspheres group (SC-low dose), 50 µL of 30% brimonidine-
loaded microspheres (w/v) and 5% (w/v) CMC in HBSS was injected into the 
supraciliary space. For the high-dose delivery of brimonidine-loaded microspheres group 
(SC-high dose), 100 µL of 30% brimonidine-loaded microspheres (w/v) and 5% (w/v) 
CMC in HBSS was injected into the supraciliary space. The total injected volume was 
increased from the SC-low dose to SC high-dose because particle concentrations higher 
than 30% (w/v) particle in 5% CMC clogged the 27 gauge microneedle. 
After the injection, animals were monitored until mobile. If there was significant 
redness, inflammation, or irritation, a steroid/antibiotic ointment was applied to the eye. 
If the animal looked agitated or in pain after the procedure, 200 µL of buprenorphine was 
given subcutaneously. Animals were euthanized with an injection of pentobarbital 
through the marginal ear vein at the end of the experiment. The eyes were enucleated and 
some were processed histologically. 
For the topical delivery group (TOP), brimonidine eye drops (0.15% Alphagan, 
Allergan, Irvine, CA) were administered 3 times per day at 8:30 am, 2:30 pm, and 8:30 
pm unilaterally to the upper conjunctival sac without anesthesia. 
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6.3.10 Intraocular pressure monitoring 
For the animals that received a microneedle injection, IOP was measured in both 
eyes with a TonoVet (iCare, Vantaa, Finland) rebound tonometer between 10 am and 2 
pm. To measure IOP, the animal was removed from the cage and restrained in a towel for 
at least 5 min. IOP was measured at least 3 times in both eyes. If there was significant 
variation between recordings, additional time was given to acclimate the animal to its 
surroundings before attempting to measure IOP again. The baseline IOP was established 
by measuring IOP daily for a week prior to the injection. IOP was not taken on the day of 
injection because the ketamine cocktail used had a significant impact on IOP 6. IOP was 
monitored on 1, 3, 5, 7, 10, 14, 17, 20, 24, 27, 30, 33, and 43 days post-injection. 
Animals that received topical eye drops had their IOP measured at 4 pm daily for a week 
using the same methods.  
The rebound tonometer had been calibrated 6 mo prior against a rabbit whose eye 
was in fluid communication to a water column eye different heights6. The rebound 
tonometer reported values that were offset by 3 mmHg with no slope adjustment.  
6.3.11 Histology 
After the animals were euthanized, some eyes were enucleated and immediately 
fixed in 10% formalin. The eyes were serially sectioned, and sections were stained with 
hematoxylin-eosin (H&E) or periodic acid Schiff (PAS). Light microscopic examination 
was performed on all histologic sections for any signs of anatomical changes and foreign 
body reaction. Histological sections were photographed at 20× magnification (DP 71; 




6.3.12 Statistical analysis 
All values are mean ± standard error of the mean (SE), unless otherwise specified. 
Time traces of IOP were calculated in two ways: by finding the difference from the 
average IOP pre-treatment and by finding the difference between the treated and 
contralateral eyes. Repeated-measures ANOVA was used to compare the time course 
data. The dose-response curve was generated by calculating the area under the curve 
(AUC) using the trapezoid rule. Fisher’s Least Square Difference test (α = 0.05) was 
performed to determine statistical significance for individual time points. 
6.4 Results  
6.4.1 Characterization of brimonidine-loaded microspheres 
Our first goal was to encapsulate brimonidine into microspheres for sustained 
release for up to one month (Figure 6.2). We initially encapsulated brimonidine in free-
acid terminated PLA (800PLA), which resulted in low efficiency and high initial burst 
(24-hour release; Figure 6.2). This is probably because brimonidine is highly water-
soluble, which caused leaching of brimonidine into the aqueous phase during 
microsphere formulation, leading to poor loading 185. The highly water-soluble nature of 
brimonidine also probably contributed to high initial burst due to rapid dissolution of 
poorly encapsulated, surface-associated drug. Initial burst is generally an undesirable 




Figure 6.2 – Representative SEM images of four microsphere formulations: (A) 800PLA, (B) 800PLA-T, 
(C) 1000PLA, (D) PLA/PLGA. Scale bars represent 10 µm. (E) Brimonidine release from four polymer 
microsphere formulations in vitro. The media was PBST (pH 7.4, 37ºC). Data are expressed as mean ± SE 
(n = 3 replicates per group). 
To improve loading efficiency and decrease initial burst from microspheres, we 
employed three alternative formulation strategies for encapsulation of brimonidine: (i) 
increasing PLA concentration to 1000 mg/mL (abbreviated 1000PLA), (ii) blending PLA 
with PLGA (PLA/PLGA), and (iii) treating the PLA to remove low molecular weight 
acids (800PLA-T). The first two strategies increased brimonidine loading and decreased 
initial burst, believed to be due to a denser polymer matrix, which is more efficient in 
trapping the molecule during microsphere formulation 186. Although these formulations 
improved loading and burst, the long-term release from these microspheres in vitro was 
incomplete through five weeks and was thus deemed unfavorable (Figure 6.2).  
To further optimize the brimonidine release kinetics, we removed acidic 
monomers and oligomers to improve polymer stability during storage and effectively 
increase molecular weight of the bulk PLA. It has been shown that biodegradable 
polymers may contain 10-20 µmoles of acid per 100 mg of polymer following synthesis. 
Furthermore, the lactic acid monomers and oligomers formed during polymerization may 
catalyze the degradation of the polymer during storage, leading to a decline in PLA 
molecular weight and a buildup of additional acidic byproduct 182. Higher molecular 
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weight polymers create a denser matrix during microsphere manufacturing, leading to 
more efficient encapsulation 182. 
This final formulation was prepared with the same free-acid terminated PLA 
202H as used in our initial formulation. However, prior to microsphere manufacturing, 
we stirred the dissolved polymer in a hot water bath to remove low molecular weight, 
water-soluble acids; a strategy that been used successfully in the past to encapsulate the 
peptide leuprolide with high efficiency and resulting in low initial burst 182. Using these 
methods, we were able to greatly improve brimonidine loading in PLA to achieve 85 ± 
0.4% efficiency (Table 6.3) These microspheres also exhibited reduced initial burst in 
vitro (8.0 ± 1.3 %) as compared to the initial 800PLA microspheres (16.5 ± 0.2 %). 
Although this formulation did not achieve complete drug release at the end of the 
experiment, it was more than 75%.  
Table 6.3 – Characterization of brimonidine encapsulation in microspheres. Data expressed as mean ± SE 











Starting PLA concentration at 
800 mg/mL 
2.3 ± 0.1 38 ± 1 16.5 ± 0.2 
800PLA-T 
Starting PLA concenration at 
800 mg/mL. Heat treatment to 
remove low molecular weight 
acids 
5.3 ± 1.3 85 ± 0.4 8.0 ± 1.3 
1000PLA 
Starting PLA concentration at 
1000 mg/mL 
3.3 ± 0.3 67 ± 6 1.8 ± 0.3 
PLA/PLGA Blending of PLA and PLGA 5.3 ± 0.7 53 ± 8 1.2 ± 0.1 
6.4.2 Targeted injection localized to the supraciliary space 
Our next objective was to target injection of the brimonidine-loaded microspheres 
to the supraciliary space adjacent to the ciliary body. Microneedles (750 ± 50 µm in 
length) were fabricated for this study (Figure 6.3). We and others have seen that injection 
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of larger volumes leads to spread over a larger area of the suprachoroidal space 6, 119, 120, 
128. To localize our formulation at the site of injection at the supraciliary space, we 
wanted to minimize the injection volume and therefore needed to give multiple injections 
in order to deliver the target dose. Histological images were acquired for all supraciliary 
microsphere injection groups (SC-blank, SC-low dose, and SC-high dose) to assess the 
degree of localization of the particles at the injection site. These images showed that the 
injected particles were localized at the anterior suprachoroidal space, which is bordered 
by the ciliary body (Figure 6.4), which we call the supraciliary space.  
 
Figure 6.3 – Hollow microneedle measuring 750 µm in length is shown opposite a 50 µL drop from a 
conventional eye dropper. Scale bars represent 1 mm 
 
Figure 6.4 – Representative histological image of a section from the rabbit eye showing brimonidine-
loaded microspheres suspended in 5% (w/v) CMC/HBSS 46 days after injection into the supraciliary space. 






To further image supraciliary injection, we added 1% (w/v) red-fluorescent 
microspheres (1 µm diameter) to blank microspheres injected into the supraciliary space 
at multiple locations around the limbus. Sixty-nine days after injection, fluorescence 
imaging of eyes cut radially from the posterior pole to the limbus and then splayed open 
similarly show localization of the injected microspheres at the sites of injection in the 
anterior suprachoroidal space near the ciliary body (Figure 6.5). This result is consistent 
with previous reports that a low volume injection of CMC was able to be localized in the 
anterior suprachoroidal space 6.  
 
Figure 6.5 – Representative fluorescence image showing localization of red-fluorescent microspheres to 
the supraciliary space. Eyes were enucleated and imaged 69 days after injection of 1% (w/v) fluorescent 
polystyrene microspheres (1 µm diameter; ex: 580 nm, em: 605 nm; FluoSpheres, ThermoFisher Scientific, 
Waltham, MA) and 5% (w/v) blank microspheres suspended in 5% (w/v) CMC in HBSS. Bright-field image 
(A) displays the interior surface of rabbit eye. The center of the sample is the anterior segment, and the 
distal ends of the “petals” form the posterior pole. Each petal contains, from superficial to deep, the sclera 
(white), choroid, and retina. Fluorescence image (B) of same eye shows microspheres localized to the 
anterior suprachoroidal space.  
6.4.3 Effect of supraciliary delivery of brimonidine-loaded microspheres on 
intraocular pressure 
Next, our goal was to inject brimonidine-loaded microspheres into the 
supraciliary space of rabbit eyes to reduce IOP for one month. The rabbits had a baseline 
IOP of 12.2 ± 2.1 mmHg (mean±SD). As a positive control, brimonidine was given 
topically (TOP group) in the form of the clinical product Alphagan®, which was 




regimen corresponds to approximately 75 µg of brimonidine administered per eye drop 
and 1,125 µg of brimonidine administered over the course of five days.  
In the TOP group, we saw a consistent IOP drop of 2 – 4 mm Hg in the treated 
eye (one-way ANOVA, p = 0.003, Figure 6.6A) with a magnitude similar to those 
reported previously for the length of the treatment 187. Five days after stopping eye-drop 
administration, the IOP of the treated eye had returned to baseline (Fisher’s LSD test, p = 
0.86). The IOP of the contralateral eye in the TOP group also showed a significant 
reduction (one-way ANOVA, p = 0.03, Figure 6.6A) with a magnitude similar to the 
treated eye (two-way ANOVA, p = 0.26, Figure 6.6B). Because the body weight of the 
rabbits (2-4 kg) was more than an order of magnitude less than a human, it is likely that 
the brimonidine that cleared from the treated eye (that was administered a human dose of 
drug) was sufficient to cause an effect on the contralateral effect, either through a 
systemic cardiovascular effect or a contralateral therapeutic effect 188.  
Guided by this positive control, we next injected brimonidine-loaded 
microspheres into the supraciliary space. To improve localization of delivery to the 
ciliary body by avoiding flow of the injectate away from the injection site, the 
microspheres were formulated with CMC to increase viscosity, and the total material 
injected was divided into multiple small injections (10-20 µL) at multiple locations 
around the eye, as was done previously to localize to the supraciliary space6. We 
delivered 15 mg (SC-low dose, containing 0.45 mg of brimonidine, Figure 5C-D) and 30 
mg (SC-high dose, containing 0.9 mg of brimonidine, Figure 6.6E-F) of microspheres 
into the supraciliary space. To control for the effect of the injection of microspheres, we 
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also injected 15 mg of blank microspheres (SC-blank) as a negative control (Figure 6.6G-
H). 
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Figure 6.6 – Effect of brimonidine delivery on IOP in the rabbit eye. Change in IOP from baseline over 
time for topical brimonidine eye drops three times per day (A), brimonidine microspheres (low dose) (C), 
brimonidine microspheres (high dose) (E), blank microspheres (G) , HBSS only (I), and 5% (w/w) CMC 
(K). Difference in IOP between treated and contralateral eye over time for topical brimonidine eye drops 3 
per day (B), brimonidine microspheres (low dose) (D), brimonidine microspheres (high dose) (F), blank 
microspheres (H), HBSS only (J), and 5% (w/w) CMC (L). Data are expressed as mean ± SE (n = 3-6). 
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Both groups that received brimonidine-loaded microspheres (i.e., SC-low dose 
and SC-high dose) experienced a decline in IOP of the treated eye of as much as 6 mm 
Hg when compared to the contralateral eye (repeated-measures ANOVA, p = 0.025 and 
0.002, respectively). It is notable that the contralateral eye showed no significant change 
in IOP (repeated-measures ANOVA, p = 0.92 and 0.73, respectively), which is consistent 
with localization of the drug to the site of injection. The SC-low dose group showed a 
reduction in the IOP of the treated eye for 14 days after the injection (Fisher’s LSD test, p 
= 0.005). The SC-high dose group showed a reduction in the IOP of the treated eye for 33 
days (Fisher’s LSD test, p = 0.03). These data are consistent with our central hypothesis 
that IOP can be reduced for one month after a single injection of brimonidine formulated 
for sustained release in the supraciliary space. 
In the negative control (SC-blank), the “treated” eye had an IOP reduction of 3 
mm Hg compared to the contralateral eye 3 days after injection (one-way ANOVA, p = 
0.02), which returned to baseline within 5 days (Fisher’s LSD test, p = 0.35). This effect 
seen in the negative control might be due to an inflammatory response caused by the 
injection, reduced aqueous humor production due to disruption of the ciliary body, or 
increased uveoscleral outflow due to stretching of the ciliary muscles 189, 190.  
6.4.4 Effect of fluid carrier on intraocular pressure 
To further elucidate the cause of IOP reduction in the SC-blank group, we 
examined the effect of the injection technique and fluid carrier on IOP. We injected 
HBSS (SC-HBSS, Figure 6.6I-J) or 5% (w/v) CMC in HBSS (SC-CMC, Figure 6.6K-L) 
into the supraciliary space to monitor their impact on IOP. There was a change in IOP 
from baseline for both SC-HBSS and SC-CMC groups that was evident immediately after 
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injection (Fisher’s LSD test, p = 0.01), but was no longer evident at the next 
measurement 2 days later (Fisher’s LSD test, p = 0.84). Possible explanations of this brief 
IOP reduction include: increased uveoscleral outflow due to ciliary muscle stretching, a 
short inflammatory reaction causing blood-aqueous-barrier breakdown and decreased 
aqueous humor production due to ciliary body distention. Further studies are needed to 
explore this phenomenon. 
There was no difference between treated eyes of SC-CMC (Figure 6.6C-D) and 
SC-blank groups (Figure 6.6G-H) (repeated-measures ANOVA, p = 0.22). This result 
shows that blank microspheres had little intrinsic effect on IOP. Therefore, the IOP 
reduction in the treated eye seen in the SC-low dose and SC-high dose groups is believed 
to be due primarily to the effect of brimonidine release from the microspheres. 
6.4.5 Integrated pharmacodynamic response of treatment groups 
As a characterization of the integrated pharmacodynamic responses, we 
determined the area under the curve (AUC) for all treatment groups by integrating the 
difference in IOP between the treated and contralateral eyes over time (Figure 6.7). The 
expected response of the brimonidine eye drop (TOP) regimen extrapolated over 30 days 
was 70 mmHg-days (Figure 6, dotted line). Unlike the other values presented in Figure 6, 
the response was calculated by finding the IOP reduction of the treated eye minus the 
IOP of the baseline (i.e., before eye drop application) over the course of one day of eye 
drop application, and extrapolating the effect by 30 days There was no statistical 
difference between the SC-blank group and the SC-HBSS group (Fisher’s LSD test, p = 
0.99) or the SC-CMC group (Fisher’s LSD test, p = 0.93). The SC-low dose group also 
did not reach statistical significance compared with the SC-blank group (Fisher’s LSD 
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test, p = 0.38) because there was considerable variation in the response among the five 
animals in the SC-low group. There was a significant response with the SC-high dose of 
brimonidine-loaded microspheres compared with the SC-blank group (Fisher’s LSD test, 



































































Figure 6.7 – Integrated pharmacodynamic response of treatment groups. Values were calculated by 
determining the area under the curve for differences in IOP between the treated and contralateral eyes 
(data from Figure 6.6) for each animal. Bars represent mean values. Dotted line indicates the expected 
response achievable with brimonidine eye drops. * = p<0.05. 
The high-dose brimonidine-loaded microspheres were necessary to ensure a 
consistent sustained effect for one month. All animals in the SC-high dose group had a 
sustained reduction in IOP for at least three weeks. On the other hand, there was 
appreciable variation among the responses of the six animals in the SC-low dose group. 
Out of the six rabbits in the SC-low dose group, one rabbit experienced no IOP drop in 
the treated eye and another had the strongest response out of all the rabbits tested. This 
variation in IOP response is possibly due to inter-animal differences in sensitivity to 
brimonidine or the microspheres releasing at the lower limit needed for a pharmacologic 
response. Since an increased dose resulted in a prolongation of the effective duration, the 
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release rate from the microspheres might have decreased after 14 days, suggesting 
nonlinear drug release rate.  
6.4.6 Initial safety assessment 
During the experiment, rabbits were inspected on a daily basis by veterinary staff 
and/or study investigators. The microneedle injection site was barely visible immediately 
post-injection (Figure 6.8A) and was not visible 1 day post-injection (Figure 6.8B). Some 
rabbits had mild redness 1 day after injection, and were subsequently treated with an 
antibiotic/steroid ointment. Three days after injection, all eyes were quiet and there were 
no signs of redness or irritation, or apparent distress in the rabbits. No serious adverse 
events were noted, and the rabbits at least maintained their weight from pre-injection. 
Assessment of visual acuity and visual fields were not performed on the rabbits though 
we would be unlikely to detect any deficit since the injection was localized to the far 
periphery of the suprachoroidal space. 
 
Figure 6.8 – Representative images of the rabbit eye 5 min (A) and 1 day (B) after microneedle injection. 
Microneedle injection site marked with arrow. 
To further assess the safety of brimonidine-loaded microspheres in the 
supraciliary space, we performed histology on the enucleated eyes. The slides were read 
by a board-certified ocular pathologist. All eyes that received a supraciliary injection 
demonstrated separation of the suprachoroidal space at the anterior region (Figure 6.9). 






Figure 6.9 – Representative histological images after microneedle injection of HBSS only (SC-HBSS, A) 88 
days post-injection; blank microspheres (SC-blank, B) 46 days post-injection; and brimonidine-loaded 
microspheres (SC-low dose, C) 69 days post-injection. No inflammatory cells were noted in the SC-HBSS 
group (A inset), whereas accumulation of macrophages was seen in eyes that received SC-blank (B inset) 
and SC-low dose (C inset), as indicated by the darkly-stained nuclei (arrows) among the voids of where the 
microspheres were. The microspheres and associated foreign-body response could also be seen in the site 
of microneedle puncture across the sclera, indicated by the yellow arrow, and in the subconjunctival space 
69 days after injection (D). Scale bars indicate 500 µm. 
Due to the histologic/staining process, the PLA microspheres were dissolved 
leaving behind voids where the microspheres were located. There was significant foreign 
body response among the microspheres in the supraciliary and subconjunctival space 
(Figure 6.9). We hypothesize this response may be due to the acidic byproducts of the 
PLA microsphere degradation or impurities in the microsphere from the fabrication 
process, because previous injections of polystyrene microspheres did not cause 
inflammation 8, 81. The foreign body response was present in both blank (Figure 6.9C) 
and brimonidine-loaded microspheres (Figure 6.9B), which further suggested that the 
accumulation of macrophages was due to the presence of microspheres (i.e., and not due 
















reponse also appeared at the injection site (Figure 6.9D, arrow) 191. Nevertheless, it is 
important to note that the eye did not look inflamed and the animals did not show signs of 
pain, irritation or distress. Further experiments are needed to investigate this. 
We were not able to observe the time frame of complete microsphere degradation. 
The PLA microspheres were still present 46 and 69 days after the injection (Figure 6.9B-
D). It is important to note that all brimonidine was released by these times (as seen with 
the in vitro drug release). As the degradation rates of this polymer are well known 192, 193 
and certainly much slower than the release rate of the drug, especially in vivo, and intact 
microspheres remained at the end of the release experiment, we did not explore the 
erosion and degradation behavior of the microspheres further. Now that we have initial 
proof-of-principle data on the success of in vivo delivery, further formulation work on 
PLGA microspheres for brimonidine and related drug molecules is warranted.  
The inability of the injection site to heal was concerning. A delayed healing 
response may be due to the release of byproducts from the particles that delayed healing, 
or the mass effect of the particles. This hole through the sclera may be a risk for 
infection, although it is expected the conjunctiva healed over the wound limiting access 
to the wound. 
6.5 Discussion  
Current glaucoma medical therapies are dominated by topical administration. Due 
to the low bioavailability of eye drops, typically less than 5% of the drug penetrates into 
the eye and reaches the target site (i.e., ciliary body) 4. The remaining 95% of the drug 
enters systemic circulation and can cause side effects throughout the body 4. For example, 
brimonidine use causes dry mouth in 33% of patients 194. Because of the low 
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bioavailability of drug at the ciliary body, patients are often required to administer 
multiple eye drops daily. Patient adherence suffers due to the complexity and rigor of the 
treatment required to control glaucoma 55-58, 176, 195, 196. It is estimated that adherence with 
use of topical eye drops is as low as 41% 4, 196.  
Glaucoma therapy delivered in a highly-targeted manner to the ciliary body could 
reduce side effects by lowering the required dose. Supraciliary delivery allows the highly 
targeted delivery of glaucoma drugs to the ciliary body with significant dose sparing 6. 
This dose sparing translates into a lower daily dose as well as fewer side effects. In this 
study, we delivered 0.9 mg of brimonidine loaded into slow-releasing polymeric 
microspheres as a single injection and demonstrated an IOP reduction for more than one 
month in the treated eye. The amount of brimonidine delivered via commercial eye drops 
three times per day for an equivalent time would result in a 7.5-times greater dose. 
Consistent with the lower administered dose, IOP reductions in the contralateral eye were 
not seen with the brimonidine-loaded microspheres groups compared with the topical eye 
drop administration. This increase in bioavailability during controlled release of 
brimonidine is lower than previously reported for bolus delivery of brimonidine in the 
suprachoroidal space6. We hypothesize that this may be due to the strong binding affinity 
of brimonidine to a2 adrenergic receptors 
181, 187 and the fast clearance from the SCS 5, 9. 
With a bolus injection, brimonidine is expected to bind all available receptors and causes 
a biological response for up to 12 h 6. However, with a controlled release system, 
brimonidine is continually released in small quantities, and this must overcome the 
clearance of brimonidine from the SCS. Because of its strong binding affinity, not all the 
brimonidine release will be able to bind receptors since the receptors are already 
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occupied by previously released brimonidine. This brimonidine is essentially ‘wasted’, 
which may at least partially explain the lower than expected dose sparing. To our 
knowledge, this is the first time that controlled-release drug delivery systems for the 
management of glaucoma have been injected into the supraciliary space. 
In this study, we have shown reduced IOP for one month, however further 
optimization of microsphere formulation and injection procedure could increase the 
duration of effect and further reduce the required dosage. Since glaucoma patients 
typically make regular visits to the eye clinic every 3 - 6 months, we envision an 
outpatient procedure performed by an ophthalmologist consisting of a single supraciliary 
microneedle injection of glaucoma drugs encapsulated within microspheres to adequately 
control IOP for the next 3 - 6 months. This would obviate the need for the patient to 
administer eye drops multiple times per day, and thus drastically raise patient adherence. 
Future studies will address the development of microparticles that release glaucoma 
drugs for 3 – 6 months and their use in the eye.  
Histology sections showed foreign body response due to the presence of 
microspheres in the supraciliary space. This may be due to impurities in the microsphere 
fabrication process, or particle degradation byproducts, though further studies are needed 
to determine the cause. Nevertheless, the animals did not show signs of distress or 
redness in the eye. Furthermore, the microspheres persisted in the supraciliary space 
despite complete drug release. Further studies are required to improve the 
biocompatibility of materials injected into the supraciliary space.  
The success of our approach is based on the combination of two advances: the 
development of sustained-release brimonidine microspheres and their placement adjacent 
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to the drug’s site of action in the ciliary body using microneedles. Roughly zero-order 
release of brimonidine with minimal burst effect was achieved by formulating the drug 
into PLA microspheres using PLA which was first treated to remove acidic monomers 
and oligomers to improve polymer stability during storage and effectively increasing 
molecular weight of the bulk PLA used for formulation. The resulting PLA microspheres 
had higher molecular weight and a denser matrix, which enabled efficient encapsulation, 
slow and continuous release with minimal burst in the first day. By increasing the PLA 
molecular weight or using an ester end-capped PLA in future studies, the release rate 
could be extended further, perhaps to achieve the target of 3 – 6 months of sustained 
release. Using different biodegradable polymers, such as poly(trimethylene carbonate), 
could reduce the inflammatory response to the microspheres because this polymer does 
not produce acidic byproducts during its degradation by surface erosion 197, 198. Other 
polymers might also biodegrade in a time frame matched to the drug release. 
Placement of the sustained-release microspheres in the supraciliary space served a 
number of functions. First, forming a drug depot adjacent to the ciliary body enabled dose 
sparing, which is not only of interest to reduce side effects, but also enables a smaller 
injection to contain enough drug for a longer duration of effect. Second, the supraciliary 
space is not in the visual axis and therefore should not affect vision the way eye drops or 
intravitreal injections can 97, 199.  
Third, injection into the supraciliary space is expected to be safe and 
straightforward to perform on an outpatient basis. This is because the microneedle used 
for injection inherently targets the supraciliary space due to its length and the injection 
procedure is almost identical to how current intravitreal injections are routinely 
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performed, except for using a shorter needle. Studies in animals and humans have shown 
that microneedle injections into the suprachoroidal space have been well tolerated 2, 7, 119, 
124, 127.  
Finally, the supraciliary space is believed to be a safe place to deposit drug 
formulations. The sclera and choroid are not tightly attached and thereby form a potential 
space that can be temporarily expanded without apparent long-term adverse effects 7, 9, 119, 
136, 146, 199-202. Sustained-release formulations placed into the suprachoroidal space of 




7 CONCLUSION  
Patients experiencing ocular pathology and/or disease can have devastating loss of 
vision and blindness, and consequently significant loss in quality of life203-206. Although 
many medications exist, delivering these drugs to the site of disease in a spatially and 
temporally controlled manner is challenging due to the eye’s small size and unique 
barriers. Traditional ophthalmic drug delivery techniques, namely topical eye drops and 
intravitreal injections, are not able to target specific tissues within the eye, resulting in 
low bioavailability at the diseased tissue(s) and/or possible side effects due to drug 
affecting non-target tissues.  
The suprachoroidal space (SCS) is a potential space found between the sclera and 
the choroid. Due to its proximity to the choroid, this space is an attractive site of drug 
delivery for posterior segment diseases because high bioavailability within the choroid 
and retina can be achieved9, 125. Thus, a lower drug dose can be used to achieve similar 
efficacy compared with traditional routes of administration6. Furthermore, the drug is 
compartmentalized in the SCS away from non-diseased tissues, which is expected to 
result in a more favorable side effect profile9, 125. Because of these reasons, drug delivery 
to the SCS has been achieved through invasive procedure and/or surgery2, 116-118, 130.  
A microneedle injection enables reliable and more efficient access to the SCS8, 81, 
compared with previous methods2, 117, 118, 130. The length of the microneedle is matched to 
the thickness of the conjunctiva and sclera so the microneedle is physically unable to 
penetrate deeper into the eye (i.e., through the choroid and retina). When fluid is injected 
at this position (deep to the sclera but superficial to the choroid), it will flow 
circumferentially within the SCS, bathing the choroid in drug. Furthermore, microneedle 
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injections can be performed in the outpatient clinic setting by ophthalmologists, and are 
well tolerated7. 
7.1 Kinetics of Suprachoroidal Space Delivery using Microneedles 
To aid in the rational design of drug delivery strategies utilizing the SCS, we 
studied the distribution and clearance of particles and molecules, as well as a controlled 
release system, injected into the SCS using a microneedle. First, we identified anatomical 
barriers to circumferential spread within the SCS. We studied the circumferential spread 
of particles and molecules co-injected into the SCS, as well as the effect of viscous 
formulations on distribution. Then, we investigated the SCS thickness and the effect of 
injection volume and formulation on this parameter over time. Next, we examined 
clearance kinetics and the routes of clearance of molecules injected into the SCS. Finally, 
we developed and tested a controlled release drug delivery system within the SCS for the 
treatment of glaucoma.  
7.1.1 Distribution in the suprachoroidal space  
The first three studies described the distribution of molecules and particles 
injected into the SCS of rabbits and humans using microneedles. We found anatomical 
barriers (the long posterior ciliary arteries in rabbits ex vivo and in vivo and the short 
posterior ciliary arteries in human cadaver eyes) that prevented circumferential particle 
spread within the SCS. Particles injected in close proximity to these vessels did not 
spread isotropically like particles injected far from these anatomical features. We posited 
that this behavior was due to a physical barrier within the SCS caused by a multitude of 
vessels that bound the sclera and choroid together tightly. In contrast, the human long 
posterior ciliary artery did not bind the sclera and choroid tightly, and was not expected 
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to form a barrier to spread. Instead, we found that the short posterior ciliary arteries in 
humans are morphologically similar to the long posterior ciliary arteries in rabbits, and 
we showed that these vessels also limited spread. Furthermore, solitary large attachments 
(i.e., the vortex vein) did not result in altered particle distribution. If the goal is to target 
the optic nerve and/or macula in human patients, further studies in live human subjects 
are warranted.  
We studied the distribution of particles and molecules co-injected into the SCS of 
ex vivo and in vivo rabbits. The purpose of this study was to ascertain if particles and 
molecules that were co-injected distributed differently. With particles suspended in 
HBSS, we found that, as injection volume increased, the area of particle spread increased, 
though the area of molecule coverage was greater than that of particles. Particle 
entrapment could be ameliorated by increasing formulation viscosity. Akin to Stoke’s 
Law, the viscous liquid formulation could form a ‘sheath’ around the particle and 
influence its interactions with the walls of the SCS. We also found that particles ranging 
from 20 to 2,000 nm in diameter also co-localized, suggesting particles of varying sizes 
behave similarly. 
We next investigated amount of distension between the sclera and the choroid, 
which we termed the SCS thickness. We found that increasing injection volume of HBSS 
did not change the thickness. We looked into why this might be the case, as the injected 
fluid could spread circumferentially or increase SCS thickness. We provide evidence that 
there are SCS fibrils that bind the sclera and the choroid, and that these fibrils limit the 
expansion of the SCS. Changing the viscosity of the formulation injected had a major 
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effect on SCS thickness, presumably since the viscous formulation could overcome the 
biomechanical forces of the tissues. 
From these three studies, we provide a model of how fluids and particles 
distribute in the SCS. The volume of fluid injected attempts to distribute itself within the 
SCS so as to minimize forces. Fluid can distribute circumferentially and/or increase the 
SCS thickness. Low-viscosity formulations are unable to overcome the biomechanical 
forces of the tissue beyond a certain SCS thickness, and thus fluid is distributed in a disc-
like region within the SCS that has a near-constant thickness. Initially, high-viscosity 
formulations resist flow and are able to overcome the tissue biomechanics, resulting in a 
localization of the fluid at the site of injection with an expanded SCS thickness. Over 
time, the viscous formulation may imbibe water to balance the increased osmotic forces 
of the fluid. This will cause swelling of the fluid at the site of injection. Alternatively, the 
viscous formulation can creep circumferentially in the SCS. Regardless of formulation, 
there are anatomical barriers in the SCS that physically limit circumferential flow 
(probably of a convective nature). These anatomical barriers are formed by tight 
adhesions as vessels traverse the sclera to anastomose with the choroid. If there is a 
solitary adhesion (as in the rabbit vortex), the effect is small and limited to just around 
the vessel. If there are many adhesions (as in the rabbit LPCA), an entire region can be 
blocked off. We hypothesize that these barriers are to convective flow so it may be 
possible to diffuse through or around them.  
Particles injected as a suspension within these formulations appear to be carried 
by the formulation. The viscosity of the formulation influences when the particles ‘fall 
out’ of suspension. ‘Falling out’ may be due to gravitational, electrostatic, or 
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morphological effects of the particles or rheological changes of the fluid. Since the 
viscosity of the formulation can change in the SCS over time due to dilution, prediction 
of particle transport time may be challenging.  
7.1.2 Clearance from the suprachoroidal space 
The second overall goal of this thesis was to study the clearance of molecules 
from the rabbit SCS in vivo. We began by investigating the rate of SCS collapse after 
microneedle injection of different liquid formulations. The rate of collapse varied from 
40 min to 14 days depending on formulation composition. Surprisingly, some viscous 
formulations expanded within the SCS well after the injection. This phenomenon was 
likely due to the viscous gel imbibing water from the local tissue environment to equalize 
osmotic (and hydration) pressure143.  
We then determined the rate of clearance of fluorescent molecules ranging from 
400 Da to 2 MDa. Whereas, small molecules (e.g., fluorescein) cleared from the SCS 
within 12 h, very large macromolecules were still in the SCS at 21 d. These very large 
macromolecules had significantly delayed clearance from the SCS likely due to the 
macromolecule being larger than the fenestrae of choriocapillaris31. Since clearance time 
of 2 MDa FITC-dextran matched the clearance of monoclonal antibodies injected 
intravitreally, this might be a viable strategy for controlled release in the SCS. 
Microspheres with similar dimensions as 2 MDa FITC-dextran were still visible in the 
SCS after 2 mo8. The macromolecule has deformable shape compared with the rigid 
microsphere, so clearance of 2 MDa FITC-dextran should still be possible.  
We set out to determine the route of clearance from the SCS. Previous studies 
have hypothesized the route of clearance as intravascular clearance from the SCS9, 126. 
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We collected fluorescein from different routes after microneedle injection. Contrary to 
those previous studies, we identified three regimes of clearance: (i) initial leakage of 
fluorescein from the injection site and perivascular leakage sites; (ii) pressure-driven 
trans-scleral movement of fluorescein, and (iii) diffusion into the choroid and subsequent 
intravascular clearance. These results were corroborated with a one-dimensional 
mathematical model of the SCS and surrounding tissues. 
7.1.3 Controlled release systems within the suprachoroidal space 
Due to the fast clearance from the SCS, we hypothesized that microparticle-based 
controlled-release drug delivery system could be used to extend time between dosing. We 
showed that such a system injected into the anterior SCS had a therapeutic effect for up to 
1 mo.  
However, this system achieved dose sparing of ~13% of the topical dose, which 
was not as much as the 1% of the topical dose achieved with bolus injections into the 
suprachoroidal space adjacent to the ciliary body (i.e., the supraciliary space)6. We 
hypothesized that this may be due to the strong binding affinity of brimonidine to a2 
adrenergic receptors and the fast clearance from the SCS. With a bolus injection, 
brimonidine was expected to bind all available receptors and cause a biological response 
for up to 12 h. However, with a controlled-release system, brimonidine was continually 
released in small quantities, and this must overcome the clearance of brimonidine from 
the SCS. Because of its strong binding affinity, not all the brimonidine release would be 
able to bind receptors since the receptors were already occupied by previously released 
brimonidine. This brimonidine was essentially ‘wasted’, which may at least partially 
explain the lower than expected dose sparing.  
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Using a more hydrophobic drug (such as latanoprost) might shrink this 
discrepancy in dose sparing between bolus and controlled release delivery. For example, 
suspensions of triamcinolone acetonide have been shown to release drug in the SCS for 
up to 2 mo2, 7, 119, 127. Another approach to have controlled release in the setting of fast 
clearance might be a drug delivery system that releases bursts of drug periodically. Drug 
would only be released during these bursts and not between the bursts. The periodicity of 
these bursts would match the time of efficacy for the drug encapsulated.  
7.2 Role of Formulation on Kinetics 
7.2.1 Liquid formulation  
Changes in formulation can have a dramatic effect on distribution, both 
circumferentially and in SCS thickness. In particular, we studied the effect of injection 
volume and formulation viscosity on distribution. Increasing injection volume had a 
reasonable effect on circumferential spread and a negligible effect on SCS thickness. On 
the other hand, increasing formulation viscosity had the dual effect of initial localization 
at the injection site, as well as increased SCS thickness. Depending on the formulation 
composition, the formulation could remain localized (for example, if the formulation 
contains physically cross-linked polymers) or it could spread. We are unsure of the 
mechanism by which viscous formulations spread, though we hypothesize it is associated 
with the biomechanical properties of the tissue.  
We achieved increased viscosity by adding high molecular weight 
macromolecules to the formulation. It would be interesting to find out if viscous 
formulations achieved with low molecular weight species would behave similarly.  
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7.2.2 Polymeric microparticles 
We and others have shown that polymeric microparticles distribute in the SCS 
and are resistant to clearance. We provide evidence that particles ranging from 20 nm to 
2,000 nm behave similarly. Even the smallest particles in this range are thought to be too 
large to fit through the fenestrae of the choriocapillaris. Thus, they are resistant to 
clearance. 
The fabrication and composition of microspheres suitable for the SCS need to be 
optimized. Although the brimonidine-loaded microsphere system was efficacious for up 
to 1 mo, the microspheres seemed to cause a significant foreign body response in the 
SCS. This might be due to the fabrication process (e.g., incomplete removal of solvent) or 
the materials used. Since the SCS is exposed to the choroidal vasculature (which is one of 
the densest vascular beds in the body), there is the strong possibility of a potent immune 
response. Furthermore, we have an incomplete understanding of the immune system in 
the SCS. Perhaps a detailed study of immune responses to materials in the SCS is 
warranted.  
Particles suspended in liquid formulations do not travel as far as the formulation. 
A theory on why this is has been presented above. This behavior might be modifiable by 
changing properties other than size.  
7.3 Limitations of the Studies 
The bulk of the studies were performed in albino New Zealand White rabbits, and 
there are inherent anatomical/physiological differences between rabbits and humans. The 
rabbit animal model was used because ocular dimensions of rabbit eyes are similar to 
humans while enabling visualization of fluorescence within the SCS. The use of smaller 
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animals (e.g., rats and mice) would be significantly more difficult since a shorter 
microneedle would need to be developed, which might decrease reliability81, 105. Larger 
animals (e.g., pigs and monkeys, for which Georgia Tech has no housing facilities) would 
require significantly more cost and study coordination. Thus, the rabbit is a good animal 
model to study suprachoroidal delivery. 
Despite limitations of the rabbit model, we believe the results of these studies are 
relevant to human health. For example, scaling microneedle dimensions is sufficient for 
reliable microneedle injections in rabbits and humans. Injection volumes should also be 
able to scale with respect to eye size. Some species-dependent parameters were deemed 
unimportant. For example, the scleral permeability of rabbits is different from that of 
humans, but sensitivity analysis indicates this parameter contributes very little to overall 
clearance.  
To study kinetics, fluorescent tracer molecules were used as proxies for drugs. 
While parameters such as molecular radius can be matched, other physiochemical 
properties (such as partition coefficient and protein affinity) cannot be matched. It is 
possible these physiochemical properties also play a role in clearance123. Thus, studies 
with drugs of interest should be performed to determine their kinetics.  
7.4 Final Note 
These studies provide an in depth look at the kinetics of microneedle injections 
into the SCS, and lay the foundation for future developments in suprachoroidal delivery 





8 FUTURE DIRECTIONS 
This work investigated the kinetics (e.g., distribution and clearance) of molecules 
and particles injected into the SCS using a microneedle. In particular, we showed that (1) 
SCS thickness can be modulated with different excipient formulations; (2) particles 
become entrapped in the SCS to a greater extent relative to molecules; and (3) very large 
macromolecules (2 MDa) have significantly slower clearance times relative to smaller 
molecules. Since the bulk of this work was performed in rabbits, correlation in human 
subjects is also warranted. We will briefly discuss applications based on these findings, 
and possible ways forward. 
8.1 SCS Thickness can be Modulated with Liquid Formulation 
With low viscosity formulations (e.g., HBSS), the SCS reaches a constant 
thickness irrespective of injection volume. With high viscosity formulations (e.g., 5% 
CMC in HBSS), the SCS can reach a maximum thickness of ≥3 mm. Though this 
phenomenon has limited practicality in ophthalmic drug delivery, it can be useful in 
modulating biomechanical properties of the eye, including aqueous humor production 
and/or clearance, axial length of the eye, and re-apposition of the choroid with the retina 
(to treat retinal detachment).  
We showed that intraocular pressure (IOP) dropped after the injection of a viscous 
formulation (with or without the drug, brimonidine). This could be due to disruption of 
the ciliary epithelium causing decreased aqueous humor production, stretching of the iris 
root causing increased uveoscleral outflow, or stretching of Schlemm’s canal causing 
increased aqueous humor outflow. Examination of the mechanism of this IOP reduction 
is warranted. A combined drug-device implant, wherein the implant could reduce IOP via 
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biomechanical effects as well release glaucoma medications, could be developed to treat 
glaucoma. Suprachoroidal drainage stents (see CyPass® micro-stent144, 147, 201 or iStent® 
Trabecular Micro-Bypass145, 207), which are biomechanical devices that function under 
similar principles, require surgery whereas the proposed drug-device implant could be 
injectable in an outpatient setting. 
Refractive errors caused by myopia are due to misalignment of the retina relative 
to the focal plane of the eye1. Typically, myopia is caused by an increased axial length of 
the eye. We propose treating myopia by injecting a semi-permanent viscous formulation 
into the SCS to shift the retina (and choroid) forward so the focal plane of the eye lies on 
the retina.  
A retinal detachment is a medical emergency where the retina detaches from the 
choroid, and can result in irreparable loss of retinal cells1. Typically, a scleral buckle is 
surgically placed around the ocular globe in an attempt to re-appose the retina to the 
choroid208. A suprachoroidal bleb could be used, instead of a scleral buckle, to achieve 
the same goal. And indeed, such a surgical procedure has been attempted with positive 
results153, 154, 209. We propose a procedure to treat retinal detachments by injecting a 
viscous formulation into the SCS to re-appose the retina to the choroid. Since time is of 
the essence with a retinal detachment, a microneedle injection is advantageous over other 
methods because it can be performed in the clinic or the emergency department, and 




We noted some ischemia caused by the CMC bleb. This might be useful to 
prevent or control choroidal blood vessel growth (as in the case of choroidal 
neovascularization or retinopathy of prematurity.  
8.2 Strategies for Controlled Release Treatments of Posterior Segment Diseases 
Many therapeutics to treat posterior segment diseases are monoclonal antibodies 
(mAbs) that bind up soluble proteins or polypeptide24, 68, 210, 211. For example, wet age-
related macular degeneration is treated with monthly intravitreal injections of mAbs 
against vascular endothelial growth factor (VEGF)68, 69. Since we and others8, 9 have 
shown that macromolecules on the order of 150 kDa clear from the SCS within 1 d, 
controlled release of these macromolecules has been proposed124. Most controlled release 
systems rely on the encapsulation of the therapeutic agent in polymeric microspheres or 
monolithic implants. However, encapsulation can affect the stability and functionality of 
mAbs212, 213. Furthermore, we have shown that microspheres do not distribute well in the 
SCS relative to molecules. 
Improving the formulation through the addition of viscous excipients should 
improve distribution of particles. Another approach might be to inject a solution of mAbs 
dissolved in a viscous solution. This should slow down the diffusion rate of mAbs to 
achieve some level of controlled release. And another approach might be to conjugate 
mAbs together to create very large macromolecules. 
8.3 Visualization of SCS Injections in Human Subjects 
Most of these studies were carried out in the in vivo and ex vivo albino New 
Zealand White rabbit eye, and species differences with humans are enough to warrant 
further experimentation. It was possible to visualize and track the kinetics of fluorescein 
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(and derivatives) in the SCS of albino rabbits since there was no pigment in the retinal 
pigment epithelium and choroid. However, most humans (and other model animals) are 
not albino and thus visualization with this method would not work. We propose the use of 
indocyanine green214 (or other fluorescent molecules with excitation/emission in the 
infrared spectra) as a marker of fluid distribution in the SCS. A near-infrared (NIR) dye 
should be visible regardless of the presence of visible-light pigment. Furthermore, 
indocyanine green is an FDA-approved molecule and there are ophthalmic imaging tools 
that have optics to visualize this molecule215.  
8.4 Future Outlook of Suprachoroidal Delivery 
Microneedle injections into the suprachoroidal space (SCS) enable reliable and 
efficient access to the SCS8, 81. The SCS is an emerging route of administration to treat 
ocular disease affecting the posterior segment and ciliary body. This work investigated 
distribution and clearance of particles and molecules injected into the SCS using a 
microneedle. We showed that distribution of particle suspensions are limited by 
anatomical barriers129; that particles spread to a lesser area than molecules; that clearance 
of molecules is by a combination of reflux, trans-scleral transport, and choroidal 
clearance; that very large macromolecules are cleared slower; and that controlled-release 
polymeric drug delivery systems in the SCS are efficacious115 but did not achieve the 
dose sparing seen with bolus injections6. From these experimental results, we generated 
theories to describe SCS kinetics.  
The knowledge gained from this thesis should aid in the rational design of 
formulations and injection strategies to attain better targeting within the SCS. Some ideas 
are highlighted in this chapter. At the same time, others are advancing the acceptability of 
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SCS injections in human medicine. Based on encouraging results from a Phase II clinical 
trial that tested the safety of a microneedle injection of triamcinolone to treat posterior 
uveitis (NCT02255032), a Phase III clinical trial (NCT02595398) is actively recruiting to 
determine the efficacy of this system in the clinic. Overall, the future for microneedle 
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